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Abstract 
 
Protein matrices for wound dressings 
 
Fibrous proteins such as silk fibroin (SF), keratin (K) and elastin (EL) are able to mimic the 
extracellular matrix (ECM) that allows their recognition under physiological conditions. The 
impressive mechanical properties, the environmental stability, in combination with their 
biocompatibility and control of morphology, provide an important basis to use these 
proteins in biomedical applications like protein-based wound dressings. Along time the 
concept of wound dressings has changed from the traditional dressings such as honey or 
natural fibres, used just to protect the wound from external factors, to the interactive 
dressings of the present. Wounds can be classified in acute that heal in the expected time 
frame, and chronic, which fail to heal because the orderly sequence of events is disrupted 
at one or more stages of the healing process. Moreover, chronic wound exudates contain 
high levels of tissue destructive proteolytic enzymes such as human neutrophil elastase 
(HNE) that need to be controlled for a proper healing. 
 
The aim of this work is to exploit the self-assemble properties of silk fibroin, keratin and 
elastin for the development of new protein materials to be used as wound dressings: i) 
evaluation of the blending effect on the physical and chemical properties of the materials; 
ii) development of materials with different morphologies; iii) assessment of the 
cytocompatibility of the protein matrices; iv) ultimately, study the ability of the developed 
protein matrices as wound dressings through the use of human chronic wound exudate; v) 
use of innovative short peptide sequences that allow to target the control of high levels of 
HNE found on chronic wounds. 
Chapter III reports the preparation of silk fibroin/keratin (SF/K) blend films by solvent 
casting evaporation. Two solvent systems, aqueous and acidic, were used for the 
preparation of films from fibroin and keratin extracted from the respective silk and wool 
fibres. The effect of solvent system used was studied by evaluating the physical-chemical 
properties of the resulting films. It was shown that SF and K are able to establish 
intermolecular interactions when mixed and, that the mechanical properties and the 
biological degradation can be tuned by the blend composition. 
In Chapter IV, SF/K films were further used to serve as a platform for the release of HNE 
inhibitors peptides. Bowman-Birk inhibitor (BBI) based peptide was incorporated onto the 
SF/K films that were consequently incubated with porcine pancreatic elastase (PPE) as a 
model for HNE, to monitor the decrease in activity. The results indicated that swelling 
properties, degradation and release rates are dependent on the amount of keratin present 
viii 
in the blend. Furthermore, no cytotoxicity was observed in the presence of mouse 
fibroblasts, which makes these SF/K films suitable candidates for interactive wound 
dressings with a specific goal – controlling high levels of HNE. 
The next step of the work, Chapter V, reports for the first time blends of silk fibroin with 
elastin (SF/EL) for the production of scaffolds. These were prepared by lyophilization 
technique and crosslinked with a natural and low toxic agent, genipin. The crosslink allows 
the control of the scaffolds morphology, such as pore size and porosity, which in turns, 
modulates the ex vivo degradation rates, by a human chronic wound exudate, and the 
release rates of model compounds. In addition, no cytotoxicity was observed for SF/EL 
samples, with and without genipin, by human skin fibroblasts. Thus, the high porosity 
observed for SF/EL scaffolds, allowing the growth and cellular attachment, together with 
their biocompatibility provide fitting characteristics for wound dressings. 
Chapter VI, describes the design of two elastase inhibitors peptides based on the reactive 
site-loop of the BBI protein in order to control the high levels HNE. To a known peptide 
sequence, modifications were made at both N- and C-terminal. Inhibition kinetics analysis 
indicated that these peptides are competitive inhibitors for HNE and PPE and, that the 
inhibitory potency can be regulated by the introduced modifications. Additionally, these 
peptides showed no toxicity with human skin fibroblasts and, were also effective in 
reducing the HNE activity found in a human chronic wound exudate, which allow them to 
be applied to those wounds. 
 
The motivation for this thesis was to combine the excellent properties of silk fibroin with 
other proteins. Blending allows modulating the physical-chemical properties of the 
resulting materials such as mechanical strength, swelling, morphology, degradation and 
release rates. Silk fibroin is widely characterized in the literature for the production of 
biomaterials, but this work is the first that successfully evaluates the blends silk 
fibroin/keratin (SF/K) and silk fibroin/elastin (SF/EL) for their application as wound 
dressings. 
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Resumo 
 
Matrizes proteicas para compressas de feridas 
 
Proteínas fibrosas como a fibroína da seda, a queratina e a elastina têm a vantagem de 
conseguir imitar a matriz extracelular, permitindo o seu reconhecimento em condições 
fisiológicas. As excelentes propriedades mecânicas destas proteínas, a estabilidade 
química juntamente com a biocompatibilidade e controlo da morfologia, são importantes 
pressupostos para o uso destas proteínas em aplicações biomédicas. Um exemplo é o 
tratamento de feridas com compressas baseadas nestas proteínas. As compressas 
usadas nas feridas sofreram grandes mudanças ao longo do tempo, partindo das 
tradicionais baseadas em mel e fibras naturais, que eram usadas apenas para cobrir e 
proteger as feridas de factores externos, até às compressas interactivas do presente. As 
feridas podem ser classificadas em agudas, que curam no tempo previsto e crónicas, que 
não cicatrizam porque o processo de cura é interrompido. Estas feridas podem ainda ser 
diferenciadas pelo tipo de exudado que produzem. Nas feridas crónicas, o exudado 
contém níveis elevados de enzimas proteolíticas como a elastase humana dos neutrófilos 
(HNE) e as metaloproteases de matriz (MMP), que precisam de ser controlados para um 
melhor processo de cicatrização. 
O objectivo deste trabalho é explorar as excelentes propriedades da fibroína, queratina e 
elastina para o desenvolvimento de novos materiais proteícos para serem usados como 
compressas. Para tal estudou-se: i) avaliação do efeito das misturas nas propriedades 
físicas e químicas dos materiais; ii) desenvolvimento de materiais com diferentes 
morfologias; iii) avaliação da toxicidade dos materiais; iv) avaliação das propriedades dos 
materiais desenvolvidos usando um exudado obtido de feridas crónicas; v) 
desenvolvimento de péptidos inibidores para controlar os elevados níveis de HNE nas 
feridas crónicas. 
No Capítulo III é descrita a preparação de membranas baseadas na mistura fibroína e 
queratina (SF/K) por evaporação de solvente. Foram utilizados dois sistemas de 
solventes, aquoso e ácido, para a preparação dos filmes a partir da fibroína e queratina 
extraídas das respectivas fibras têxteis, seda e lã. Estudou-se o efeito dos solventes 
usados nas propriedades físico-químicas das membranas resultantes. Verificou-se que a 
fibroína e a queratina estabelecem interacções intermoleculares e, as propriedades 
mecânicas e a degradação podem ser moldadas através da composição da mistura. 
No Capítulo IV, as membranas desenvolvidas foram posteriormente utilizadas para a 
libertação de inibidores da elastase. Péptidos baseados na proteína inibidora Bowman-
Birk (BBI) foram incorporados nas membranas de fibroína e queratina verificando-se que 
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após incubação com a elastase há uma diminuição da actividade da mesma. Os 
resultados demonstram que as propriedades de inchamento, degradação e libertação 
dependem da quantidade de queratina presente na mistura. Adicionalmente, os materiais 
não apresentam toxicidade na presença de fibroblastos de ratinho. Os resultados indicam 
que estas membranas são candidatas adequados para o uso em compressas interactivas 
com uma actividade específica – controlar os elevados níveis de HNE. 
O próximo passo do trabalho, Capítulo V, reporta pela primeira vez, o desenvolvimento 
de estruturas esponjosas baseadas na mistura de fibroína e elastina (SF/EL). Estes 
materiais foram preparados por liofilização e fixados com um agente de fixação natural e 
de baixa toxicidade, a genipina. Este passo de fixação permite controlar a morfologia dos 
materiais como o tamanho dos poros e porosidade, que têm influência directa na 
degradação pelo exudado e na libertação de compostos modelo. Observou-se também, 
que as estruturas esponjosas não apresentam toxicidade para fibroblastos humanos de 
pele, mesmo depois da fixação com genipina. Consequentemente, a biocompatibilidade 
demonstrada juntamente com a porosidade observada nestes materiais, que permitem a 
adesão e crescimento de células, são características importantes para o uso destes em 
compressas para feridas. 
O Capítulo VI descreve o desenvolvimento de dois péptidos inibidores da elastase 
baseados no centro activo da proteína BBI de forma a controlar os elevados níveis de 
HNE presentes nas feridas crónicas. Foram introduzidas modificações nos terminais C e 
N de uma sequência conhecida. Estudos cinéticos de inibição indicam que estes péptidos 
são inibidores competitivos para a elastase de diferentes fontes, humana e porcina, e que 
a capacidade inibitória depende das modificações introduzidas. Adicionalmente, os 
péptidos não são tóxicos na presença de fibroblastos humanos de pele sendo eficazes na 
redução da actividade da elastase presente num exudado de uma ferida crónica. Estes 
resultados indicam que os péptidos desenvolvidos podem ser usados no tratamento das 
mesmas. 
A motivação deste trabalho partiu das excelentes propriedades da fibroína, queratina e 
elastina. O desenvolvimento de novos materiais baseados em misturas destas proteínas 
permite moldar as propriedades finais como a força mecânica, inchamento, morfologia, 
degradação e libertação de compostos. O uso da fibroína em biomateriais está 
vastamente descrito na literatura. Contudo, este trabalho descreve pela primeira vez, com 
sucesso, o uso das misturas fibroína/queratina e fibroína/elastina para a sua aplicação 
em compressas para feridas. 
xi 
Table of contents 
Acknowledgments ...................................................................................................v 
Abstract ................................................................................................................. vii 
Resumo.................................................................................................................. ix 
Table of contents....................................................................................................xi 
List of abbreviations ............................................................................................. xvi 
List of figures.........................................................................................................xx 
List of tables ........................................................................................................ xxv 
List of equations .................................................................................................xxvii 
Introduction to the thesis format ........................................................................xxviii 
CHAPTER I ............................................................................................................ 3 
Fibrous protein-based wound dressings: a review ................................................. 3 
1. Introduction ..................................................................................................... 5 
1.1. Silk fibroin-structure and properties.......................................................... 5 
1.1.1. Silk fibroin-based biomaterials ........................................................... 7 
1.1.2. Silk fibroin films.................................................................................. 9 
1.1.3. Silk fibroin sponges/scaffolds .......................................................... 12 
1.1.4. Silk fibroin-based wound dressings ................................................. 14 
1.2. Keratin-structure and properties............................................................. 16 
1.2.1. Keratin-based biomaterials .............................................................. 18 
1.2.2. Keratin films..................................................................................... 19 
1.2.3. Keratin sponges/scaffolds................................................................ 21 
1.2.4. Keratin-based wound dressings....................................................... 22 
1.3. Elastin-structure and properties ............................................................. 24 
1.3.1. Elastin-based biomaterials............................................................... 26 
1.3.2. Elastin-based wound dressings ....................................................... 29 
1.4. Wounds and wound healing process...................................................... 31 
1.4.1. Principles of wound healing ............................................................. 32 
1.4.2. The proteolytic environment of chronic wounds............................... 34 
1.4.3. Wound dressings ............................................................................. 35 
1.4.4. Mechanism-based wound dressings................................................ 36 
1.5. Human neutrophil elastase (HNE).......................................................... 37 
1.5.1. Biological functions .......................................................................... 40 
xii 
1.6. Bowman-Birk Inhibitor (BBI) ................................................................... 41 
1.7. Final remarks and research objectives ................................................... 44 
CHAPTER II ......................................................................................................... 47 
Materials and methods ......................................................................................... 47 
2.1. Materials................................................................................................. 47 
2.2. Reagents ................................................................................................ 47 
2.3. Preparation of stock solutions ................................................................ 47 
2.3.1 Silk fibroin ......................................................................................... 47 
2.3.2. Keratin ............................................................................................. 48 
2.4. Preparation of blended systems ............................................................. 48 
2.4.1. Films ................................................................................................ 48 
2.4.2. Scaffolds .......................................................................................... 49 
2.4.2.1. Crosslinking reaction ................................................................. 49 
2.4.2.2. Degree of crosslinking............................................................... 50 
2.5. Characterization techniques ................................................................... 51 
2.5.1. Amino acid analysis ......................................................................... 51 
2.5.2 SDS-PAGE ....................................................................................... 52 
2.5.3. Fourier transform infrared (FT-IR) spectroscopy.............................. 52 
2.5.4. Differential scanning calorimetry (DSC) ........................................... 52 
2.5.5. Mechanical properties...................................................................... 53 
2.5.6. Atomic force microscopy (AFM) ....................................................... 53 
2.5.7. Scanning electron microscopy (SEM) .............................................. 53 
2.5.8. Mass spectrometry........................................................................... 53 
2.6. Swelling ratio .......................................................................................... 54 
2.7. In vitro degradation................................................................................. 54 
2.8. Cytotoxicity evaluation............................................................................ 55 
2.8.1. Cell culture....................................................................................... 55 
2.8.2. Cytotoxicity by indirect contact......................................................... 55 
2.8.3. Cytotoxicity by direct contact............................................................ 56 
2.9. Cell viability and proliferation assays...................................................... 57 
2.9.1. Resazurin assay .............................................................................. 57 
2.9.2. Alamar blue assay ........................................................................... 57 
2.9.3. MTS assay....................................................................................... 57 
2.9.4. F-actin fluorescent labelling ............................................................. 58 
xiii 
2.11. In vitro release...................................................................................... 58 
2.11.1. Release kinetics............................................................................. 59 
2.12. Elastase activity determinations ........................................................... 59 
2.12.1. Mechanisms and kinetics of inhibition............................................ 60 
CHAPTER III ........................................................................................................ 65 
Biodegradable materials based on silk fibroin and keratin ................................... 65 
3.1. Introduction ............................................................................................ 67 
3.2. Materials and methods ........................................................................... 69 
3.2.1. Preparation of stock solutions.......................................................... 69 
3.2.2. Preparation of blended films ............................................................ 69 
3.2.3. In vitro degradation .......................................................................... 70 
3.3. Results and discussion........................................................................... 70 
3.3.1. Amino acid and SDS-PAGE analysis............................................... 70 
3.3.2. Mechanical properties...................................................................... 73 
3.3.3. FT-IR analysis.................................................................................. 74 
3.3.4. DSC analysis ................................................................................... 78 
3.3.5. In vitro degradation .......................................................................... 81 
3.4. Conclusions............................................................................................ 83 
CHAPTER IV........................................................................................................ 87 
Protein matrices for improved wound healing: Elastase inhibition by a synthetic 
peptide model....................................................................................................... 87 
4.1. Introduction ............................................................................................ 89 
4.2. Materials and methods ........................................................................... 90 
4.2.1. Materials .......................................................................................... 90 
4.2.2. Preparation of aqueous silk fibroin and keratin solutions................. 90 
4.2.3. Preparation of blended silk fibroin/keratin films ............................... 91 
4.2.4. In vitro degradation .......................................................................... 91 
4.2.5. Swelling ratio of SF/K films .............................................................. 91 
4.2.6. Protein adsorption to protein films ................................................... 92 
4.2.7. Cytotoxicity evaluation ..................................................................... 92 
4.2.8. In vitro release ................................................................................. 92 
4.2.9. Elastase activity determinations....................................................... 93 
4.3. Results and discussion........................................................................... 93 
4.3.1. Characterization of protein blend films............................................. 94 
xiv 
4.3.2. In vitro release ................................................................................. 99 
4.3.3. Inhibitory activity ............................................................................ 101 
4.4. Conclusions.......................................................................................... 104 
CHAPTER V....................................................................................................... 107 
Novel silk fibroin/elastin scaffolds crosslinked with genipin for wound dressings 107 
5.1. Introduction........................................................................................... 109 
5.2. Materials and methods ......................................................................... 110 
5.2.1. Materials ........................................................................................ 110 
5.2.2. Preparation of Silk fibroin solution.................................................. 111 
5.2.3. Silk fibroin/Elastin blends preparation; Crosslinking reaction; Scaffold 
formation.................................................................................................. 111 
5.2.4. Degree of crosslinking ................................................................... 111 
5.2.5. Swelling ratio.................................................................................. 112 
5.2.6. In vitro degradation ........................................................................ 112 
5.2.7. In vitro release ............................................................................... 112 
5.2.8. Cytotoxicity evaluation ................................................................... 113 
5.3. Results and discussion......................................................................... 113 
5.3.1. Biochemical and biophysical properties of SF/EL scaffolds ........... 113 
5.3.2. In vitro and ex vivo biological degradation ..................................... 124 
5.3.3. In vitro release ............................................................................... 126 
5.3.4. Cytocompatibility of SF/EL scaffolds in vitro .................................. 129 
5.4. Conclusion............................................................................................ 130 
CHAPTER VI ...................................................................................................... 133 
Tailoring elastase inhibition with synthetic peptides ........................................... 133 
6.1. Introduction........................................................................................... 135 
6.2. Materials and methods ......................................................................... 137 
6.2.1. Materials ........................................................................................ 137 
6.2.2. Collection of wound exudate.......................................................... 137 
6.2.3. Determination of activity loss over time.......................................... 137 
6.2.4. Inhibition kinetics............................................................................ 138 
6.2.5. Determination of IC50 for proteases using synthetic substrates ..... 138 
6.2.6. Determination of IC50 for HNE and exudate using insoluble elastin139 
6.2.7. Silk fibroin films preparation and peptide incorporation.................. 139 
6.2.8. Cytotoxicity evaluation ................................................................... 140 
xv 
6.3. Results and discussion......................................................................... 140 
6.3.1. Activity loss over time .................................................................... 141 
6.3.2. Inhibition kinetics ........................................................................... 142 
6.3.3. IC50 for proteases .......................................................................... 144 
6.3.4. Peptides inhibitory activity after incorporation into SF films ........... 145 
6.3.5. Molecular-docking analysis............................................................ 147 
6.3.6 Cytotoxicity evaluation .................................................................... 149 
6.4. Conclusion ........................................................................................... 150 
CHAPTER VII..................................................................................................... 153 
7.1. General conclusions............................................................................. 153 
7.2. Future perspectives.............................................................................. 158 
References......................................................................................................... 160 
 
xvi 
List of abbreviations 
 
2-D - Two-dimensional 
2-Me - 2-mercaptoethanol 
3-D - Three-dimensional 
∆H - Enthalpy variation 
µg - Micrograms 
µL - Microliters 
α1-PI - α1-Protease inhibitor 
t1/2 - Half-life time of an enzyme 
A - Alanine 
AC=O - Area of C=O stretching 
AFM - Atomic Force Microscopy 
Ala - Alanine 
ALP - Alkaline phosphatase 
AN-H - Area of N-H bending 
ASCs - Adipose-derived stem cells 
ATR - Attenuated total reflectance spectroscopy 
ATCC - American Type Culture Collection 
Asp - Aspartic acid 
Arg - Arginine 
B. mori - Bombyx mori 
BBI - Bowman-Birk inhibitors  
BMP-2 - Bone morphogenetic protein-2 
CAM - Chorioallantoic membrane 
CG - Cathepsin G 
CM/PL - Compression-molded/particulate leaching 
CS - Chondroitin sulphate 
Cys - Cysteine 
DAPI - 4,6-diamidino-2-phenylindole 
DMEM - Dulbecco's Modified Eagle's Medium 
DMSO - Dimethylsulfoxide 
DNA - Deoxyribonucleic acid 
Dox - Doxorubicin 
xvii 
DSC - Differential scanning calorimetry 
DTT – D,L-Dithiothreitol 
ECACC - European Collection of Cell Cultures 
ECM - Extracellular matrix 
EDTA - Ethylenediaminetetraacetic acid 
EGF - Epidermal growth factors 
EGDE - Ethylene glycol diglycidyl ether 
ELPs - Elastin-like polymers 
EL - Elastin 
ESI - Electrospray Ionization 
F-actin - Filamentous actin 
FBS - Fetal bovine serum 
FITC-BSA - Fluorescein isothiocyanate-Bovine serum albumin 
FT-IR - Fourier transform infrared 
G – Glycine 
GAGs - Glycosaminoglycans 
GDE - Glycerol diglycidyl ether 
GE - Genipin 
Glu - Glutamic acid  
Gly - Glycine 
HA - Hyaluronic acid 
HFIP - 1,1,1,3,3,3-hexafluoro-2-propanol 
HGTPs - High glycine-tyrosine proteins 
His - Histidine 
hMSCs - Human mesenchymal stem cells 
HNE - Human neutrophil elastase 
HPLC - High performance liquid chromatography 
HRP - Horseradish peroxidase 
HSPs - High sulfur proteins 
HT50 - Half healing time 
IFPs - Intermediate filament proteins 
IGF-I - Insulin growth factor I 
IC50 - Half maximal inhibitory concentration 
Ile - Isoleucine 
xviii 
K - Keratin 
LbL - Layer-by-layer 
LCST - Lower critical solution temperature 
LDV - Leucine-aspartic acid-valine 
Leu - Leucine 
Lys - Lysine 
MEFs - Murine embryonic fibroblasts cells 
Met - Methionine 
mM - Milimolar 
MMPs - Metalloproteinases 
MMP-9 - Gelatinase 
MNEI - Monocyte/neutrophil elastase inhibitor 
MTS-3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium 
NGF - Nerve growth factor 
Nle – Norleucine 
ORC - Oxidized regenerated cellulose 
PA6 - Polyamide 6 
PBS - Phosphate buffered saline 
PCU - Poly(carbonate)-urethane 
PDB - Protein data bank 
PDLLA - Poly(D,L-lactic acid  
PEG - Polyethylene glycol 
PEO - Poly(ethylene oxide) 
PET - Poly(ethylene glycol terephthalate 
pHA - Polarized hydroxyapatite 
PHEMA - Poly 2-hydroxyethylmethacrylate 
Phe - Phenylalanine 
PI9 - Protease inhibitor 9 
PLA - Poly(lactic acid) 
PLGA - Poly(lactide-co-glycolic acid) 
PMN - Polymorphonuclear elastase 
PPE - Porcine pancreatic elastase 
Pro - Proline 
xix 
PS - Penicillin/Streptomycin 
PTH - Parathyroid hormone 
PU - Polyurethane 
PVA - Polyvinyl alcohol 
RCL - Reactive centre loop 
RFU - Relative fluorescence units 
RGD - Arginine-glycine-aspartic acid 
SD - Standard deviation 
SDS - Sodium dodecyl sulfate 
Ser - Serine 
SEM - Scanning electron microscopy 
SF - Silk fibroin 
SELPs - Silk-elastin like polymers 
SLPI - Secretory leukocyte protease inhibitor 
Suc-(Ala)3-pNA - Succinyl-Ala-Ala-ala-p-nitroanilide 
TCPS - Tissue culture polystyrene 
Thr - Threonine 
Tyr - Tyrosine 
TCA - Thricloroacetic acid 
Tg - Glass transition temperature 
UHSPs - Ultra-high sulfur proteins 
uPA - Urokinase-type plasminogen activator 
UV - Ultra-violet 
Val – Valine 
 
xx 
List of figures 
 
Figure 1.1. Silk fibroin β-sheet crystals. ................................................................. 6 
 
Figure 1.2. Silk fibroin processing into different morphologies adapted from [83]: 
(silk cords by twisting [6]; non-woven silk mats [84]; non-woven silk fibers [85]; aqueous- 
and solvent-based porous sponges [53]; hydrogels [86] and films [15, 87])..................... 8 
 
Figure 1.3. Possible interactions between keratin protein chains [137]. .............. 16 
 
Figure 1.4. Schematic diagram of a wool fiber showing the independent structures 
found in the cortical cells reprinted from CSIRO Textile & Fibre Technology. ...... 17 
 
Figure 1.5. Intermolecular elastin crosslinks desmosine and isodesmosine formed 
from four lysine residues from two different tropoelastin molecules. .................... 25 
 
Figure 1.6. The phases of cutaneous wound healing (Reprinted from [304]). ..... 32 
Figure 1.7. Ribbon representation of the three-dimensional structure of HNE (PDB 
code 1B0F). The side chains of the amino acids of the catalytic triad are shown in 
red. ....................................................................................................................... 38 
 
Figure 1.8. Reaction mechanism of serine proteases.......................................... 39 
 
Figure 1.9. Complete covalent structure of the Bowman-Birk inhibitor protein 
(assumed from Birk [358]). Amino acids at the trypsin-inhibitory site are shown as 
solid black circles and, the amino acids at the chymotrypsin-inhibitory site are 
shown as white circles; available carboxylic acid moieties are marked in grey. ... 42 
 
Figure 1.10. The amino acid sequence of the core disulfide-linked reactive site 
sequence form BBI. Xaa represents any amino acid. ............................................ 43 
 
Figure 2.1. Crosslinking reaction of genipin with biopolymers containing free 
amine groups (NH2). ......................................................................................... 50 
 
xxi 
Figure 2.2. Mechanism of reaction of ninhydrin with compounds containing free 
amine groups (NH2).......................................................................................... 51 
 
Figure 3.1. SDS-PAGE of a) wool keratin and b) silk fibroin solutions................. 72 
 
Figure 3.2. FTIR spectra of pure films of silk fibroin (SF1) and keratin (K1) 
aqueous solutions. ............................................................................................... 75 
 
Figure 3.3. FTIR spectra of pure films of silk fibroin (SF2) and keratin (K2) 
dissolved in formic acid. ....................................................................................... 76 
 
Figure 3.4. FTIR spectra of blended films with silk fibroin (SF1) and keratin (K1) 
aqueous solutions. ............................................................................................... 76 
 
Figure 3.5. FTIR spectra of blended films with silk fibroin (SF2) and keratin (K2) 
dissolved in formic acid. ....................................................................................... 77 
 
Figure 3.6. Behaviour of intensity ratio of the amide II bands typical of SF1 
(1518 cm-1) and K1 (1533 cm-1) in water and, SF2 (1514 cm-1) and K2 (1539 cm-1) 
in formic acid. ....................................................................................................... 77 
 
Figure 3.7. DSC curves of blended films with silk fibroin and keratin (SF1/K1) 
aqueous solutions. (a)100SF, b) 80/20SF1/K1, c) 60/40SF1/K1, d) 40/60SF1/K1 
and e) 100K1)....................................................................................................... 80 
 
Figure 3.8. DSC curves of blended films with silk fibroin and keratin (SF2/K2) 
dissolved in formic acid. (a) 100SF, b) 75/25SF2/K2, c) 50/50SF2/K2, d) 
25/75SF2/K2 and e) 100K2)................................................................................. 80 
 
Figure 3.9. Enthalpy variation (∆H) of decomposition peak of SF2 and K2 
(temperature range: 200-350°°C).................... ..................................................... 81 
 
Figure 3.10. Weight loss of SF1/K1 films (water system) incubated in buffer (Ct) 
and Trypsin solution (Ez) as a function of time..................................................... 82 
xxii 
Figure 3.11. Weight loss of SF2/K2 films (formic acid system) incubated in buffer 
(Ct) and Trypsin solution (Ez) as a function of time. ............................................. 82 
 
Figure 4.1. In vitro degradation of protein films incubated with 0.1 U/mL of 
elastase solution at 37 °C for several days........ ................................................... 95 
 
Figure 4.2. Swelling ratio calculated after 24 h of incubation in 100 mM Tris-HCl 
buffer, pH 8.0 at 37 °C............................ .............................................................. 95 
 
Figure 4.3. AFM height images of pure and blend silk fibroin/keratin films. (a) 100 
SF; b) 80 SF; c) 60 SF; d) 40 SF; e) 100 K). The area measured was 10×10 µm.96 
 
Figure 4.4. NIH 3T3 cell viability at 24 and 72 h of culture post contact with 
extracts of the different materials tested (72 h extraction time). The results obtained 
with the four materials were compared among each other and with the controls: * = significantly 
different from all the other tested conditions; δ = significantly different from 100 SF, 80/20 SF/K and 
60/40 SF/K............................................................................................................... 97 
 
Figure 4.5. NIH 3T3 cell proliferation on discs of 100 SF, 80/20 SF/K and 
60/40 SF/K............................................................................................................ 98 
 
Figure 4.6. Fluorescent labelling of F-actin (green) and DNA (blue) of NIH 3T3 
cells cultured for 48 h on TCPS(a and b) and discs prepared from 80/20 SF/K film 
(c and d). .............................................................................................................. 98 
 
Figure 4.7. In vitro release profile of the peptide from SF/K films incubated with 
0.1 U/mL of PPE solution...................................................................................... 99 
 
Figure 4.8. PPE activity loss after 24 h of incubation with SF/K films with and 
without peptide incorporated............................................................................... 104 
 
Figure 5.1. FT-IR absorbance spectra of pure silk fibroin (100SF) and crosslinked 
with genipin (100SF0.1GE and 100SF0.5GE). ................................................... 117 
xxiii 
Figure 5.2. FT-IR absorbance spectra of pure elastin (100EL) and crosslinked with 
genipin (100EL0.1GE and 100EL0.5GE). .......................................................... 117 
 
Figure 5.3. DSC scans of pure silk fibroin (100SF) and crosslinked with genipin 
(100SF0.1GE and 100SF0.5GE)........................................................................ 120 
 
Figure 5.4. DSC scans of pure elastin (100EL) and crosslinked with genipin 
(100EL0.1GE and 100EL0.5GE). ....................................................................... 121 
 
Figure 5.5. SEM images of SF/EL scaffolds without genipin (100SF a), 80SF b) 
and 50SF c)) and after genipin crosslinking (100SF0.5GE d), 80SF0.5GE e) and 
50SF0.5GE f)). ................................................................................................... 122 
 
Figure 5.6. The pH-dependent swelling ration of 100SF a) 80SF b) and 50SF c) 
scaffolds after 24 h of immersion at 37 °C......... ................................................. 123 
 
Figure 5.7. In vitro degradation of SF/EL scaffolds incubated with 0.1 mg/ml of 
PPE and wound exudate (2.4 µg/mL of total protein content) at 37 °C for 21 days.
........................................................................................................................... 125 
 
Figure 5.8. Cumulative release of trypan-blue a) and FITC-BSA b) from SF/EL 
scaffolds incubated with 0.1 mg/ml of PPE at 37 °C for 21 days. ....................... 127 
 
Figure 5.9. Viability of human normal skin fibroblasts after 24 h, 48 h and 72 h of 
contact with conditioned medium (culture medium where scaffolds were 
incubated). Only the positive control (treatment with Triton detergent) revealed diminished cell 
viability. (***= significantly different from all the other tested conditions, p<0.001). ................. 130 
 
Figure 6.1. Three-dimensional structure of soybean trypsin/chymotrypsin 
Bowman-Birk inhibitor in solution (PDB code 1BBI [355]). Loop I is shown is red, 
loop II is blue and the disulphide bond is yellow................................................. 136 
 
Figure 6.2. Representation of the peptide sequences mimicking the reactive site 
loop of the Bowman-Birk Inhibitor protein........................................................... 141 
xxiv 
Figure 6.3. Activity loss obtained after 30 min of incubation at 25 °C of elastases 
with 20 µM of peptides 2, 3 or elastatinal. (Peptide 2 = MGWCTASVPPQCYG, peptide 
3 = MGWCTASVPPQCYG(GA)7) ........................................................................... 142 
 
Figure 6.4. Progress curves for the inhibition of HNE by peptide 2 (a) and peptide 
3 (b) for the hydrolysis of the synthetic substrate. The correspondent Lineweaver-
Burk plots are represented in c) peptide 2 and d) peptide 3. (Peptide 2 = 
MGWCTASVPPQCYG, peptide 3 = MGWCTASVPPQCYG(GA)7)............................. 143 
 
Figure 6.5. Activity loss of HNE after 1 h of incubation at 25 °C with SF films 
incorporating peptide 2, 3 and elastatinal. (Peptide 2 = MGWCTASVPPQCYG, 
Peptide 3 = MGWCTASVPPQCYG(GA)7) ............................................................... 147 
 
Figure 6.6. Docking images of the interactions between HNE and peptides 1 (a), 2 
(b) and 3 (c). The catalytic triad is shown in red. (Peptide 2 = MGWCTASVPPQCYG, 
Peptide 3 = MGWCTASVPPQCYG(GA)7) ............................................................... 149 
 
Figure 6.7. Viability of human normal skin fibroblasts after 24 h (left panel) and 
48 h (right panel) of contact with peptides 2, 3 and elastatinal. Only the positive control 
(treatment with Triton detergent) revealed diminished cell viability. (* = significantly different from all 
the other tested conditions, p<0.05). (Peptide 2 = MGWCTASVPPQCYG, Peptide 3 = 
MGWCTASVPPQCYG(GA)7) ..................................................................................... 150 
 
xxv 
List of tables 
 
Table 1.1. Main properties of the studied proteins ............................................... 31 
 
Table 1.2. Type of cells involved in the wound healing process........................... 34 
 
Table 1.3. Characteristics of human neutrophil elastase ..................................... 40 
 
Table 3.1. Amino acid composition of silk fibroin and keratin............................... 71 
 
Table 3.2. Mechanical properties of SF1/K1 blends............................................. 73 
 
Table 3.3. Mechanical properties of SF2/K2 blends............................................. 73 
 
Table 3.4. Results from the curve fitting of the amide I range of the FT-IR 
spectrum of SF films............................................................................................. 78 
 
Table 4.1. Model compound release kinetic data obtained from fitting experimental 
release data to Ritger-Peppas equation where “n” is the diffusion exponent and R2 
is the correlation coefficient ............................................................................ 100 
 
Table 4.2. Hal-life time of PPE activity after 24 h of incubation with different 
peptide (5(6)-Carboxyfluorescein-YCQPPWSATCF-OH) concentrations at room 
temperature .................................................................................................... 101 
 
Table 4.3. Hal-life time of PPE after 24 h of incubation with SF/K films with 20 µM 
of peptide incorporated................................................................................... 103 
 
Table 5.1. Amino acid composition of silk fibroin and soluble elastin................. 114 
 
Table 5.2. Degree of crosslinking obtained for SF/EL scaffolds for the different 
reaction conditions ............................................................................................. 115 
 
xxvi 
Table 5.3. Deconvolution results obtained from the amide I region in the FT-IR 
spectra of SF scaffolds ....................................................................................... 118 
 
Table 5.4. Peak areas of AC-O-C (1150-940 cm-1), AN-H (1580-1470 cm-1) to AC=O 
(1790-1580 cm-1) as a function of scaffold composition and crosslinking conditions
........................................................................................................................... 119 
 
Table 5.5. Degradation rates of SF/EL scaffoldscalculated from the linear slope of 
the weight loss (%) versus time (days) ............................................................... 126 
 
Table 5.6. Model compound release kinetic data obtained from fitting the 
experimental release data to Equation 5, Chapter II........................................... 129 
 
Table 6.1. Inhibition constants (Ki) obtained for the peptides against PPE, HNE 
and wound exudate. (*Values were obtained from the literature [495], Peptide 1 = 
WCTASVPPQCYG, peptide 2 = MGWCTASVPPQCYG, peptide 3 = 
MGWCTASVPPQCYG(GA)7) ............................................................................. 144 
 
Table 6.2. Inhibitory activity of peptides and elastatinal against PPE, HNE and 
wound exudate using synthetic and natural substrates. (Peptide 2 = 
MGWCTASVPPQCYG, peptide 3 = MGWCTASVPPQCYG(GA)7)......................... 145 
 
 
xxvii 
List of equations 
 
Equation 2.1. Degree of crosslinking where“nc” and “c” are respectively, the mole 
fraction of free NH2 in non crosslinked and crosslinked samples.......................... 51 
 
Equation 2.2. Swelling ratio where WS is the mass of the swollen material and Wd 
is the initial dry mass. ........................................................................................... 54 
 
Equation 2.3. Weight loss where m0 is the initial dry mass of the sample and, mf is 
the final dry mass. ................................................................................................ 54 
 
Equation 2.4. Ritger-Peppas equation. ............................................................... 59 
 
Equation 2.5. Modified Ritger-Peppas equation. ................................................. 59 
 
Equation 2.6. Michaelis-Menten equation. .......................................................... 60 
 
Equation 2.7. Modified Michaelis-Menten equation for competitive inhibition. .... 60 
 
Equation 2.8. Modified Michaelis-Menten equation for noncompetitive inhibition.61 
 
Equation 2.9. Modified Michaelis-Menten equation for mixed inhibition. ............. 61 
 
Equation 2.10. Modified Michaelis-Menten equation for uncompetitive inhibition.62 
 
Equation 2.11. Determination of IC50................................................................... 62 
xxviii 
Introduction to the thesis format 
 
This thesis is divided into seven chapters, with four of them being experimental 
research. According to a philosophy that has been implemented in our laboratory, 
the thesis format is based on published or submitted papers, including the 
introduction chapter. The contents of each chapter are summarized below. 
 
Chapter I 
The first chapter of this thesis is based on a review paper and presents a 
comprehensive overview on the novel protein-based biomaterials based on silk 
fibroin, keratin and elastin. Their physical, chemical and biological properties are 
discussed for their application on the context of wound dressing materials. The 
type of wounds and wound healing process are also reviewed. 
 
Chapter II 
Chapter II describes the materials and methods used along the work. The main 
objective was to complement the information given in each of the following 
experimental chapters. 
 
Chapter III to VI 
The chapters included within this section are based on the series of related papers 
that resulted from research work already published or submitted for publication. 
Chapter III describes the development of silk fibroin/keratin films and their 
physical-chemical characterization. 
Chapter IV reports the application of the silk fibroin/keratin films as platforms for 
the release of elastase inhibitors. 
Chapter V illustrates the development of new scaffolds based on silk fibroin and 
elastin and their application as wound dressing materials. 
Chapter VI describes the design of new elastase inhibitors and the type of 
inhibition mechanism. 
 
Chapter VII 
This thesis ends with Chapter VII, which is the summary and conclusions of the 
research work under the scope of this thesis. 
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CHAPTER I 
 
Fibrous protein-based wound dressings: a review 
 
Abstract 
 
Wound dressings have experienced continuous and significant changes over the 
years based on the knowledge of the biochemical events associated with chronic 
wounds. The development goes from natural materials used to just cover and 
conceal the wound, to interactive materials that can facilitate the healing process 
addressing specific issues in non healing wounds. 
Recently the wound dressing research is focusing on the replacement of synthetic 
polymers by natural protein materials to delivery bioactive agents to the wounds. 
This review provides an overview on the novel protein-based wound dressings 
such as silk fibroin keratin and elastin. The processing methods, physical, 
chemical and biological properties of these biomaterials will be discussed. The 
different types of wounds and the effective parameters of healing process will be 
reviewed. A special attention will be given to human neutrophil elastase (HNE), a 
destructive proteolytic enzyme present in a chronic wound environment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: Andreia Vasconcelos, & 
Artur Cavaco-Paulo, Protein-based wound dressings: a review, Submitted 
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1. Introduction 
Fibrous proteins such as silk fibroin, keratin and elastin are characterized by high 
mechanical strength and represent architectural functions in nature. They often 
possess relatively homogeneous secondary structures via self-assembly. The 
ability of these proteins to self-assemble into various physical states was exploited 
for the development of new biomaterials. These have shown to undergo materials 
with improved mechanical strength, control of morphology and surface 
modifications options, allowing their application in controlled delivery systems and 
tissue engineering. Furthermore, wounds treated with these materials have shown 
to promote the healing by enhanced cellular proliferation, growth and 
differentiation and, reduced inflammation when applied to in vivo models. 
1.1. Silk fibroin-structure and properties 
Silks are naturally occurring protein polymers produced by a wide variety of 
insects and spiders [1-3]. The diverse functions of silks range from web 
construction and prey capture (spider webs), safety lines (draglines) to 
reproduction (cocoons) [4-6]. Silk in its natural form is composed by a filament 
core protein, silk fibroin, and a glue-like coating consisting of sericin proteins. 
The most widely studied silks are cocoon silk from the silkworm Bombyx mori and 
dragline silk from the spider Nephila clavipes [3, 7]. Silk fibroins from these 
species are characterized as natural block copolymers composed of hydrophobic 
blocks with highly preserved repetitive sequences consisting of short side-chains 
amino acids such as glycine and alanine and, hydrophilic blocks with more 
complex sequences that consist of larger side-chain as well as charged amino 
acids [4, 8]. The hydrophobic blocks tend to form β-sheet crystals through 
hydrogen bonding and hydrophobic interactions which are the basis for the high 
tensile strength of silk fibroins [9, 10]. These ordered hydrophobic blocks combine 
with the less ordered hydrophilic blocks to give elasticity and toughness of silk 
fibroin [3, 11]. In general, silks represent a unique family of structural proteins that 
are biocompatible, degradable and mechanically superior, are amenable to 
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aqueous or organic solvent processing and can be chemically or biologically 
modified to suit a wide range of biomedical applications. 
Silk fibers from the domesticated silkworm B. mori are 10-25 µm in diameter and 
consist of two proteins: a light chain (≈ 26 kDa) and a heavy chain (≈ 390 kDa) 
which are present in a 1:1 ratio and are linked by a single disulfide bond that holds 
the fibroin together [12]. These proteins are coated with a family of hydrophilic 
proteins, sericin (20-310 kDa) which counts for 25% of the silk cocoons mass [2, 
12-14]. The amino acid composition of silk fibroin from B. mori consists mainly of 
glycine (Gly) (44%), alanine (Ala) (29%) and serine (Ser) (11%) [15]. The 
crystalline domains in the fibers consists of Gly-X repeats, with X being Ala, Ser, 
threonine (Thr) and valine (Val) [16]. 
In the solid state, silk fibroin can assume two polymorphs including the glandular 
state prior to crystallization/spinning (silk I) and, the spin silk state which consist of 
the β-sheet secondary structure (silk II) [2, 7, 17]. The silk I structure is water 
soluble and, upon exposure to heat, physical spinning and organic solvents easily 
converts to silk II structure [18]. The β-sheet structures (silk II) are asymmetrical 
with one side occupied by hydrogen side chains from glycine, and the other 
occupied by the methyl side chains from the alanine that populates the 
hydrophobic domains. The β-sheets are arranged so that the methyl groups and 
hydrogen groups of opposing sheets interact to form the intersheet stacking in the 
crystals (Figure 1.1). Strong hydrogen bonds (inter- and intra-chain) and van der 
Waals interactions generate a structure that is thermodynamically stable [12, 19]. 
The silk II is water insoluble as well in several solvents including mild acid and 
alkaline conditions and several chaotropes. For a better elucidation of readers a 
resume of the main structural properties of the studied proteins will be provided 
(Table 1.1.). 
 
Figure 1.1. Silk fibroin β-sheet crystals. 
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1.1.1. Silk fibroin-based biomaterials 
Silk fibers from B. mori have been primarily used in biomedical applications as 
sutures [20] and, during decades of use, silk fibers proven to be effective in many 
clinical applications. Nevertheless, immunological reactions observed to virgin silk 
suture have been attributed to the sericin protein [21]. It has been showed that 
sericin is a potential allergen causing a type I allergic reaction [22, 23]. In this way, 
removal of sericin from silk is necessary to prepare non-allergic and non-cytotoxic 
silk-based materials. However, a recent study using sericin/gelatin blends for the 
fabrication of films and sponges, reported cytocompatibility using feline fibroblasts 
cells and, low immunogenicity [24]. 
Methods to extract and regenerate silk fibroin have been developed. The studies 
that will be described wherein report the use of sodium carbonate (Na2CO3, 
boiling, 60 min) and autoclaving (120 °C, 30 min) f or the removal of sericin. The 
most common and used method for the extraction of fibroin from degummed 
(without sericin) silk fibers is dissolution in a concentrated solution of lithium 
bromide (LiBr 9 M, 60 °C, 4 h) [25-50]. A ternary s olvent system of calcium 
chloride/ethanol/water (CaCl2-CH3CH2OH-H2O, 80 °C, 2 h) in a 1:2:8 molar ratio 
had also been used by some authors [36, 51-59]. Deriving from these methods, 
regenerated fibroin can be further dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol 
(HFIP, (CF3)2CHOH) [53, 60-62] and formic acid (HCOOH) [15, 51, 52, 57, 63]. 
After filtration and dialysis, the regenerated fibroin solutions will be further used to 
prepare silk-based biomaterials. 
Silk films can be prepared by solvent casting or layer-by-layer (LbL) deposition of 
solutions [15, 26, 33-35, 38, 40, 41, 46-48, 57, 59, 60, 62, 64-67]; SF sponges or 
scaffolds can be formed after lyophilization, porogens or gas foaming [25, 27, 31, 
32, 36, 45, 53, 56, 58, 61, 63, 68-71]; SF hydrogels are formed via sol-gel 
transitions, sonication, vortexing or the presence of acid and/or ions [49]; SF 
nanofibers are prepared by electrospinning [28, 36, 43, 44, 59] and SF 
micro/nanospheres have been prepared by water/oil emulsion, spray-drying, lipid 
vesicles, salt leaching and sonication [72-76]. The different morphologies of SF 
can be observed in Figure 1.2. To be further used, it is necessary to induce β-
sheet crystallization so that silk-based materials became water insoluble and 
slower degraded. This can be achieved through the use of organic solvents such 
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as methanol and formic acid, mechanical stress, high concentrations of salts and 
thermal treatment [51, 52, 77, 78]. Water-based annealing procedure and very 
slow drying have shown to induce the formation of β-sheet crystal of SF materials 
[79, 80]. Recently, it was reported that blending with other molecules induces the 
crystallization of SF. Studies made on SF/keratin blends indicated that addition of 
keratin induces the β-sheet formation most likely due to the high polarity of keratin 
protein that act as a organic solvent [81]. In another study, blending SF with 
hyaluronic acid (HA) enhances higher levels of β-sheet formation in the presence 
of methanol or water [82]. Accordingly to the US Pharmacopeia, a degradable 
material is defined as one that “loses most of its tensile strength within 60 days” 
post-implantation in vivo. By this definition, silk is classified as non-degradable. 
However, based on the literature, fibroin is proteolytically degradable over longer 
time periods [6, 37]. 
 
 
 
Figure 1.2. Silk fibroin processing into different morphologies adapted from [83]: 
(silk cords by twisting [6]; non-woven silk mats [84]; non-woven silk fibers [85]; aqueous- 
and solvent-based porous sponges [53]; hydrogels [86] and films [15, 87]). 
B. mori cocoons Degummed silk fiber 
Silk cord 
Non-Wooven mats 
Aqueous SF solution 
Electrospinning 
Sericin extraction Twisted fibers Wire ropes 
Partial solubilized 
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Porogen 
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Transition 
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1.1.2. Silk fibroin films 
Silk fibroin films have been cast from aqueous or organic solvent systems as well 
as after blending with other polymers. Silk films possess oxygen and water vapor 
permeability depending on the content of silk I and silk II structures [88, 89]. 
Mechanical and degradability properties of the films are also affected by these silk 
structures [89]. Research has shown the importance of surface topography and 
texture in controlling the shape, orientation and gene expression of adherent cells 
[47, 66]. Gupta et al. extended the versatility of silk fibroin further in developing 
patterned films cast directly from fibroin solubilized in an ionic liquid. In addition, 
these films were found to support normal keratinocytes proliferation and 
differentiation [66]. 
The controlled release of active compounds from SF films has been extensively 
evaluated [40]. It was found that the release is affected by the amounts of β-sheet 
crystals. Furthermore, the methanol treatment performed to induce the 
crystallization of the films does not affect the activity of the compounds as shown 
by the study performed by Uebersax et al., where nerve growth factor (NGF) is 
continuously released from SF films up to 3 weeks without loss in the NGF 
bioactivity [41]. The utility of SF films to promote long-term adenosine release from 
adenosine kinase deficient embryonic stem cells was investigated [90, 91]. These 
studies demonstrate that SF constitutes a suitable material for the direct 
differentiation of embryonic stem cells and for cell-mediated therapeutic release of 
adenosine. In a recent study, SF films were used for the stabilization of enzymes 
or therapeutic proteins [48]. Glucose oxidase, lipase and horseradish peroxidase 
(HRP) were entrapped in silk films over 10 months with significant activity retained. 
This study demonstrates that SF films can be used for the stabilization of enzymes 
without the need for cryoprotectants, emulsifiers, covalent immobilization or other 
technique. The biomedical applications of SF films could be broadened by surface 
modifications with RGD (arginine-glycine-aspartic acid) or specific growth factors. 
As shown by Sofia et al. and Chen et al. RGD coupling (via carbodiimide 
chemistry) to SF films promotes the attachment, spreading, proliferation and 
differentiation of human osteoblasts, fibroblasts and bone marrow stromal cell [60, 
92]. This is most likely due to an increase in cell density that promotes cell-cell 
interactions [92]. 
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The surface of SF films was modified with parathyroid hormone (PTH), involved in 
the induction of bone formation, and it was showed that adhesion of human 
osteoblasts on SF films was promoted by surface modification [60]. Immobilization 
of bone morphogenetic protein-2 (BMP-2) in SF films, by carbodiimide reaction, 
enhanced osteogenic differentiation of human bone marrow stromal cells [93]. 
Overall, these studies demonstrated that the diversity of amino acid residues 
present in fibroin facilitates surface modification and immobilization of adhesion 
ligands and growth/morphogens factors. This allows selective modifications of SF 
biomaterials to encode specific functions. The in vitro inflammatory response was 
first reported by Santin et al. It was demonstrated that interactions of fibroin with 
the humoral components of the inflammatory system were comparable with those 
of controls, i.e., no added inflammatory response was observed [35]. Meinel et al. 
studied the inflammatory response of SF films (with or without covalently bonded 
RGD) in vitro and in vivo [62]. It was reported that cell proliferation in vitro was 
enhanced on SF or SF-RGD in comparison to controls (collagen and TCPS). In 
vivo, the inflammatory reaction and foreign body response to SF and SF-RGD is 
similar or less with that of controls. 
The structure and properties of SF films can be further modified by blending with 
other natural and synthetic polymers such as polyethylene glycol (PEG) [33, 94, 
95], polyacrylamide [96], cellulose [97, 98], polyallylamine [99], chitosan [100, 
101], polyethylene oxide (PEO) [87], collagen [102], gelatin [67] and tropoelastin 
[26]. Generally, the blend systems showed better properties when compared to the 
pure components like, improved mechanical strength [26, 59, 65, 94, 96, 99] and 
thermal stability [65, 96], controlled release [49] and improved cellular attachment 
and proliferation [26, 99, 102]. Blend systems can also introduce changes in the 
morphology of the resulting film SF blended with cellulose and chitosan resulted in 
the formation of microporous [59, 98] and, addition of PEO to SF leads to films 
with a highly regular patterned microstructure [87]. 
There is considerable research in the development simple and versatile methods 
to assemble robust, biocompatible and functional biomaterial coating that directs 
cells outcomes. The self-assembly of SF to form coatings is dominated by 
hydrophobic and some electrostatic interactions. Therefore, both hydrophilic and 
hydrophobic materials could be coated. In general, the thickness of the coating is 
linearly correlated with the number of layers, which in turns depends on the SF 
Protein matrices for wound dressings 
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and salt concentrations used in the process. Coatings of SF have been studied to 
provide interfaces for biomaterials, Petrini et al. coated the surface of 2D and 3D 
polyurethane (PU) scaffolds in order to modify their surface [90]. After methanol 
treatments, SF-coatings showed good stability in physiological-like conditions and 
promote the adhesion and growth of human fibroblasts cells. The effect of SF 
coating at 2D poly(carbonate)-urethane (PCU) substrates on attachment, 
proliferation, metabolism and extracellular matrix (ECM) synthesis of four strains of 
human fibroblasts was reported by Chiarini et al. [103]. SF-PCU improved cell 
attachment by 2.2 fold in comparison to uncoated PCU films. At the same time, SF 
coating significantly affected the metabolism of fibroblasts and enhanced the 
extracellular assembly of collagen Type I, the major ECM contribution from 
fibroblasts. The last, seeded on SF-coated substrates did not secrete appreciable 
levels of cytokines which are implicated in inflammation reaction and tissue repair 
during wound. In a similar study, SF-coating on 3D PU scaffolds showed that cell 
attachment, proliferation and cellular metabolism is similar to the 2D PU substrates 
[104]. The surface modification of poly(D,L-lactic acid) (PDLLA) by SF coating 
improved the interactions between osteoblasts cells and PDLLA films [105]. Using 
the same substrates, SF coating was performed by carbodiimide chemistry and 
physical entrapment. The results showed that the SF coating via entrapment, 
presented higher osteoblasts viability and proliferation on the PDLLA films than the 
carbodiimide reaction [106]. Wang et al. employed an all-aqueous stepwise (layer-
by-layer) deposition technique to assemble nanoscale thin films SF coating on a 
number of substrates [38]. The assembled films were stable under physiological 
conditions and supported human bone marrow stem cells adhesion, growth and 
differentiation. Furthermore, it was found that film thickness is linear to the number 
of SF layers. Thus, the release of drugs from these types of coatings can be 
controlled by the number of layers and secondary structure. Nanolayer coatings of 
SF to retain model compounds such as rhodamine B and azoalbumin have been 
prepared using the same procedure [107] and, it was found that higher crystallinity 
and thickness leads to the suppression of the initial burst release and prolonged 
the duration of the same. Multilayer SF coatings are also an effective system for 
the release of heparin, paclitaxel and clopidrogel [67]. Paclitaxel and clopidrogel 
were successfully released from SF-coatings inhibiting the proliferation of smooth 
muscle and endothelial cells. Heparin release was demonstrated by the promotion 
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of human aortic endothelial cell proliferation [67]. SF coating performed on 
poly(lactide-co-glycolic acid) (PLGA) and alginate microspheres stabilized the 
same from degradation, providing mechanically stable shells with a diffusion 
barrier that significantly delays the release from the microspheres [42]. When a 
chemical crosslinking of SF coating is employed, zero-order release kinetics can 
be achieved [54]. Recently, solid adenosine powder coated with SF was 
investigated for local and sustained delivery of the anticonvulsant adenosine from 
encapsulated reservoirs [29]. An increase in the thickness of the coating and 
crystallinity delayed adenosine burst release, decrease average daily release rate 
and increased the duration of the same. 
These reports demonstrate that SF coatings generate biomaterials with controlled 
morphological and structural features for several applications such as drug 
delivery and tissue engineering. 
1.1.3. Silk fibroin sponges/scaffolds 
Silk-based porous sponges are attractive biomaterials for tissue engineering 
applications, cell attachment, proliferation and migration and, for nutrient and 
waste transport. SF sponges have been formed using porogens (sodium chloride 
(NaCl) or sugar), gas foaming and lyophilization. Solvent-based sponges can be 
prepared by dissolving aqueous derived SF, after freeze drying, in HFIP [53], or by 
adding small amounts of organic solvents (ethanol, methanol (CH3OH), 
dimethylsulfoxide (DMSO, (CH3)2SO)) into aqueous SF solution before 
lyophilization [68]. 
Aqueous-based SF sponges can be prepared using salt crystals as porogens with 
control of pore sizes from 490-900 µm, by manipulating silk concentration and the 
size of salt crystals [61]. Due to partial solubilization of salt, aqueous-based 
sponges have rougher surface morphology than solvent-based ones. Higher 
porosity and better mechanical strength is obtained from aqueous-based sponges 
depending on SF concentration [61]. Furthermore, enzymatic degradation is faster 
for aqueous-based sponges [61, 108]. The same behavior is observed in vivo. 
Solvent and aqueous-derived SF sponges were implanted in rats. All scaffolds 
were tolerated by the animals with a mild immune response. Moreover, aqueous-
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based sponges degraded completely between 2 and 6 months whereas solvent-
based sponges persisted beyond 1 year [32]. 
The principal feature of the sponge materials is the cellular attachment and 
proliferation on the porous structures. SF-based sponges have shown to promote 
the adhesion, proliferation and differentiation of human dermal fibroblasts [71], 
human cervical cells [25], human mesenchymal stem cells [69, 109] and 
chondrocyte cells [31]. Silk sponges had been used successfully in the healing of 
critical size femur defect in rats [110]. Aqueous and solvent-based SF sponges 
were used for bone tissue engineering and, trabeculae bone-like structures were 
observed with higher organization for aqueous-derive SF sponges [111]. SF-
sponges seeded with chondrocytes cells also supported a cartilage tissue 
engineering [112] yielding a frictional coefficient similar to that of native cartilage 
[113]. Additionally, SF micromolded sponges supported a significant enhancement 
in cell attachment, spreading, mitochondrial activity and proliferation, in 
comparison to tissue culture plates as controls [114], showing, once again, how 
matrix surface and topography is important for cellular interactions [63]. 
SF sponges have also been used for the incorporation of compounds. Vepari and 
Kaplan reported the immobilization (via carbodiimide chemistry) of horseradish 
peroxidase (HRP) enzyme gradients to prepare new functional scaffolds [115]. SF 
sponges loaded with BMP-2 induced human bone marrow stromal cells to undergo 
osteogenic differentiation when the seeded sponges were cultured for 4 weeks 
[116]. Uebersax et al. reported that the release of insulin growth factor I (IGF-I) 
from silk sponges promoted chondrogenic differentiation of human bone marrow 
mesenchymal stem cells [117]. Adenosine release via silk-based implants to the 
brain has been developed for the refractory epilepsy treatments [118, 119]. SF 
sponges loaded with adenosine demonstrated therapeutic ability, including the 
sustained release of adenosine, manipulated by slow degradation of silk, 
biocompatibility and the delivery of predetermined doses of adenosine [118]. 
The properties of SF sponges had also been exploited by blend systems. 
Improved mechanical properties can be achieved by blending SF with PEG [95] 
and chitosan [120]. Furthermore, degradation studies on SF/chitosan sponges 
showed that the blend sponges maintained the porous structures till 6 weeks of 
degradation in phosphate buffered saline (PBS) at 37 °C [56]. Silva et al. reported 
that crosslinking of SF/chitosan sponges with genipin promoted the formation of 
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stable structures that favored adhesion, proliferation and matrix production on 
chondrocyte-like cells [45]. SF/collagen sponges retained the excellent mechanical 
properties of SF-based sponges and, when heparin was loaded into the sponges, 
these become blood compatible due to the slow release of heparin [55]. In a 
different study, Lu et al. showed that growth of fibroblasts and vascular smooth 
muscle cells is improved in the SF/collagen relatively to pure SF sponge [58]. 
SF sponges blended with calcium alginate beads, loaded with drugs, resulted in a 
prolonged release without initial burst when compared to calcium alginate beads 
without SF [70]. Recently, a green process avoiding the use of organic solvents 
and harsh chemical processes was used for the preparation of SF/gelatin 
sponges. Addition of gelatin induces conformational changes to SF, which resulted 
in the formation of porous structures during lyophilization [27]. 
1.1.4. Silk fibroin-based wound dressings 
Pure SF and blend systems had been applied in the development of new wound 
dressing materials. Yeo et al. reported the effect of polyvinyl alcohol 
(PVA)/Chitosan/SF (PCS) sponges on the wound healing in rats [121]. PCS-
sponges covered an excised wound and, it was observed that PCS absorbed the 
exudate gaining flexibility and softness. The histopathological inspection of the 
wound showed an increase of vascular ingrowth and the absence of inflammatory 
cells after 12 days of implantation. Moreover, it was found that accelerated wound 
healing is obtained with PCS-sponges in comparison with control and the pure 
components or in various combinations [121]. Silk fibroin films were used in full-
thickness wounds of mice [122]. It was reported that the area of the wound was 
reduced by 10% and the healing time of the wounds dressed with SF films was 7 
days shorter when compared to control, DuoActive, a conventional hydrocolloid 
dressing. Furthermore, a higher collagen regeneration and reduced inflammation 
was obtained with SF films. When compared to lyophilized porcine dermis (Alloask 
D), which is used as a dressing for burns, ulcers and decubitus, the promotive 
effects of the wounds with SF films were similar or slightly better [122]. In another 
study, SF/alginate (SF/AA) sponges were applied to the same type of wounds 
[123]. It was reported that the half healing time (HT50) was dramatically reduced by 
SF/AA sponges in comparison to control or pure SF and alginate. The same trend 
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was observed on the significant increase of re-ephitelialization and in the number 
of proliferative cells. These results indicate that SF and alginate act synergistically 
for the promotion of wound healing [123]. Polarized hydroxyapatite (pHA) and SF 
composite dressing gel were also tested on the epidermal recovery from full-
thickness porcine skin wounds [124]. It was found that the blend with polarized 
hydroxyapatite showed higher promotive effects, re-ephitelialization and matrix 
formation that pure SF or the blend without polarized hydroxyapatite. Tsubouchi et 
al. patented a wound dressing material containing silk fibroin and sericin [125]. 
The dressing was applied to a corium-flayed mouse and it was observed that the 
SF/sericin dressing inhibited edematization and functioned as a wound dressing 
material. Silk wound dressings that selectively sequester targeted proteases from 
wound sites were patented by Mcdevitt and Tyrell [126]. It was found that silk 
wound dressing effectively removes human neutrophil elastase from the wound 
site, protecting from proteolytic degradation thus, accelerating the healing. More 
recently, the properties of electrospun silk mats have bee evaluated for wound 
dressing applications [127]. Electrospun silk materials exhibited absorption, water 
vapor transmission, oxygen permeability and enzymatic degradation suitable for 
full-thickness wound sites. Electrospun silk mats loaded with epidermal growth 
factors (EGF) increased the time of wound closure to 90% [128]. Altman et al. 
reported the potential of SF/chitosan scaffold as a delivery vehicle for human 
adipose-derived stem cells (ASCs) in a murine soft tissue wound model [129]. It 
was found that scaffolds with seeded cells enhance wound healing and show 
differentiation into fibrovascular, endothelial and epithelial components of restored 
tissue when compared to non seeded scaffolds and control. The feasibility of SF 
films to construct artificial skin substitutes for wound healing was demonstrated 
through cytocompatibility evaluation. No cytotoxicity or adverse influence on the 
adhesion and cell cycle was observed. Therefore, SF films provide a framework 
for reparation after trauma in clinical applications [130].  
Overall, the healing properties presented by the SF-based materials are related to 
the physical properties of SF such as water absorption and vapor permeability. 
The ability to absorb wound exudate forms a flexible dressings that sticks to the 
wound, preventing excessive flow cell-proliferating substances, exudate and 
proteins. At the same time, smooth regeneration of the skin is accelerated, 
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because the flexible dressings moves when the skin moves without stimulating the 
wound  
1.2. Keratin-structure and properties  
Keratin is the major structural fibrous protein providing outer covering such as hair, 
wool, feathers, nails and horns of mammals, reptiles and birds [131]. Keratin 
proteins are self-assembled into fibers in the follicle by a high proliferative process 
controlled by more than 30 growth factors and cytokines [132-136]. After extrusion 
through the skin, the fiber is formed into a highly stable structure formed by 
covalent, ambient oxygen catalyzed disulfide crosslinking and non covalent 
interactions (Figure 1.3), which can occur between separate polypeptide chains 
(intermolecular) but also, between different points of the same polypeptide chain 
(intramolecular). 
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Figure 1.3. Possible interactions between keratin protein chains [137]. 
 
Keratin fibers, such as wool and human hair, consist of two major morphological 
parts: the cuticle layer which is composed of overlapping cells that surround the 
cortex, the inner part of the fiber. The cortex comprises spindle-shaped cortical 
cells that are separated from each other by a cell-membrane complex (Figure 
1.4.), which consists of non-keratinous proteins and lipids [137-141]. 
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Figure 1.4. Schematic diagram of a wool fiber showing the independent structures 
found in the cortical cells reprinted from CSIRO Textile & Fibre Technology. 
 
The cuticle cells comprise 10% of the total weight and are laminar with a 
rectangular shape forming a sheath of overlapping scales surrounding the cortex 
[139, 142, 143]. They are composed of three distinct layers showed in Figure 1.4. 
The outer resistant surface membrane is named epicuticle; the next layer is the 
exocuticle which is subdivided into two main layers (A and B) that differ in their 
cysteine content; the endocuticle is the cuticular layer nearest the cortex [137, 
140, 143, 144]. Keratin proteins can be roughly classified into two groups: the 
intermediate filament proteins (IFPs) and the matrix proteins. The most abundant 
are the IFPs also known as α-keratin that reside in the fiber cortex. They have a α-
helical secondary structure, are low in sulfur content and have an average 
molecular mass in the range of 40-60 kDa. The matrix proteins or γ-keratin are 
globular, have a low molecular weight and are noted for the high content in either 
cysteine, glycine and tyrosine residues. The ones with high sulfur content can be 
divided in high sulfur proteins (HSPs) or ultra-high sulfur proteins (UHSPs) 
depending on their cysteine content and have a molecular weight in the range of 
11-26 kDa. The high glycine-tyrosine proteins (HGTPs) have a molecular weight 
between 6 and 9 kDa [145-147]. 
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The matrix proteins function surround the IFPs and interact with them through 
intermolecular disulfide bonds [141]. The formation of the crosslinked IF-matrix 
composite is crucial in conferring to the α-keratin their high mechanical strength, 
inertness and rigidity [148]. The packing of the IFPs combined with the matrix 
proteins form the macrofibrils within the cortex [148, 149]. There is also another 
group of keratin proteins, the β-keratin. These form the majority of the cuticle and 
their function is to protect keratin fibers from physical and chemical damage. The 
β-keratin is difficult to extract and do not form especially useful reconstituted 
structures [149, 150]. For a better elucidation of readers a resume of the main 
structural properties of the studied proteins will be provided (Table 1.1.). 
1.2.1. Keratin-based biomaterials 
Keratins are extracted from the fibers through the use of chemicals to break the 
disulfide bonds. The IF and matrix proteins are converted into their non-
crosslinked forms by oxidation [149, 151-153] or reduction [149, 154-156], during 
which cystine is converted to either cysteic acid or cysteine, respectively. The free 
proteins extracted with denaturating solvents produce a solution that can be 
purified by filtration and dialysis. 
Oxidative extraction [151-153] with peracetic acid (CH3CO3H) or hydrogen 
peroxide (H2O2), e.g., yields keratins that are hygroscopic, non-disulfide 
crosslinkable, water-soluble and, susceptible to hydrolytic degradation at extremes 
pH values due to polarization of the backbone caused by the electron withdrawing 
properties of the cysteic acid. These characteristics lead to biomaterials that can 
degrade relatively fast in vivo, i.e. on the order of days to weeks. 
Reductive extraction [154-156] commonly uses dithiothreitol (DTT, 
HSCH2CH(OH)CH(OH)CH2SH) or 2-mercaptoethanol (2-Me, HSCH2CH2OH) with 
a protein extraction of approximately 80% [157]. Extraction with sodium disulfite 
(Na2S2O5) forms cysteine and Bunte salts residues, temporally modified S-sulfo 
group [131, 158, 159]. With this method the keratin extracted is about 30% of the 
total protein content of the original wool [160]. Reduced keratins are, less polar 
and as a consequence less soluble in water, more stable at extreme pH and, can 
be re-crosslinked through oxidative coupling of cysteine groups. This results in 
biomaterials that persist in vivo for weeks to months. 
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The interest of using keratin as a biomaterial in medical applications is based on 
several key properties that contribute to the overall physical, chemical and 
biological behavior of these biomaterials. Extracted keratin proteins have an 
intrinsic ability to self-assemble and polymerize into fibrous and porous films gels 
and scaffolds. The spontaneous self-assembly of keratin has been studied 
extensively at both microscale [161-163] and macroscale levels [164]. 
Furthermore, the presence of cell adhesion sequences, arginine-glycine-aspartic 
acid (RGD) and leucine-aspartic acid-valine (LDV) on the keratin protein derived 
from wool and hair, makes keratin biomaterials able to support cell attachment and 
growth [165, 166]. These are the same sequences found in several extracellular 
matrix (ECM) proteins [167, 168]. The processing of keratin protein solutions into 
derivatives physical states such as gels, films and scaffolds start to appear in the 
literature in 1972 [169-171], then the first study using a keratin biomaterial 
appeared wherein a vascular graft coated with keratin was successfully implanted 
into a dog for more than 200 days without thrombosis [172]. Since then, keratin 
have been studied for its application in biomaterials for wound healing [173-178], 
bone regeneration [179], hemostasis [180] and recently in peripheral nerve repair 
[181, 182]. 
1.2.2. Keratin films 
A stable aqueous solution of keratin was obtained after reductive extraction from 
wool fibers. The ability of this solution to self-assemble into films was described by 
Yamauchi et al. [183] and, the physicochemical properties and biodegradability of 
the solvent-cast keratin films were evaluated. Pure keratin films presented low 
mechanical strength but the addition of glycerol resulted in transparent films, with 
increased mechanical strength, flexible and biodegradable both in vitro (trypsin) 
and in vivo (subcutaneous implantation in mice) [183]. Furthermore, these films 
proven to promote and increased cell adhesion and growth when compared to 
collagen and glass [184]. Fujii et al. developed a new procedure for the extraction 
of keratin from human hair without a surfactant agent, with a protein extraction 
yield greater than 70% [185]. The developed films were effective on the controlled-
release of alkaline phosphatase (ALP) that retains its biological activity after 
incorporation into keratin films [185]. The same films were further used and, gauze 
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was coated with the translucid keratin film. This results in improved mechanical 
strength of the gauzes and, when applied to human skin, a reduced allergic 
reaction was observed [186]. Like many natural-derived biomaterials, keratin-
based ones present poor mechanical strength. As a consequence, several 
approaches for controlling the physical and biological properties have been 
studied such as, blend systems with natural [15, 187-190] and synthetic [160, 191] 
polymers, use of crosslinking agents [192] and new preparation techniques [158, 
186, 193]. Addition of chitosan to keratin forms strong and flexible films with 
improved swelling properties. Furthermore, the composite film demonstrated to be 
a good substrate for mammalian cell culture [189]. Lee at al. first reported keratin-
silk fibroin (SF) blend films. This study aimed to understand the interactions that 
occur between the two proteins and how they affect the overall properties of the 
biomaterials. The results indicated that addition of keratin induces the transition 
from random coil to β-sheet of the SF chains. It was consider that keratin plays a 
similar role of a polar solvent due to the abundant polar groups in its amino acid 
composition [188]. Moreover, the antithrombogenicity and biocompatibility of 
keratin-SF films was improved when compared to pure keratin and SF films [81]. 
In a different study, the properties of keratin-SF films were further studied and, it 
was described that keratin and SF interactions are not simply additive but the two 
proteins are able to establish intermolecular interactions like hydrogen bonding. 
Furthermore, degradation rates are controlled by blend composition. The 
knowledge and strength of the interactions as well the degradation rates allows the 
design of matrices with controlled-release properties [15]. In addition to natural 
biopolymers, keratin interaction with synthetic polymers has also been studied 
[160, 191]. The properties of keratin films blended with poly(ethylene oxide) (PEO) 
were described by Tonin et al. [160], it was concluded that at appropriate levels, 
keratin is able to inhibit PEO crystallization. Moreover, PEO interferes with the 
keratin self-assembly, inducing a more thermally-stable β-sheet secondary 
structure. The intermolecular interactions between keratin and polyamide 6 (PA6) 
have also been studied and, the results indicated that the addition of keratin 
improves the miscibility and hydrophilicity [191]. 
Another common technique to improve the mechanical strength is the use of 
crosslinking agents. Keratin films prepared by casting a reduced keratin solution, 
were chemically crosslinked with ethylene glycol diglycidyl ether (EGDE, C8H14O4) 
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and glycerol diglycidyl ether (GDE, C9H16O5) [192]. It was reported that keratin 
crosslinked films have similar mechanical properties and improved waterproof 
characteristics when compared to keratin-chitosan films previously described 
[189]. Furthermore, chemical crosslinking does not have detrimental effects on cell 
biocompatibility [192]. Improved mechanical properties can also be achieved by 
alternative fabrication techniques. Compression molding of S-sulfo keratin powder 
for the production of films was developed [158]. The mechanical properties of the 
films can be modulated by controlling the molding temperature and water content. 
The biocompatibility was also demonstrated by cell adhesion and proliferation onto 
the films [158]. Recently, Yang et al. described the use of keratin for layer-by-layer 
(LbL) self-assembly [193]. In this study, keratin extracted from wool is used either 
as a polyanion or polycation by adjusting the pH of the solution to fabricate 
multilayer films. Although the mechanical properties were not evaluated, it is clear 
that a multilayer film will possess an increased mechanical strength when 
compared to a unilayer film. Reichl et al. demonstrated two approaches for 
substrate coating: keratin precipitation with thricloroacetic acid (TCA, Cl3CCOOH) 
and casting a keratin nanosuspension. The latter presented improved cell growth 
in comparison to uncoated polystyrene or TCA coating [194]. 
1.2.3. Keratin sponges/scaffolds 
The ability of extracted keratin to self-assemble into three dimensional porous 
structures has led to their development as scaffolds for biomedical applications. 
Wool keratin sponges were first reported by Tachibana et al. [165]. The sponge 
scaffolds were fabricated by lyophilization of an aqueous keratin solution after 
controlled freezing. This resulted in sponges with homogeneous porous 
microstructures. Additionally, the sponges exhibited cell attachment and 
proliferation over a long-term cultivation period of 23-43 days [165]. 
The diameter and interconnectivity of the scaffolds pores is important for obtaining 
adequate cellular infiltration and nutrient delivery. Sponges with controlled pore 
size and porosity were developed by Katoh et al. [159] by means of S-sulfo keratin 
sponges prepared by a compression-molded/particulate leaching (CM/PL) 
technique. The sponges presented adequate mechanical properties and were 
water-insoluble [159]. In another study, a reduced keratin solution was mixed with 
CHAPTER I. Fibrous Protein-Based Wound Dressings: a Review 
22 
dried calcium alginate beads. After lyophilization and leaching, a keratin sponge 
with high porosity and interconnectivity was obtained, in addition to cellular 
adhesion and growth[168]. 
The presence of free cysteine residues within keratin sponges allows the 
immobilization of bioactive agents. Lysozyme was immobilized in a keratin sponge 
via disulfide and thioether bonds. Disulfide-linked lysozyme was released over a 
21-days period unlike lysozyme linked via thioether bonds that remains in the 
sponge up to two months. This study showed that the release properties from 
keratin sponges can be controlled by the selection of the crosslinker [195]. 
Functionalization of the active free cysteine residues in the keratin sponges can be 
achieved by chemical treatments with iodoacetic acid (ICH2CO2H), 2-
bromoethylamine (C2H6BrN) and iodoacetamide (ICH2CONH2), to produce 
carboxyl-, amino- and amide-sponges. These chemically-modified keratin sponges 
have been shown to mimic ECM proteins and, the large presence of active groups 
allows further hybridization with bioactive molecules. Tachibana et al. [179] 
demonstrated the hybridization of keratin sponges with calcium phosphate 
(Ca3O8P2). Two types of hybrids sponges were obtained by either chemically 
binding of calcium and phosphate or, by trapping commercially available 
hydroxyapatite particles within the modified keratin sponge. Both hybridized 
sponges supported osteoblasts cultivation and altered their differentiation pattern 
[179]. Keratin carboxy-sponges have also been functionalized with bone 
morphogenetic protein-2 (BMP-2). BMP-2 was confined within the modified keratin 
sponge, without protein loading into the surrounding media, which was 
accompanied by preosteoblasts differentiation and growth [196]. 
The in vivo biodegradation of keratin sponges, with bars shape, was assessed by 
subcutaneously implantation in adult rats [197]. It was showed a gradual decrease 
in the mass of the bars over the 18 weeks of study. On the contrary, the elastic 
modulus of the bars decrease abruptly indicating an internal change in the 
structure and shape of the keratin bars [197]. 
1.2.4. Keratin-based wound dressings 
The above described materials are latent wound dressings due to the cellular 
biocompatibility demonstrated. The cells used in the mentioned studies were 
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NIH3T3, L929 fibroblasts, MC3T3-E1 pre-osteoblasts, epithelial and mesenchymal 
human cells. In general, all have showed good cellular adhesion and proliferation 
on keratin materials in comparison to standard controls such as tissue culture 
plastic or other biomaterials like collagen. 
In the field of wound healing, several patents have been published using keratin 
materials as wound healing promoters [173-178]. Keratin powder used as an 
absorbent wound dressing showed the promotion of skin healing due to the 
release of keratin derivative peptides to the wound [176]. Crosslinked keratin 
powder, films and hydrogels showed significant proliferation of wound healing cell 
lines like microvascular endothelial cells, keratinocytes and fibroblasts. Moreover, 
incubation of keratin materials with lymphocytes (T cells) and activated 
lymphocytes showed, respectively, no proliferation and normal growth, indicating 
that keratin materials are non-immunogenic and, that the body’s normal cell-
mediated immune response is not inhibited by keratin materials. These were also 
applied to wounds on animals (rats) and humans, and it was observed a faster 
healing of the wounds treated with keratin materials and, in the human model with 
reduced pain [173, 174]. Water-soluble keratin peptides derived from an oxidative 
extraction from human hair, showed to be wound healing agents enhancing the 
proliferation of human dermal fibroblasts [175]. More recently, keratin derivatives 
obtained either by oxidative and reductive methods, were applied to burn wounds 
using animal and human models. The burn wounds treated with keratin materials 
showed a decrease in wound size and, accelerated wound healing. When applied 
to bleeding wounds, the keratin materials formed a physical seal of the wound site 
providing a porous scaffold for cell infiltration and granulation tissue formation 
compared to clotted blood [178]. Keratin was also effectively blended with other 
components to form new wound dressings. Keratin-collagen sponges were used in 
rats showing tissue compatibility and accelerated wound healing by stimulating cell 
proliferation and vascularization [198]. An analogue keratin-collagen sponge 
containing poly 2-hydroxyethylmethacrylate (PHEMA) was applied to burn wounds 
in rats. The composite showed healing promotion by allowing in vivo construction 
of tissue engineered epidermis [199]. In another recent study, keratin-gelatin used 
in full-thickness wounds in dogs promoted the healing due to the early presence of 
hair follicles, sebaceous gland and normal thickness of the epidermis [200]. 
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The immunogenicity/inflammation is another important parameter to be evaluated 
for wound dressing applications. The immunogenicity response of keratin-based 
materials was first evaluated by Ito et al. in which polyester mesh coated with 
keratin was implanted into the muscle of rabbits and dogs. The acute immune 
response was characterized as mild [180]. Keratin films extracted from rat hair 
implanted into rabbits degraded after two weeks showing a weak immunological 
reaction [180]. Yamauchi et al. reported that keratin films implanted into 
subcutaneous space of mice and retrieved after 18 weeks, showed less 
degradation than collagen IV and poly(lactic acid) (PLA). In addition, no adhesions 
or “abnormal” scar tissue was observed [183]. Keratins extracted from mousse 
and human hair and nails showed no rejection or allergic reactions using an 
animal model [185, 201]. More recently, keratin discs implanted subcutaneously 
into mice showed no inflammation or capsule formation. Moreover, no visibly 
degradation occurred after three months of implantation [150]. Keratin matrices 
implanted in the distal femur of the sheep, to study the biocompatibility and 
osseointegration, showed granulation tissue surrounding and infiltrating the 
implants followed by new bone formation [202], exploring the ability of keratin 
materials to be used in the field of bone regeneration. 
1.3. Elastin-structure and properties 
Elastin is an extracellular matrix (ECM) protein that is known for providing elasticity 
to tissues and organs. As a result, elastin is most abundant in organs that need to 
stretch and recoil like blood vessels, elastic ligaments, lungs and skin [203-205]. 
Elastin is synthesized by a variety of cells including smooth muscle cells, 
endothelial cells, fibroblasts and chondrocytes.  Elastin is an amorphous protein, 
with about 75% of hydrophobic amino acid residues (Gly, Ala, Val) and highly 
insoluble due to interchain crosslinks [206]. This protein is secreted as the 
precursor tropoelastin (≈ 72 kDa) that is soluble, non glycosylated and highly 
hydrophobic [207-209], which will be further converted into the insoluble elastin 
polymer. The tropoelastin molecule consist of two types of domains encoded by 
separate exons: hydrophobic domains with many Gly, Val, Ala and Pro residues 
which often occur in repeats of several amino acids, like Gly-Val-Gly-Val-Pro, Gly-
Val-Pro-Gly-Val and Gly-Val-Gly-Val-Ala Pro, and hydrophilic domains with many 
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Lys and Ala residues that correspond to the potential crosslinking domains of 
tropoelastin. 
The two predominant crosslinks of native elastin are desmosine and isodesmosine 
(Figure 1.5) each involving four lysine (Lys) residues that are crosslinked by lysyl 
oxidase. In the absence of this enzyme, tropoelastin tends to associate with 
glycosaminoglycan (GAG) due to the presence of α-amino groups in the elastin 
Lys residues. These residues offer positive charges for binding with negative 
charges of glycosaminoglycan. In the absence of lysyl oxidase, such electrostatic 
interaction could be important and prevent newly synthesized tropoelastin 
molecules from spontaneous random aggregation far from the cell surface [210, 
211]. 
N+
(CH2)3
H
C NHOC
(CH2)2 (CH2)2HC
CO
NH
CH
CO
NH
(CH2)4
CH NHOC
N+
(CH2)2 (CH2)2HC
CO
NH
CH
CO
(CH2)4
CH NHOC
NH
(CH2)3 CH CO
NH
Desmosine Isodesmosine
 
 
Figure 1.5. Intermolecular elastin crosslinks desmosine and isodesmosine formed 
from four lysine residues from two different tropoelastin molecules. 
 
The assembly of tropoelastin into a polymeric matrix is accompanied by the elastin 
binding protein (67 kDa) that releases tropoelastin into a pre-formed microfibrillar 
network, which serves as a scaffold for tropoelastin deposition [212-215]. The 
lysine residues become further modified by lysyl oxidase allowing crosslinking into 
a stable polymeric matrix. The biophysical properties crucial for the 
biochemical/physiological role of elastin in the body are elasticity [216-218], glass 
transition [219] and coacervation [220]. Three distinct mechanisms have been 
proposed to explain the elasticity of elastin and, despite the differences they share 
the argument that the driving force for the spontaneous recoil of stretched elastin 
results from a predominantly entropic mechanism [221-223]. The glass transition 
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temperature (Tg) is an important characteristic of polymers. Below the Tg a polymer 
will generally behave as a rigid/brittle material and, above Tg the polymer behaves 
as an elastomer or a viscous fluid. The glass transition temperature of elastin 
depends on its water content [224, 225]. In the dehydrate state, Tg is about 200 °C 
and at 30% of hydration is around 30 °C [226]. 
A second phase transition that can occur with elastin and elastin-based materials 
is coacervation. This is a reversible phase separation in which a protein in solution 
separates from the solvent after increasing the temperature [227, 228]. The non-
polar domains of elastin have been suggested to be responsible for the 
coacervation process through an entropic mechanism of hydrophobic association. 
The loss of entropy from the protein chains is compensated by the release of 
water [229, 230]. Elastin-based polymers lacking hydrophobic domains, e.g. those 
based on crosslinking domains cannot coacervate [231, 232].The onset 
temperature for coacervation is dependent on protein concentration, 
hydrophobicity (amino acid composition and distribution), pH and ionic strength of 
the solvent [229, 233-235]. Coacervation is a lower critical solution temperature 
(LCST) phenomenon which means that elastin forms ordered structures upon 
raising the temperature, unlike other proteins that are denaturated. It was reported 
that synthetic peptides based on hydrophobic sequences of elastin form fibrilar 
structures following coacervation [236, 237]; tropoelastin forms an open, string-like 
network of fibrils upon coacervation that, after overnight incubation above the 
coacervation temperature, the loose network became a compact aligned fibrilar 
structure [238]. For a better elucidation of readers a resume of the main structural 
properties of the studied proteins will be provided (Table 1.1.). 
1.3.1. Elastin-based biomaterials 
Elastin can be used in biomaterials in different forms including insoluble elastin, 
occurring in autografts, allografts and xenografts, decellularized extracellular 
matrix and in purified elastin preparations. By synthetic or recombinant techniques, 
repeated elastin-like sequences had also been used in biomaterials. Soluble 
elastin is obtained from the hydrolysis of insoluble elastin with oxalic acid 
(HO2CCO2H) or potassium hydroxide (KOH) [239, 240]. These treatments will not 
release tropoelastin from insoluble elastin, but will break peptide bonds yielding 
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soluble fragments of elastin and leaving the crosslinks intact [239, 240]. It has 
been shown that elastin soluble peptides influence signaling, chemotaxis, 
proliferation and protease release via the elastin receptor [241]. Therefore, 
biomaterials containing solubilized elastin may exert biological effects like 
increasing elastin synthesis. 
The self-assembly behavior of elastin was used to obtain different biomaterials like 
hydrogels [242, 243], films [244], nanoparticles [245], sponges [246] and 
nanoporous materials [247]. These forms can be further applied in cellular 
orientation, small-diameter blood vessels and drug or growth factor delivery 
systems. Solubilized elastin has been used as a coating to improve the 
biocompatibility of synthetic materials such as poly(ethylene glycol terephthalate) 
(PET) [248]. It was showed that the elastin coating on PET promotes endothelial 
cell growth maintaining their phenotypic character. This composite was further 
applied as prosthesis in a baboon arteriovenous shunt, to study the effect on acute 
thrombogenicity [249] and, excellent short-term blood-contacting properties were 
demonstrated. Mithieux et al. reported the chemical crosslinking of recombinant 
human tropoelastin to construct elastic sponges, sheets and tubes [243]. It was 
found that the properties of the materials were similar to the native elastin. 
Furthermore, cells proliferated on the constructs and they were well tolerated after 
in vivo implantation. Similar results were obtained elsewhere [250, 251]. High 
pressure CO2 have been used to produce porous elastin hydrogels [252, 253] and 
tropoelastin/elastin hydrogels [254] followed by a chemical crosslinking. When 
high pressure was applied it was observed an increase in the porosity, mechanical 
properties and swelling ratios. Additionally, due to the fabrication of large pores in 
the hydrogels, cellular proliferation and growth were substantially promoted. 
Elastin-like polymers (ELPs) and hybrids of the same with other proteins have 
been extensively studied. These offer the possibility to produce an assortment of 
biomaterials with specific functions. Urry et al. showed that the transition 
temperature, Tt, of polymers based on Val-Pro-Gly-Xaa-Gly)n could be manipulated 
by the amino acid Xaa. As an example, a more hydrophobic amino acid resulted in 
a lower Tt [255]. High molecular mass polymers are favorable for the preparation 
of functional materials. Urry et al. prepared various elastin-like materials by 
polymerization of elastin penpapeptides by chemical synthesis and recombinant 
expression system [256-258]. These were further applied in intervertebral disc 
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restoring in a rabbit model [259] and filling material for urinary incontinence, 
urinary bladder reconstruction and prevention of post-operative tissue adhesions 
[260]. ELPs are attractive as polymeric carriers for drug delivery, because they 
undergo an inverse temperature phase transition [233, 261]. Below Tt, ELPs are 
structurally disordered and highly solvated. Above Tt they undertake a sharp 
phase transition leading to desolvation and hydrophobic aggregation of the 
biopolymer, which is a completely reversible process when temperature is lowered 
below Tt. The delivery properties of ELPs containing doxorubicin (Dox, antitumor 
agent) were evaluated by applying mild hyperthermia to the tumor site [262] and, 
cytotoxicity of uterine sarcoma cells was enhanced by 20-fold. The mechanical 
properties of ELPs can be further improved by chemical crosslinking [263]. 
Silk-elastin like polymers (SELPs) comprise a class of genetically engineered 
biomaterials composed of amino acid motifs from two proteins, B. mori silk (Gly-
Ala-Gly-Ala-Gly-Ser) and elastin (Gly-Val-Gly-Val-Pro) [264]. By recombinant 
techniques, functional motifs can be introduced into SELPS that provides the 
control over gelation, crosslinking, biodegradation, biorecognition and stimuli-
sensitive [265], with applications in drug [266] and gene delivery systems [267, 
268]. Megeed et al. reported the controlled release of non-viral and viral genes 
from SELP hydrogel for cancer gene therapy. This resulted in increase 
transfections by a 1-3 order of magnitude, in a murine model of tumor breast 
cancer [267]. 
Elastin combined with fibrin [269] and collagen [270] has been prepared. Their 
potential was examined in vivo as a tympanic membrane [269] and a dural 
substitute [270]. Chemical crosslinking by carbodiimide reaction, of 
collagen/elastin materials improved the thermal stability [271] and decrease the 
enzymatic degradation rate [272]. Molecularly-defined scaffolds were obtained 
with collagen, elastin and chondroitin sulphate (CS) [273]. The scaffolds are 
biocompatible and the properties of the material are improved by the synergistic 
effect of each component. Incorporation of elastin on collagen-based vascular 
grafts increased the tensile strength and improved the viscoelastic properties 
[274]. Furthermore, higher contents of elastin promote cell adhesion and viability 
[275]. Calcification is a common problem associated to implants. The effect of 
collagen/elastin materials implanted in young Sprague Dawley rats, a sensitive 
calcification model, was evaluated [276, 277]. It was showed that collagen/elastin 
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reduced the calcification when compared to collagen material [276]. If solubilized 
elastin was used, no calcification was observed and angiogenesis was induced 
[277]. Electrospinning of collagen/elastin [278], collagen/elastin/gelatin [279] and 
poly(lactide-co-glycolide)(PLGA)/gelatin/elastin [280] resulted in scaffolds that 
support cellular attachment and growth. Electrospun polydioxanone-soluble elastin 
blends had been characterized for their used in vascular grafts [281]. Addition of 
elastin creates scaffolds that exhibited properties resembling that of pig artery and 
native human artery. Elastin was also found to be primary cause of cell-mediated 
immunosupression of the same materials [282]. 
1.3.2. Elastin-based wound dressings 
Elastin-based materials have been applied as skin substitutes to treat burn or 
chronic wounds. Scaffolds of type I collagen coated with elastin and applied to a 
full-thickness wound, contributes to dermal regeneration and reduce wound 
contraction [283]. The same type of dressings applied to a porcine excised wound 
model showed reduced wound contraction, improved tissue regeneration and 
absence of myofibroblasts when compared to control (skin substitute without 
collagen/elastin) [284]. Collagen/elastin dermal substitute with seeded fibroblasts 
cells, applied to the last wound model, was reported by Lamme et al. [285]. 
Fibroblasts seeded on collagen/elastin matrix survived and proliferated, reducing 
the migration/proliferation of unwanted subcutaneous fibroblasts into the wound. 
Furthermore, the degradation of the implanted dermal substitute was retarded, 
indicating a protective activity of the seeded fibroblasts. In another study, 
collagen/elastin membranes were grafted in a rat excised wound model to serve 
as a template for the formation of neo-dermis [286]. The results showed that the 
graft becomes populated and vascularised by cells from the wound bed and 
margin. The grafted collagen/elastin is digested and induces the formation of a 
tissue-layer, whit a dermis-like texture, in which the presence of elastin is essential 
[286]. 
Clinical trials were conducted to compare the conventional treatment (split-
thickness autograft) and a collagen/elastin dermal substitute in combination with 
an autograft. Skin elasticity was improved [287, 288] and other parameters like 
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rete ridges, basement membrane maturation and epidermal thickness were also 
improved by collagen/elastin dermal substitute [289]. 
The inflammatory response of collagen/elastin membrane was studied in vitro and 
in vivo using the chorioallantoic membrane (CAM) assay of the chick embryo as a 
model [290]. The results showed that the collagen/elastin membrane induces the 
activation of macrophages, angiogenesis and the formation of inflammatory tissue, 
which can result in a chronic wound. Hashimoto et al. reported the development of 
alginate wound dressings covalently bound hybrid laminin and elastin-derived 
peptides [291]. The hybrid peptides promoted the attachment of human dermal 
fibroblasts. When applied in vivo, in a rabbit ear skin defect mode, alginate 
dressings linked to elastin peptide showed significantly greater ephitelialization 
and a larger volume of regenerated tissue in comparison to alginate-laminin 
dressing. The proteolytic digestion of elastin induced elastic fiber deposition and 
synthesis when injected in the skin of nude mice [288]. This result shows the 
importance of soluble elastin peptides on physiological events. 
The commercially available wound dressing Matriderm® composed of collagen and 
elastin was evaluated as a dermal substitute for the treatment of severe hand 
burns [292] and for the reconstruction of joint-associated defects [293]. Full range 
of motion was achieved in both cases with no blisters and scars. In a recent study, 
new SF/elastin scaffolds were evaluated using a human wound exudate [294]. 
Degradability of the scaffolds under wound exudate showed that when applied to 
the wounds, necrosis can be avoided by competition. In addition, the scaffolds 
supported adhesion and proliferation of human skin fibroblasts. 
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Table 1.1. Main properties of the studied proteins 
 
 Silk fibroin Keratin Elastin 
Protein 
 
Fibrous Fibrous Fibrous 
Secondary 
conformation 
 
β-sheet α-helix Tropoelastin 
(random coil) 
Molecular 
mass (kDa) 
 
Light chains (≈26 kDa) 
Heavy chains (≈390 kDa) 
IFPs (40-60 kDa) 
Matrix (6-26 kDa) 
Tropoelastin 
(≈72 kDa) 
Major 
residues 
Glycine (44%) 
Alanine (29%) 
Serine (11%) 
 
Cysteine (9%) Glycine (32%) 
Alanine (24%) 
Proline (12%) 
Valine (11%) 
 
Source Silk fibers (silkworm, spider 
webs, draglines) 
 
Wool, hair, nails, 
feathers 
Connective tissues, 
ligaments 
Solvents LiBr 9 M, 60 °C, 4 h  
CaCl2-CH3CH2OH-H2O, 80 °C, 
2 h 
Reducing (DTT), 
Oxidant agents 
(H2O2) 
HO2CCO2H  
KOH 
1.4. Wounds and wound healing process 
A wound, according to the Wound Healing Society, is the result of “disruption of 
normal anatomic structure and function” [295]. Based on the nature of the repair 
process wounds can be classified in acute wounds and chronic wounds. Acute 
wounds usually heal completely within 8-12 weeks with minimal scaring [296]. The 
primary causes of acute wounds include mechanical injuries and burns. 
Chronic wounds fail to heal in the expected time frame and persist beyond 12 
weeks, with the possibility to reoccur. A chronic wound does not heal properly 
because the orderly sequence of events is disrupted at one or more stages of the 
healing [297-299]. These types of wounds are produced as a result of specific 
diseases such as diabetes, tumors and severe physiological contaminations [300, 
301]. Chronic wounds include decubitus wounds (pressure sores) and leg ulcers. 
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1.4.1. Principles of wound healing 
Wound healing is a specific biological process related to the general phenomenon 
of growth and tissue regeneration. There are several reports describing the 
various biological and physiological stages of healing [300, 302, 303]. Wound 
healing process can be summarized into five independent and overlapping stages 
including hemostasis, inflammation, migration, proliferation and maturation (Figure 
1.6).These events involve numerous cellular responses, with its respective impact 
on the healing process, which are described in Table 1.2. 
 
 
 
Figure 1.6. The phases of cutaneous wound healing (Reprinted from [304]). 
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Hemostasis and inflammation 
 
This stage occurs soon after the damage of the skin, which is often accompanied 
by bleeding. This activates hemostasis through fibrinogen that leads to the 
coagulation of exudates (blood without cells and platelets) and, together with the 
formation of a fibrin network, produces a clot in the wound that stops the bleeding. 
Inflammation occurs almost simultaneously with hemostasis, from within a few 
minutes to 24 h and lasts for about 3 days, involving both cellular and vascular 
responses. 
 
Migration 
 
The migration phase involves the movement of epithelial cells and fibroblasts to 
the injured area to replace damaged and lost tissue. These cells regenerate from 
the margins, rapidly growing over the wound under the clot followed by epithelial 
thickening. 
 
Proliferation 
 
This phase occurs almost at the same time or just after the migration. This is 
characterized by the formation of granulation tissue and collagen is synthesized by 
fibroblasts giving strength and form to the skin. 
 
Maturation 
 
This phase is also named remodeling phase and involves the formation of cellular 
connective tissue and strengthening of the new epithelium which determines the 
nature of the final scar. 
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Table 1.2. Type of cells involved in the wound healing process 
 
Cell type Function in wound healing 
Platelets  
 
 
 
- Involved in thrombus formation 
- Rich source of inflammatory mediators including cytokines 
- Major initial stimulus for inflammation 
Neutrophils  
 
 
- First cells to infiltrate the wound 
- Phagocytosis and intracellular killing of invading bacteria 
Monocytes  
(macrophages) 
 
 
 
- Phagocytosis and killing of invading bacteria 
- Clear debris and necrotic tissue 
- Rich source of inflammatory mediators including cytokines 
- Stimulate fibroblasts division, collagen synthesis and angiogenesis 
Lymphocytes 
 
 
- Not clearly defined 
- May produce cytokines in certain types of wounds 
Fibroblasts  - Produce various components of the ECM including collagen, 
fibronectin, hyaluronic acid, proteoglycans 
- Synthesized granulation tissue 
- Help to reorganize the “provisional” ECM 
1.4.2. The proteolytic environment of chronic wounds 
Wound fluid is a key component in all stages of wound healing, irrigating the 
wound continuously and keeping it moist [305]. Exudate supplies nutrients and 
leukocytes to the wound which helps to control bacteria and infection. In chronic 
wounds there is excessive amount of exudate that can cause maceration of 
healthy tissue around the wound [306]. In addition, exudate from chronic wounds 
differs from that of acute wounds with relatively higher levels of tissue destructive 
proteases namely metalloproteinases (MMPs) and polymorphonuclear elastase 
(PMN) [307]. Exudate obtained from chronic wounds has shown to contain human 
neutrophil elastase (HNE), Cathepsin G (CG), urokinase-type plasminogen 
activator (uPA) and gelatinase (MMP-9) [308, 309]. Herein, it will be described the 
role of human neutrophil elastase (HNE) in the next section. 
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1.4.3. Wound dressings 
Early humankind employed many different materials from the natural surroundings 
to treat the wounds. These include natural fibers such as wool and linen, honey, 
eggs and animal fat [310, 311]. Continuous development result in the development 
of wound dressings with improved performance. Wound dressings can be 
classified covering different aspects [312, 313] as follows: 
i) Passive dressings such as gauze and tulle that act to cover the wound. Gauze 
can stick to the wound and disrupt the wound bed when removed thus, are 
suitable for minor wounds. Tulle is as greasy gauze suitable for minimal to 
moderate exudates; 
ii) Interactive dressings contain polymeric films and foams and hydrogels which 
are transparent and permeable to water and atmospheric oxygen. These are 
suitable for heavily exudating wounds (foams and hydrogels) and good barriers 
against permeation of bacteria to the wound environment; 
iii) Bioactive dressings such as hydrocolloids, alginates, collagen and hydrofibers 
produced from a variety of biopolymers such as collagen, hyaluronic acid (HA), 
chitosan, alginate and elastin [314, 315]. These types of dressings have the ability 
to modify facing the physiological condition of the wound promoting the healing. 
The bioactive normally contain active ingredients such as antimicrobials and 
antibiotics [316] or, can target the reduction of high proteases levels on the wound 
[287, 317]. Depending on the wound type and its healing, one or more different 
types of dressings can be applied. The desirable properties of wound dressings, 
and their impact on wound healing, are described in Table 1.3. 
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Table 1.3. Properties of wound dressings and their impact on healing 
 
Properties Impact on wound healing 
Debridement  
(wound cleansing) 
- Enhances migration of leukocytes into the wound bed 
- Supports accumulation of enzymes 
 
Provide and 
maintain moist 
- Prevents desiccation and cell death 
- Promotes epidermal migration, angiogenesis and connective 
tissue synthesis 
- Supports autolysis by rehydration of desiccated tissue 
 
Absorption  
(blood and excess of 
exudate) 
 
- Excessive exudate blocks the proliferation and cellular activity and 
degrades connective tissue, factors that delay the healing 
- Causes maceration of healthy tissue surrounding the wound 
Permeable  
(water, vapor, air) 
 
 
- Permeability to water vapor controls the management of exudate 
- Low tissue oxygen levels stimulate angiogenesis 
- High tissue of oxygen stimulates ephitelialization and fibroblasts 
Bacterial barrier 
 
 
 
- Infection prolongs the inflammatory phase and delays collagen 
synthesis, inhibits epidermal migration and induces additional 
tissue damage 
Provide thermal 
insulation 
 
- Normal tissue temperature improves the blood flow to the wound 
bed and enhances epidermal migration 
Low adherence - Adherent dressings may be painful and difficult to remove causing 
further tissue damage 
1.4.4. Mechanism-based wound dressings 
The knowledge of the biochemical events associated with pathogenesis of the 
chronic wound result in the development of interactive wound dressings with 
specific activities including the regulation of HNE levels on the wound. Edwards et 
al. reported the inhibition of elastase by cotton fabric bounded to a synthetic 
elastase inhibitor [318]. This was assayed in commercial HNE and in a chronic 
wound exudate and, inhibition with cotton-inhibitor was similar to that obtained with 
free inhibitor. Incorporation of oleic acid albumin formulations into positively and 
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negatively charged cotton wound dressings also shown to inhibit HNE under 
aqueous conditions mimicking the chronic wound [319]. Modification of cotton 
dressings either by blending with alginate [320] or by phosphorylation [321] and 
sulfonation [322] also showed to effective on the control of HNE activity. Cotton/ 
alginate dressings are a suitable matrix for the release of an elastase inhibitor 
[320]. Phosphorylated cotton wound dressings were prepared to sequester 
elastase from wound exudate, through a cationic uptake binding mechanism 
involving salt bridge formation of the positively charged amino acids side chains of 
elastase with the phosphate counterions of the wound dressing fiber. These had 
shown to lower elastase activity by 40-80% more effectively than unmodified 
cotton dressings [321]. Other dressings such as collagen, oxidized regenerated 
cellulose (ORC) and blends of collagen/ORC have shown to bind and inactivate 
HNE. HNE binds to collagen by electrostatic interactions and, the negatively 
charged groups of ORC interact with the arginine side chains of HNE [323]. 
PROMOGRAN is a commercial available interactive wound dressing composed of 
collagen and ORC that physically modifies the wound microenvironment, and 
thereby promotes granulation tissue formation and stimulates wound repair [324]. 
Recognition sequences of elastase, Val-Pro-Val, were applied to cotton dressings 
with Gly used as a linker of the recognition sequence to the cotton cellulose. 
Solutions of elastase that were treated with Val-Pro-Val-Gly cellulose cotton 
gauze, demonstrated reduced elastase activity. This study demonstrates the use 
of elastase recognition sequences as sequestering agents of elastase when 
attached to cotton fibers and constitutes a model for the design of peptide-
cellulose analogs in dressing fibers for chronic wounds [325]. Recently, silk 
fibroin/keratin films incorporating a small peptide HNE inhibitor, based on the 
reactive-site loop of Bowman-Birk inhibitor (BBI) protein, have shown to reduce 
elastase activity through the controlled release of inhibitor from the films [326]. 
1.5. Human neutrophil elastase (HNE) 
Human neutrophil, or leukocyte, elastase (HNE, HLE) is a serine-protease of the 
chymotrypsin family stored in the azurophilic granules of polymorphonuclear 
neutrophils (PMNs). The serine proteases are characterized by the presence of a 
serine group in their active site [327] that is completed by histidine (His) and 
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aspartic acid (Asp) amino acids. These residues are widely separate in the primary 
sequence but are brought together at the active site of the enzyme in its tertiary 
structure. By convention, the catalytic triad for chymotrypsin-like serine proteases 
is numbered as Asp102, Ser195, His57 (Figure 1.7). 
 
 
Figure 1.7. Ribbon representation of the three-dimensional structure of HNE (PDB 
code 1B0F). The side chains of the amino acids of the catalytic triad are shown in 
red. 
 
The hydrolysis by serine proteases follows and acylation-deacylation mechanism 
(Figure 1.8). The first step of the catalytic reaction, after the formation of the 
enzyme-substrate or Michaelis complex, is the acylation step; that starts with the 
attack of the catalytic serine on the carbonyl group of the cleavable amide bond 
and the transfer of the hydroxyl hydrogen of the serine to the histidine (1). This 
leads to the release of the C-terminal end of the substrate and the formation of a 
covalent intermediate (i.e. the acyl enzyme) between the enzyme and the N-
terminal part of the substrate (2). The second step of the reaction (termed 
deacylation) starts with the attack of a nucleophilic water on the substrate carbonyl 
and (3) ends with the release of the N-terminal part of the substrate, when the 
catalytic triad is regenerated (4). The nitrogen atoms of residues Gly193 and 
Ser195 stabilize the so-called oxyanion hole. 
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Figure 1.8. Reaction mechanism of serine proteases. 
 
The nomenclature for describing the interaction of a substrate with a protease was 
introduced by Schechter and Berger in 1967 [328]. In this system, the binding site 
for a polypeptide substrate on a protease is visualized as a series of subsites, 
where each subsite interacts with one amino acid of the substrate. The substrate 
amino acid residues are called P (for peptide) and, the subsites in the protease are 
called S (for subsite). S subsites on the protease accommodate P residues in the 
substrate N-terminal side upstream of the scissile bond whereas, S’ subsites 
accommodate P’ residues on the substrate C-terminal side, downstream of the 
cleavage site. 
X-ray analysis of the complex between HNE and natural and synthetic substrates 
[329-331] indicated that S1-S4 pockets are mostly made of hydrophobic amino 
acids [332, 333]. For this reason, substrates with small, hydrophobic side chains at 
P1 are effectively cleaved by HNE with the preference for valine (Val) over alanine 
(Ala) or phenylalanine (Phe). Substrates with isoleucine (Ile) [334] and methionine 
(Met) can also be cleaved but, oxidation of Met decreases the affinity of HNE 
[335]. The activity of HNE increases with the length of synthetic substrates, 
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indicating that HNE has an extended substrate binding site [329, 336]. 
Consequently, HNE substrate specificity depends not only on the nature of the P1 
amino acid, but also on secondary interactions with S and S’ subsites. The main 
characteristics of HNE are resumed in Table 1.3. 
 
Table 1.3. Characteristics of human neutrophil elastase 
 
Properties HNE 
Length 
 
218 residues 
Molecular mass (kDa) 
 
29-33 
Isoelectric point (pI) 
 
≈10.5 
Nº. glycosylation sites 
 
2 
Nº. disulfide bridges 
 
4 
Optimal pH 
 
8.0-8.5 
Substrate specificity 
 
 
Small hydrophobic residues at P1 
(Val, Ala, Met, Ile, Leu, Ser) 
Source 
 
 
Neutrophil, monocyte, mastocyte, 
eosinophil 
Endogenous inhibitors 
α2-Macroglobulin 
α1-PI/MNEI/PI9 
SLPI/Elafin/pre-elafin 
1.5.1. Biological functions  
HNE is expressed by neutrophils (PMNs), blood borne phagocytic cells, which act 
as a first line of defense against invading pathogens [337]. However, when the 
activity of neutrophil-derive proteases is excessive and/or prolonged, they can 
mediate tissue damage associated with chronic inflammatory diseases such as 
periodontal disease, rheumatoid arthritis, adult respiratory distress syndrome, 
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cystic fibrosis and chronic wounds [309, 338, 339].  HNE has broad substrate 
specificity capable of degrading the components of the extracellular matrix (ECM), 
remodeling damage tissues and can facilitate neutrophil migration into or through 
tissue [340]. HNE may also degrade critical soluble factors such as platelet-
derived growth factor [341, 342] and cell surface receptor proteins [343-345]. HNE 
regulates inflammatory responses: induces degradation of cytokines, degrades 
chemokines, stimulates macrophages and inhibits lymphocyte migration [346, 
347]. 
In an acute wound environment, the activity of HLE is regulated by endogenous 
inhibitors of the serpin (α1-PI, MNEI, PI9), chelonianin (SLPI, elafin) families, and 
to a lesser extent by the polyvalent protease inhibitor α2-macroglobulin. The 
serpins are high molecular weight inhibitors (40 to 50 kDa: 350-500 amino acids) 
that fold into a conserved, metastable structure and act as suicide substrate-like 
inhibitors using their reactive centre loop (RCL) [348, 349]. The exposed serpin 
reactive centre loop acts as a pseudosubstrate for the target protease forming a 
reversible, non-covalent Michaelis complex. Conformational changes results in the 
entrapment of the covalent inhibitory complex in which both molecules are 
inactivated. During infection and /or high levels of HNE the activity of these 
inhibitors is supplemented by the activity of secretory leukocyte protease inhibitor 
(SLPI, 11.7 kDa) and elafin (9.9 kDa) that are non-glycosylated proteins, produced 
by epithelial cells and cells of the immune system. In chronic wounds the 
continuous activation of inflammatory cells is followed by the release of large 
quantities of proteases which inactivate the inhibitor defense. Therefore, there has 
been considerable interest in the design of HNE inhibitors that may restore the 
normal levels of this enzyme in the above diseases. In addition to natural or 
engineered inhibitors proteins with high molecular masses, it was observed an 
increase in the research of both peptide-based and non-peptide small inhibitors 
compounds [350]. 
1.6. Bowman-Birk Inhibitor (BBI) 
The Bowman-Birk inhibitors (BBI) are bi-headed serine proteinase inhibitors found 
in various plants of the Fabaceae family [351]. These were first isolated from 
soybean by Bowman [352] and then characterized by Birk [353]. These proteins 
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have a low molecular weight (6 – 9 kDa) and are characterized by the presence of 
seven disulphide bridges which allow the formation of a symmetrical structure 
comprising two independent heads located at opposite sides of the molecule 
(Figure 1.9). Each head is made of a tricyclic domain in which the functional 
reactive site loop is located. Loop I typically inhibits trypsin and loop I’ 
chymotrypsin [354-357]. 
 
 
Figure 1.9. Complete covalent structure of the Bowman-Birk inhibitor protein 
(assumed from Birk [358]). Amino acids at the trypsin-inhibitory site are shown as 
solid black circles and, the amino acids at the chymotrypsin-inhibitory site are 
shown as white circles; available carboxylic acid moieties are marked in grey. 
 
The interaction of BBI with serine proteases occurs via a well-defined disulfide 
linked short beta-sheet region which generates a non-covalent complex that 
renders the serine protease inactive [359]. The conformation of the reactive site 
loop is complementary to the active site of the protease inhibited and allows BBI to 
bind tightly to the protease [354]. Upon complex formation between BBI and 
protease, BBI is cleaved very slowly [360]. The inhibition kinetics of human 
neutrophil elastase (HNE) by BBI occurs in two steps: the first step involved a 
rapid interaction between BBI and HNE to form BBI-HNE complex with a inhibition 
constant (Ki) of 28 nM, and in the second step the BBI-HNE complex underwent a 
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slow conversion/rearrangement to a tighter-binding BBI-HNE complex with a Ki of 
2.3 nM [361]. BBI-derived synthetic peptides have previously demonstrated to 
retain the inhibitory activity of the complete protein [359, 362, 363]. The structure 
of the peptides is based on the short disulfide bonded β-hairpin motif that forms 
the reactive site loop of the BBI protein. This loop adopts the same conformation 
as that of a bound peptide substrate [364, 365]. The primary contact region 
contains the scissile peptide bond P1-P1’. The specificity of the inhibition depends 
on the sequence of the reactive site, with P1 residue dominating the specificity 
which typically reflects the substrate preference of the target enzyme [366, 367]. 
Figure 1.10 represents the typical amino acid sequence of the nine-residue loop 
disulfide-linked of BBI. 
 
 
 
Figure 1.10. The amino acid sequence of the core disulfide-linked reactive site 
sequence form BBI. Xaa represents any amino acid. 
 
In order to retain the canonical inhibition motif, there are some structural 
requirements for BBI-peptides. These include covalent cyclization given by the 
disulfide bond at P3-P6’. Removal of this bond resulted in loss of inhibition [368-
370]. A cis-Pro (cis-proline) in the P3’ position which is absolutely conserved in all 
BBI proteins [371]. Finally, an extensive intramolecular hydrogen-bond network 
given by, the main-chain to main-chain hydrogen bond between P2 and P1’, which 
is instrumental in projecting the P1 side-chain outwards for the primary interaction 
with the enzyme [371]. BBI-peptides were further optimized for the inhibition of 
HNE using a combinatorial approach [362]. A peptide library was created with 
variations at P4, P1 and P2’ and, the consensus sequence had norleucine (Nle), 
alanine (Ala) and isoleucine (Ile), respectively, with a Ki of 65 nM [362]. BBI 
peptides are competitive inhibitors because they bind in the same manner as 
substrates. They are generally slowly hydrolyzed by the enzymes they inhibit 
[372]. The susceptibility to hydrolysis is sequence dependent and does not 
correlate with inhibitory potency [362, 370, 371, 373, 374]. Hydrolysis of the 
peptides results in the loss of inhibitory activity [368]. 
Cys Thr/Ala Pro/Ala Xaa Ser/Ala Xaa Pro Xaa Cys 
P1 
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1.7. Final remarks and research objectives 
This review has considered the different types of wounds and the effective 
parameters of healing process. Wounds can be classified in acute that heal in the 
expected time frame and chronic wounds, which fail to heal because the orderly 
sequence of events is disrupted at one or more stages of the healing process. 
Exudates from chronic wounds have shown to contain high levels of destructive 
proteolytic enzymes such as metalloproteases and human neutrophil elastase, 
which can delay the healing and cause maceration of healthy tissue around the 
wound. These enzymes are normally regulated by endogenous inhibitors that are 
inactivated by high levels of proteolytic enzymes. Therefore, there is a concern for 
the development of new inhibitors that can be applied to chronic wounds. 
Furthermore, wound dressings with this specific action have also been developed. 
Fibrous proteins such as silk fibroin, keratin and elastin have the ability to self-
assemble into various physical states. These have shown to undergo materials 
with improved mechanical strength, control of morphology and surface 
modifications options, allowing their application in controlled delivery systems and 
tissue engineering. Furthermore, wounds treated with these materials have shown 
to promote the healing by enhanced cellular proliferation, growth and 
differentiation and, reduced inflammation when applied to in vivo models.  
 
The aim of this work, based on these exceptional characteristics, was the 
development of new protein materials to be used as wound dressings with the 
specific target of controlling high levels of elastase found on chronic wounds. 
Protein dressings (films and scaffolds) were developed by blend systems: silk 
fibroin/keratin and, for the first time, silk fibroin/elastin. The reduction of elastase 
levels was accomplished by the incorporation of new elastase inhibitors peptides 
into the materials. The physical, chemical and biofunctional properties of these 
materials were evaluated in the context of wound healing needs. 
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CHAPTER II 
 
Materials and methods 
2.1. Materials 
Silk cocoons from Bombyx mori were donated from “Sezione Specializzata per la 
Bachicoltura” (Padova). Wool fabric was provided by Albano Antunes Morgado 
Lda (Portugal). 
2.2. Reagents 
Unless otherwise stated, all the chemical reagents used in the experimental 
results were purchased from Sigma-Aldrich (Spain). They presented analytical 
purity and were not submitted to further purification. 
The inhibitor peptides used herein were synthesized by JPT Peptide Technologies 
GmbH (Germany). The NIH 3T3 cell line (mouse embryonic fibroblasts) was 
purchased from the European Collection of Cell Cultures (ECACC) and BJ5ta cell 
line (telomerase-immortalized human normal skin fibroblasts) was purchased from 
the European Collection of Cell Cultures (ECACC). Wound exudate was kindly 
supplied by Technical University of Graz (Austria).  
2.3. Preparation of stock solutions 
2.3.1 Silk fibroin 
Silk fibroin (SF) was purified from its sericin content as previously described [15]. 
The cocoons were cut, cleaned from debris and larvae and autoclaved for 30 
minutes at 120 °C. SF was then thoroughly washed wi th distilled water and dried 
overnight at room temperature. SF solutions were prepared by dissolving 
degummed silk fibers in 9.6 M lithium bromide (LiBr) solution at 60 °C for 3 h. The 
resulting solution was filtered, and dialyzed against distilled water until complete 
removal of salts, using cellulose tubing (molecular-weight cut-off of 12000-
14000 Da). The regenerated silk fibroin solution was either stored at 4 °C or 
freeze-dried. 
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2.3.2. Keratin 
Lipids were removed from wool fabric using an organic solvent extraction 
procedure. Wool fabric was cut in small pieces and incubated with ethanol 100% 
(CH3CH2OH) 1:20 (w/v) for 2 h, with agitation, at room temperature. The 
supernatant was removed and a mixture of 1:2 (v/v) methanol/chloroform 
(CH3OH/CHCl3) was added to the fabric. This mixture was incubated 24 h, with 
agitation at room temperature. The delipided wool fabric was washed and dried for 
further applications. Two solvent systems were used for the extraction of keratin. 
They will be explained here and, the type of extraction used will be stated in 
further sections. 1. Keratin (K) solutions were prepared by immersing delipided 
wool in a solution containing 8 M urea (NH2CONH2), 0.2 M sodium dodecyl sulfate 
(SDS, CH3(CH2)11OSO3Na) and 0.5 M sodium disulfite (Na2S2O5). The mixture 
was heated to 100 °C for 30 min. 2. Delipided wool was dissolved in a solution 
containing 0.1 M Tris-HCl buffer (Trizma/Hydrochloric acid, NH2C(CH2OH)3/HCl), 
pH 9.0, 8 M urea and 0.1 M DL-dithiothreitol (DTT, HSCH2CH(OH)CH(OH)CH2SH) 
at 50 °C for 24 h in a shaker bath. The solutions w ere filtered and dialyzed against 
distilled water using cellulose tubing (molecular-weight cut-off of 12000-14000 Da). 
The regenerated keratin solutions were either stored at 4 °C or freeze-dried. 
2.4. Preparation of blended systems 
2.4.1. Films 
Protein films were prepared by blends of silk fibroin and keratin (SF/K) by solvent 
cast evaporation. Keratin and silk fibroin solutions (10 ml of final volume) were 
blended in the ratios of 80/20, 60/40 and 40/60 of SF/K. The blends were cast in 
plastic Petri dishes with a circular area of about 40 cm2 and dried at room 
temperature. The controls are 100SF and 100K. 
Freeze-dried keratin and silk fibroin were dissolved in formic acid (HCOOH) to 
prepare 1% (w/v) solutions. The solutions were blended in the ratios of 75/25, 
50/50 and 25/75 of SF/K. The blends were cast in plastic Petri dishes with a 
circular area of about 40 cm2 and dried at room temperature. The controls are 
100SF and 100K. The resulting films were 0.03 mm in average thickness. 
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In order to induce the transition of SF from random coil to β-sheet structure and 
consequently insolubility, the films were immersed in 90% (v/v) methanol solution 
for 30 minutes and then washed in distilled water and air dried. Unless otherwise 
stated, all films used were submitted to this treatment. 
2.4.2. Scaffolds 
Protein scaffolds were prepared by blending silk fibroin with soluble elastin 
(SF/EL) and subsequently lyophilized. Soluble elastin (EL) from bovine neck 
ligament was dissolved in distilled water to prepare EL solution. SF and EL were 
mixed to prepare blends of 100/0 SF/EL, 80/20 SF/EL and 50/50 SF/EL. The 
solutions were cast on 96-well plates and frozen at -20 °C for 2 days and freeze 
dried for 2 days to remove the solvent completely. To induce the transition of SF 
from random coil to β-sheet structure and consequently insolubility, sponges were 
immersed in 90% (v/v) methanol solution for 30 minutes and then washed in 
distilled water and air dried. Unless otherwise stated, all scaffolds used were 
submitted to this treatment. 
2.4.2.1. Crosslinking reaction 
SF/EL scaffolds were further crosslinked with Genipin (GE, C11H14O5). Genipin is 
obtained from geniposide, via enzymatic hydrolysis with β-glucosidase. 
Geniposide is isolated from the fruits of Genipa Americana and Gardenia 
jasminoides Ellis, and constitutes for about 4-6% of dried fruit. Earlier studies 
indicated the formation of dimmers of genipin in the presence of glycine, which 
suggested that genipin could be used to covalent crosslink of proteins containing 
primary amines [375]. Since then it has been used to crosslink collagen [376], 
gelatin [377], chitosan [378] and silk fibroin [45, 294]. The major advantage of 
genipin is a lower cytotoxicity when compared to the widely used glutaraldehyde 
(OHC(CH2)3CHO) [379, 380]. The mechanism of interaction of genipin with 
proteins is similar to that observed for amino-group containing compounds (Figure 
2.1). This reaction starts with an initial nucleophilic attack to the C3 carbon of 
genipin from a primary amine to form an intermediate aldehyde group. The 
opening of the dihydropyran ring is followed by the attack on the resulting 
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aldehyde group by the secondary amine formed in the first step of the reaction. A 
heterocyclic compound of genipin linked to both lysine and argine residues of SF 
and elastin is formed. An inherent phenomenon of genipin crosslinking is the 
formation of blue pigments obtained by the oxygen radical-induced polymerization 
of genipin, and dehydrogenation of the intermediate compounds, resulting from the 
ring-opening of genipin [381, 382]. 
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Figure 2.1. Crosslinking reaction of genipin with biopolymers containing free 
amine groups (NH2). 
2.4.2.2. Degree of crosslinking 
The cross-linking degree was determined by the ninhydrin (C9H6O4) assay [383, 
384]. The reaction of ninhydrin with primary amino groups forms a purple dye 
named Ruhemann’s purple (λ=570 nm, ε=22000) [383]. The reaction involves a 
nucleophilic-type displacement of an OH group of ninhydrin hydrate by a 
nonprotonated amino group. The products of the reaction are carbone dioxide and 
an aldehyde.  
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Figure 2.2. Mechanism of reaction of ninhydrin with compounds containing free 
amine groups (NH2). 
 
The concentration of free amine (NH2) groups in the sample was determined from 
a standard curve of glycine (NH2CH2COOH) concentration vs absorbance. SF/EL 
scaffolds prepared without genipin were used as control materials. The degree of 
crosslinking was determined by equation 2.1. 
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Equation 2.1. Degree of crosslinking where“nc” and “c” are respectively, the mole 
fraction of free NH2 in non crosslinked and crosslinked samples. 
2.5. Characterization techniques 
2.5.1. Amino acid analysis 
The amino acid composition of silk fibroin, keratin and elastin samples was 
determined after acid hydrolysis with 6 N HCl, at 105 °C for 24 h, under vacuum. 
Free amino acids analyzed by HPLC according to the AccQ-Tag Method (Waters). 
The eluate was detected at 254 nm. Samples were analyzed in duplicate (error: 
± 2 %). The quantitative amino acid composition, expressed as mol % for each 
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amino acid, was determined by external standard calibration (Amino Acid 
Standard H, Pierce). 
2.5.2 SDS-PAGE 
SDS-PAGE was carried out using the Mini-PROTEAN 3 Cell system from Bio-
RAD. The resolving gels (15 % acrylamide of about 0,75 mm thickness) were run 
at a constant voltage (170 V) and prepared according to the method described by 
Laemmli [385]. Proteins were visualized by Coomassie Brilliant blue G 250 
staining using Phosphorylase b (97 kDa), Albumin (66 kDa), Ovalbumin (45 kDa), 
Carbonic Anhydrase (30 kDa), Trypsin inhibitor (20.1 kDa) and α-lactalbumin 
(14.4 kDa) for calibration. 
2.5.3. Fourier transform infrared (FT-IR) spectroscopy 
FT-IR spectra of SF/K films were measured with a Nicolet FT-IR Nexus 
spectrometer (Thermo Scientific), equipped with a ZnSe ATR cell (Smart 
Performer). FT-IR spectra of SF/EL scaffolds were measured with a Perkin-Elmer 
(Spectrum One FTIR) spectrometer with a ZnSe ATR cell. When stated, 
deconvolution of Amide I band was performed using Origin software (OriginLab 
Corporation, MA, USA). 
2.5.4. Differential scanning calorimetry (DSC) 
Thermal analysis was performed to both SF/K films and SF/EL scaffolds with a 
DSC-30 instrument (MettlerToledo), from room temperature to 120 °C, at a heating 
rate of 10 °C/min, and kept at 120 °C for 10 min, t o induce dehydration of samples. 
The temperature was lowered to room temperature and increased to 500 °C at a 
heating rate of 10 °C/min. Sample weight was 2-3 mg . The open aluminum cell 
was swept with N2 during the analysis. 
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2.5.5. Mechanical properties 
The tensile properties of the SF/K films were determined using a tensile testing 
machine Instron dynamometer 5500. SF/K films strip with 1 cm width were 
measured using an Instron dynamometer 5500, with a 30 mm gauge length at a 
crossbar rate of 15 mm/min, corresponding to strain rate of 1.0×10−2.s−1.Tensile 
force was taken as the maximum force in the force deformation curve. Tensile 
modulus was estimated from the initial slope of the stress–strain curve. The values 
reported were the average of at least three specimens. 
2.5.6. Atomic force microscopy (AFM) 
Surface analysis of the SF/K films was performed in tapping mode using a 
Nanoscope III scanning probe microscope controller (Multimode Digital 
Instruments) with a silicon probe (RTESP14, Veeco). Root mean square (RMS) 
roughness data were collected from each sample according to manufacture 
instructions. 
2.5.7. Scanning electron microscopy (SEM) 
SEM analysis was performed on SF/EL scaffolds. Cross-sections were prepared 
by cutting the SF/EL samples with a razor blade in liquid nitrogen. Before analysis, 
the scaffolds were coated with gold and examined morphologically using a NOVA 
Nano SEM 200 FEI. The morphology was determined for SF/EL scaffolds with and 
without methanol treatment. 
2.5.8. Mass spectrometry 
Mass spectrometry analysis was performed to determine the hydrolysis rate of the 
inhibitor peptide by porcine pancreatic elastase (PPE). Mass spectra were 
obtained using a LxQ MS Detector, Thermo Electron Corporation. Samples were 
dissolved in methanol and ionized by Electrospray Ionization (ESI). The scan 
range was from m/z 100 to 2000 in positive-ion mode. 
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2.6. Swelling ratio 
Swelling ratio was determined to both SF/K films and SF/EL scaffolds. Dried films 
and scaffolds (60 °C for 24 h), methanol treated, w ere immersed, respectively, in 
100 mM Tris-HCl buffer, pH 8.0 and phosphate buffered saline (PBS) buffer (pH 
3.0; 7.4 and 11) at 37 °C for 24 h. The excess of b uffer was removed and the wet 
weight of the film was determined. The swelling ratio of the samples was 
calculated by equation 2.2. 
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Equation 2.2. Swelling ratio where WS is the mass of the swollen material and Wd 
is the initial dry mass. 
2.7. In vitro degradation 
The biological degradation of SF/K films was determined using Trypsin from 
porcine pancreas and porcine pancreatic elastase (PPE) and, for SF/EL sponges, 
PPE and wound exudate were used. Dried (60 °C for 2 4 h) and methanol treated 
materials were incubated with respective enzyme solutions, for several days, at 
37 °C. Solutions were changed and collected daily. Control samples were 
incubated in the buffer solutions without enzyme and submitted to the same 
conditions. At designated time points, samples were washed thoroughly with 
distilled water, dried in a desiccator, and weighed to estimate the extent of 
degradation by equation 2.3. 
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Equation 2.3. Weight loss where m0 is the initial dry mass of the sample and, mf is 
the final dry mass. 
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2.8. Cytotoxicity evaluation 
2.8.1. Cell culture 
The NIH 3T3 cell line (mouse embryonic fibroblasts) was maintained in Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) of fetal bovine 
serum (FBS) inactivated (20 min. at 56 °C) and 1% ( v/v) of Penicillin/Streptomycin 
(PS; 10,000 units/ml penicillin and 10,000 µg/ml streptomycin), all supplied by 
Gibco. The cells were maintained at 37 °C in a humi dified atmosphere of 5% CO2. 
The medium was refreshed every 2 to 3 days. At pre-confluence, cells were 
harvested using trypsin (0.25% (w/v) trypsin, 0.1% (w/v) glucose and 0.05% (w/v) 
ethylenediaminetetraacetic acid – EDTA – in phosphate-buffered saline solution 
(PBS)).  
The BJ5ta cell line (normal human skin fibroblasts) was maintained according to 
ATCC recommendations (4 parts Dulbecco's Modified Eagle's Medium (DMEM) 
containing 4 mM L-glutamine, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, and 1 
part of Medium 199, supplemented with 10% (v/v) of fetal bovine serum (FBS), 
1% (v/v) of Penicillin/Streptomycin solution and 10 µg/ml hygromycin B). The cells 
were maintained at 37 °C in a humidified atmosphere  of 5% CO2. Culture medium 
was refreshed every 2 to 3 days. 
2.8.2. Cytotoxicity by indirect contact 
SF/K films: Discs (φ=8mm) were punched out of the films with skin biopsy punches 
(Acu-Punch, USA) and sterilized by immersion in serial dilutions of ethanol (90%, 
70% and 50% v/v) for 15 min, then hydrated and rinsed with PBS. The extracts 
were obtained by the incubation of the membranes in 2 ml of Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 1% (v/v) PS in an orbital incubator at 
37 °C for either 24 and 72 h at 180 rpm. At the end  of these time points, the 
membranes were removed and the extracts were obtained. Before use, the 
extracts were supplemented with 10% (v/v) FBS and subsequently, serially diluted 
(100%, 50%, 25% and 10% (v/v)) in complete culture medium. A sample of the 
extract vehicle subjected to the same extraction conditions was used as a negative 
control, whereas a 1% (v/v) solution of Triton X-100 (Sigma) prepared in fresh 
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culture medium was used as a positive control. Cells seeded at a density of 
5x103 cells/200 µl/well on 96-well tissue culture polystyrene (TCPS) plates 
(Greiner Bio-one) were exposed to the serial dilutions of the extracts and 
incubated at 37 °C in a humidified atmosphere of 5%  CO2. At the end of each 
culture period (24 and 72 h) the cell viability was assessed using a resazurin 
based assay. Medium containing extract was refreshed ever 24 h of contact with 
the cells. 
SF/EL scaffolds: Scaffolds (φ=3 mm and 6 mm thickness) were sterilized by 
immersion in ethanol 70% for 30 min, then hydrated and rinsed with PBS. The 
extracts were obtained by the incubation of the scaffolds in 1 ml of DMEM in a CO2 
incubator at 37 °C for 5 days. At the end, the mate rials were removed and the 
extracts were obtained. Before use, the extracts were filtered to remove degraded 
material and, subsequently, diluted (100%, 50% (v/v)) in complete culture medium. 
A sample of the extract vehicle subjected to the same extraction conditions was 
used as a negative control, whereas a 1% (v/v) solution of Triton X-100 (Sigma) 
prepared in fresh culture medium was used as a toxicity positive control.  
Cells were seeded at a density of 20x103 cells/100 µl/well on 96-well tissue culture 
polystyrene (TCPS) plates (TPP, Switzerland) the day before experiments and 
then exposed to extracts and incubated at 37 °C in a humidified atmosphere with 
5% CO2. At the each time point (24, 48 and 72 h) the cell viability was assessed 
using the Alamar Blue assay (alamarBlue® Cell Viability Reagent, Invitrogen). 
2.8.3. Cytotoxicity by direct contact 
SF/K films: Discs, prepared and sterilized as previously described (φ=14mm), were 
gently place in 24-well TCPS plates (Greiner Bio-one) and fixed with sterilized 
silicone rings (o-rings) with a 12 mm internal diameter (Epidor, Spain). The discs 
were let to dry overnight in a laminar flow hood. Prior to cell seeding, discs were 
equilibrated in PBS and subsequently in DMEM with 1% v/v PS (37 °C for 1 h). 
2x104 cells/ml/well were seeded and cultured for 24, 48 and 72 h. TCPS in the 
presence of the o-rings were used as control. Medium was refreshed daily. After 
each incubation periods, cell proliferation was determined quantitatively using the 
resazurin based assay and cell morphology was assessed using F-actin 
fluorescent labelling. 
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Peptides: Cells were seeded at a density of 10x103 cells/100 µl/well on 96-well 
tissue culture polystyrene (TCPS) plates (TPP, Switzerland) the day before 
experiments and then exposed to different peptide concentrations added to fresh 
culture medium. At 24 and 48 h of exposure, cell viability was determined using 
the MTS assay (CellTiter 96® Non-Radioactive Cell Proliferation Assay, Promega, 
EUA). 
2.9. Cell viability and proliferation assays 
2.9.1. Resazurin assay 
Resazurin is a blue, non fluorescent molecule that is reduced by several 
mitochondrial and cytoplasmic enzymes to a pink fluorescent product, called 
resorufin. 10% (v/v) of resazurin solution (0.1 mg/ml, in PBS) was added to each 
well. After 4 h of incubation at 37 °C, 200 µl of t he medium was transferred into a 
black walled 96-well plate (Greiner Bio-one) and fluorescence was measured in a 
microplate reader (Spectra Max Gemini XS – Molecular devices) at excitation and 
emission wavelengths of 530 nm and 590 nm, respectively. 
2.9.2. Alamar blue assay 
Resazurin, the active ingredient of alamarBlue® reagent, is a non-toxic, cell 
permeable compound that is blue in colour and reduced to resorufin, red colour 
compound, by viable cells. 10 µL of alamarBlue® reagent were added to each well 
containing 100 µL of culture medium. After 4 h of incubation at 37 °C the 
absorbance at 570 nm was measured, using 600 nm as a reference wavelength, 
in a microplate reader (Spectramax 340PC). The quantity of resorufin formed is 
directly proportional to the number of viable cells.  
2.9.3. MTS assay 
MTS assay (CellTiter 96® Non-Radioactive Cell Proliferation Assay, Promega, 
EUA). MTS tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) is a coloured formazan 
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substrate which is converted by several mitochondrial and cytoplasmic enzymes in 
viable cells into a soluble, pink fluorescent product. 20 µL of MTS compound were 
added to each well containing 100 µL of culture medium. After 4 h of incubation at 
37 °C the absorbance at 490 nm was measured in a mi croplate reader 
(Spectramax 340PC). The quantity of formazan formed is directly proportional to 
the number of viable cells 
2.9.4. F-actin fluorescent labelling 
After each incubation period, the samples were rinsed with PBS and fixed with 
4% (w/v) p-formaldehyde in PBS for 10 min. After washing with PBS, cells were 
permeabilized with 0.1% (v/v) Triton X-100 (Sigma) in PBS for 10 min and then 
washed three times with PBS. Cell cytoskeletal filamentous actin (F-actin) was 
visualized by treating the cells with 5 U/mL Alexa Fluor® 488 phalloidin (Molecular 
Probes) for 20 min in the dark. Cells were then washed three times with PBS and 
cell nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) dye. 
Cells were examined using an inverted fluorescent microscope (Axiovert 200M, 
Zeiss, Germany). 
2.11. In vitro release 
The release of model compounds from SF/K films and SF/EL scaffolds was 
evaluated by the incorporation of FITC-BSA and Trypan-blue. Detailed information 
will be given in further sections. The resulting materials incorporating model 
compounds were incubated with enzymes and buffer solutions at 37 °C for several 
days. Solutions were changed every day. At determined time points, aliquots were 
taken and fluorescent and absorbance measurements were conducted. After each 
measurement, the samples were added back to the medium to restore the 
equilibrium conditions. FITC-BSA release was monitored by a multiplate reader 
(Synergy HT W/TRF from BioTek) in the fluorescence mode at emission 
wavelength of 490 nm. Trypan-blue release was determined by measuring the 
absorbance at 595 nm using a Heλios γ ThermoSpectronic spectrophotometer. 
The quantification of the release was established by a standard curve of both 
dyes. 
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2.11.1. Release kinetics 
The release behaviour of compounds from polymeric systems can be determined 
by fitting the release data to the empirical relationship given by Ritger-Peppas 
equation [386]. 
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Equation 2.4. Ritger-Peppas equation. 
 
Mt/M∞ is the fractional drug release at time t; “t” is the release time; “k” is the kinetic 
constant that measures the drug release rate and, “n” is the diffusion exponent 
that depends on the release mechanism and on the geometry of the matrix. To 
determine “n” values, equation 2.4 is modified in equation 2.5 and, “n” is 
determined from the slope of the plot of log (%release) versus log t. 
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Equation 2.5. Modified Ritger-Peppas equation. 
2.12. Elastase activity determinations 
The activity of porcine pancreatic elastase (PPE) was measured according to a 
method previously reported [387] using the synthetic substrate N-Succinyl-Ala-Ala-
Ala-p-nitroanilide. The reaction was carried out for 5 min at 37 °C and the 
cleavage of the substrate was monitored spectrophotometrically at 410 nm. One 
unit is defined as the amount of enzyme that will hydrolyze 1.0 µmol of N-Succinyl-
Ala-Ala-Ala-p-nitroanilide per minute at 25 °C, pH 8.0.  
The activity of human neutrophil elastase (HNE) was measured according to a 
method previously reported [388] using the synthetic substrate N-Methoxysuccinyl-
Ala-Ala-Pro-Val-p-nitroanilide. The reaction was carried out for 1 min at 37 °C and 
the cleavage of the substrate was monitored spectrophotometrically at 410 nm. 
One unit will release 1.0 nmol of p-nitroanilide per second from N-
CHAPTER II. Materials and Methods 
60 
Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide at 37 °C, pH 6.5. Determination of 
half-life time and inhibition rates will be explained in further sections 
2.12.1. Mechanisms and kinetics of inhibition 
The mechanism of enzyme catalysis can be explained by the Michaelis-Menten 
equation. 
 
mKS
SVV
+
×= ][
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max
 
 
Equation 2.6. Michaelis-Menten equation. 
 
V is the enzyme reaction velocity; Vmax is the maximum enzyme reaction velocity 
which is attained when all the subsites of the enzyme are occupied by the 
substrate; [S] is the substrate concentration and Km is the Michaelis-Menten 
constant that represents the substrate concentration when half of the binding sites 
are occupied. The enzyme reaction velocity can be reduced by four mechanisms 
of inhibition: 
 
1. Competitive Inhibition  
 
A competitive inhibitor is a molecule that resembles the substrate and occupies 
the catalytic site because of its similarity in structure, but is completely unreactive. 
By occupying the active site, the inhibitor prevents normal substrates from binding 
and being catalyzed. Unlike other mechanisms, inhibition can be reversed by 
increasing substrate concentration. Competitive inhibitors cause an apparent 
increase of Km (i.e., the inhibitor interferes with substrate binding), but does not 
affect Vmax (inhibitor cannot bind to the complex enzyme-substrate). 
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Equation 2.7. Modified Michaelis-Menten equation for competitive inhibition. 
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[I] is the inhibitor concentration and Ki (inhibition constant) is the dissociation 
constant of the enzyme-inhibitor complex. 
 
2. Noncompetitive Inhibition  
 
A noncompetitive inhibitor is one that binds reversibly to the enzyme, but not at the 
active site itself, so that the substrate can still bind at the active site, but there is no 
catalysis. Non-competitive inhibitors have identical affinities for enzyme and 
complex enzyme-substrate (Ki = Ki'). A noncompetitive inhibitor decreases Vmax 
without affecting the apparent Km. 
 
m
i
KS
S
K
I
VV
+
×
+
=
][
][
][1
max
 
 
Equation 2.8. Modified Michaelis-Menten equation for noncompetitive inhibition. 
 
3. Mixed Inhibition  
 
Mixed inhibitors are capable of binding to both free enzyme and enzyme-substrate 
complex with different affinities (Ki ≠ Ki'). Thus, mixed-type inhibitors interfere with 
substrate binding (increase Km) and with catalysis in the enzyme-substrate 
complex (decrease Vmax). 
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Equation 2.9. Modified Michaelis-Menten equation for mixed inhibition. 
 
 
 
 
 
CHAPTER II. Materials and Methods 
62 
4. Uncompetitive Inhibition  
 
Uncompetitive inhibition is a special case of mixed inhibition and occurs when the 
inhibitor only binds to the enzyme-substrate complex. Both Vmax and Km decrease 
(maximum velocity decreases as a result of removing activated complex while 
binding efficiency increases as a result of Le Chatelier's principle). 
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Equation 2.10. Modified Michaelis-Menten equation for uncompetitive inhibition. 
 
The half maximal inhibitory concentration (IC50) is a measure of the 
effectiveness of a compound in inhibiting biological or biochemical function i.e. is 
defined as the concentration of inhibitor necessary to cause the decrease of 50% 
in enzyme activity. For competitive binding studies, the IC50 can be determined 
using the Cheng-Prusoff equation [389]. 
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Equation 2.11. Determination of IC50. 
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CHAPTER III 
 
Biodegradable materials based on silk fibroin and keratin 
 
Abstract  
 
Wool and silk were dissolved and used for the preparation of blended films. Two 
systems are proposed: 1) blend films of silk fibroin and keratin aqueous solutions; 
2) silk fibroin and keratin dissolved in formic acid. The resulting silk fibroin/keratin 
(SF/K) films were characterized and, the non-linear trend of the different 
parameters obtained from FTIR analysis and DSC curves of both SF/Keratin 
systems indicate that when proteins are mixed do not follow additives rules but are 
able to establish intermolecular interactions.  
Degradable polymeric biomaterials are preferred candidates for medical 
applications. It was investigated the degradation behavior of both SF/keratin 
systems by in vitro enzymatic incubation with Trypsin. The SF/Keratin films cast 
from water underwent a slower biological degradation than the films cast from 
formic acid. The weight loss obtained is a function of the amount of keratin in the 
blend. This study encourages the further investigation of the type of matrices 
presented here to be applied whether in scaffolds for tissue engineering or as 
controlled release drug delivery vehicles. 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: Andreia Vasconcelos, 
Giuliano Freddi & Artur Cavaco-Paulo, Biodegradable Materials Based on 
Silk Fibroin and Keratin, Biomacromolecules 2008, 9, 1299–1305 
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3.1. Introduction  
Keratin is the major structural fibrous protein providing outer covering such as hair, 
wool, feathers, nail and horns of mammals, reptile and birds [131]. At the 
molecular level, the most distinctive feature is the high concentration in cysteine 
residue (7-20 number% of the total amino acid residues) [390]. These cysteine 
residues are oxidized to give inter and intra-molecular disulfide bonds, which 
decide about mechanical, thermal and chemical properties of wool fibers. Wool 
keratins are a family of proteins that can be roughly classified into two groups: the 
intermediate filament proteins (IFPs) and the matrix proteins. The most abundant 
are the fibrous, low-sulphur keratins that are part of the IFPs. They have a α-
helical structure and have an average molar mass in the range of 40-60 kDa. The 
matrix proteins have a high content in either cysteine or glycine and tyrosine 
residues. The ones with high cysteine content are referred to the high-sulphur 
proteins (HSPs) and have a molecular weight in the range of 11-26 kDa. Those 
high in glycine and tyrosine residues are referred to high-glycine/tyrosine proteins 
(HGTPs) and have a molecular weight between 6-9 kDa. The matrix proteins are 
thought to surround the IFPs and interact with them through inter-molecular 
disulfide bonds [141]. The keratin macromolecule in wool fiber takes the following 
conformations: helical (α-keratin), rectal (β-keratin) and undefined. The α-helix 
conformation is characteristic for wool fiber in its native state, it is, the fiber that is 
not stretched along its axis. During stretching, the α-helix declines and β-keratin 
appears. It is an unstable conformation and when the stretching force disappears 
the conformation of keratin reverts to α-helical [145-147]. 
Extraction of keratins from wool has been conducted in various ways [151-157] but 
all of them involve the presence of reducing or denaturant agents to break 
disulfide bonds. Regenerated keratin from wool is then dissolved in proper 
solvents before processing into other applications. Although regenerated keratin 
has been used for many applications [161-164], this material presents poor 
mechanical strength so that the use of crosslinking agents and blending with 
structural fibrous polymers is often necessary to improve its processing and final 
mechanical properties. Regenerated keratin blended with silk fibroin has already 
CHAPTER III. Biodegradable Materials Based on Silk Fibroin and Keratin 
68 
been reported [188] and formic acid represents an ideal medium for this polymer 
blend because while wool is partially soluble in formic acid, regenerated keratin 
and silk fibroin are readily soluble [64, 391].  
Silk from silkworms and orb-weaving spiders represent a unique family of 
structural proteins that are biocompatible, degradable, mechanically superior, offer 
a wide range of properties such as environmental stability, controlled proteolytic 
biodegradability, morphologic flexibility and can be chemically modified to suit a 
wide range of biomedical applications [6, 37, 39, 61, 85, 93, 102, 111, 115]. The 
silk fibers from silkworm Bombyx mori consist of two proteins: a light chain 
(≅ 25 kDa) and a heavy chain (≅ 390 kDa) which are present in a 1:1 ratio and 
linked by a single disulphide bond [12]. These proteins are coated with a family of 
hydrophilic proteins called sericins (20-310 kDa) [2, 12-14] which correspond to 
25-30 % of silk cocoons mass that is removed during the degumming process. 
The amino acid composition of silk fibroin from B. mori consists primarily of 
glycine, alanine and serine amino acids in the molar ratio of 3:2:1 which forms 
typical -(-ala-gly-)n- repeating motifs [2]. In the fiber, fibroin chains are aligned 
along the fiber axis held together by a close network of interchain hydrogen bonds 
with adjacent -(-ala-gly-)n- sequences forming the well known β-sheets crystals 
[12, 392] 
Both keratin and fibroin are excellent biopolymers with outstanding properties that 
make them extremely valuable in the biomedical field. Keratin films prepared from 
reduced keratin are biodegradable in vivo and in vitro [183] supporting cell 
adhesion and proliferation [183, 189]. Silk fibroin films which are easily prepared 
by casting aqueous silk proteins solutions at room temperature are highly 
attractive for their discrete permeability to oxygen and water vapor [88, 89]. Silk 
fibroin has also been used for the preparation of polymer-hydroxyapatite 
composites for bone regeneration [393], wireropes for the substitution of the 
anterior cruciate ligament [394], novel silk-based sutures and protective gauzes for 
the treatment of skin burns with improved blood compatibility [395], for supporting 
cell adhesion and growth, as scaffolds for skin and bone regeneration [34, 60, 396, 
397].  
In the present work, blend films of silk fibroin from B. mori and regenerated keratin 
from merino wool were prepared by water and formic acid casting and 
characterized in the solid state by FT-IR spectroscopy, DSC thermal analysis, and 
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tensile measurements. The corresponding solutions were characterized by amino 
acid analysis and SDS-PAGE electrophoresis. 
3.2. Materials and methods 
Herein it will be given a detailed description of some of the methods presented in 
the previous chapter. All other techniques were performed as described in Chapter 
II. 
3.2.1. Preparation of stock solutions 
Silk was purified from its sericin content as previously described in section 2.3, 
Chapter II. SF, 1 % (w/v) (SF1) was prepared by dissolving 1 g of degummed silk 
fibers into 10 ml of saturated aqueous LiBr at 60 °C for 3 h. The solution was then 
diluted by adding 90 ml of deionised water, filtered, and dialyzed against distilled 
water until complete removal of salt, using cellulose tubing (molecular-weight cut-
off of 12000-14000 Da). A similar solution was prepared in the same manner that 
was then freeze-dried (SF2). 
Keratin 1 % (w/v) (K1) solution was prepared by immersing 1 g of delipided wool in 
10 ml of a solution containing 8 M Urea, 0.2 M SDS and 0.5 M Na2S2O5. The 
mixture was heated to 100 °C for 30 min. The soluti on was then diluted with 90 ml 
of distilled water, filtered and dialyzed against distilled water using cellulose tubing 
(molecular-weight cut-off of 12000-14000 Da). Delipided wool (1 g) was dissolved 
in 25 ml of a solution containing 0.1 M Tris-HCl, pH 9.0, 8 M Urea and 0.1 M DTT 
at 50 °C for 24 h in a shaker bath. The solution wa s filtered and dialyzed against 
distilled water using cellulose tubing (molecular-weight cut-off of 12000-14000 Da). 
After dialysis the solution was freeze-dried (K2). 
3.2.2. Preparation of blended films 
Keratin (K1) and silk fibroin (SF1) solutions (10 ml of final volume) were blended in 
the ratios of 80/20, 60/40 and 40/60 of SF1/K1. The blends were cast in plastic 
Petri dishes with a circular area of about 40 cm2 and dried at room temperature. 
The controls are 100 % SF1 and 100 % K1. 
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Freeze-dried keratin (K2) and silk fibroin (SF2) were dissolved in formic acid to 
prepare 1% (w/v) solutions. The solutions were blended in the ratios of 75/25, 
50/50 and 25/75 of SF2/K2. The blends were cast in plastic Petri dishes with a 
circular area of about 40 cm2 and dried at room temperature. The controls are 
100 % SF2 and 100 % K2. The resulting films were 0.03 mm in average thickness. 
3.2.3. In vitro degradation 
Protein matrices were incubated at 37 °C in 6 ml of  a solution containing 0.5 mg/ml 
of Trypsin from Porcine Pancreas prepared in phosphate-buffered saline (PBS) or 
in PBS as a control. Before incubation with Trypsin, SF1/K1 films were treated with 
90 % (v/v) of methanol during 1 h at room temperature. The SF2/K2 films were 
directly used for the degradation studies. Solutions were changed and collected 
daily. At designated time points, samples were washed thoroughly with distilled 
water, dried in a desiccator, and weighed to estimate the extent of degradation 
determined by equation 2.3., Chapter II. 
3.3. Results and discussion 
3.3.1. Amino acid and SDS-PAGE analysis 
The protein solutions of wool keratin and silk fibroin were characterized by amino 
acid analysis and SDS-PAGE electrophoresis. Amino acid analysis on Table 3.1 
indicated that the cysteine residues occupied 8 – 9 mol% of the total amino acid 
residues of the reduced keratin as already described before [162, 398]. The amino 
acid composition of SF is characterized by a high content of Gly, Ala, and Ser, 
residues which corresponds to about 85 mol% of total mass; Tyr accounts for 5.3 
mol%; acidic and basic amino acids are a total of about 3.0 and 1.1 mol%, 
respectively. This characteristic amino acidic pattern results from the contribution 
of two polypeptides, i.e. the heavy and light chains. The heavy chain represents 
about 90% of the total weight of silk fibroin and predominates with its characteristic 
-(Gly-Ala)n- rich sequences [12] over the more heterogeneous primary structure of 
the light chain [13]. 
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Table 3.1. Amino acid composition of silk fibroin and keratin 
 
Amino acid Silk fibroin (mol 
%) 
Keratin (mol %) 
Cyst 
Asp 
Ser 
Glu 
Gly 
His 
Arg 
Thr 
Ala 
Pro 
Cys 
Tyr 
Val 
Met 
Lys 
Ile 
Leu 
Phe 
- 
1.67 
11.48 
1.37 
43.68 
0.20 
0.62 
0.96 
29.34 
0.67 
0.10 
5.30 
2.23 
0.10 
0.33 
0.66 
0.58 
0.72 
0,46 
5,94 
10,77 
10,96 
11,02 
1,00 
5,55 
5,12 
4,52 
7,06 
9,09 
6,26 
5,29 
0,37 
1,17 
3,06 
8,46 
3,88 
 
The electrophoretic pattern of wool keratin (Figure 3.1) shows the main two groups 
of keratin associated proteins, the intermediate filament proteins (IFPs) and the 
matrix proteins. It can be observed (Figure 3.1a) two high molecular weight bands 
(60-45 kDa) attributed to the low-sulphur IFPs that are mainly α-helical, and 
several low molecular weight bands attributed to the high-sulphur (HSPs) (20 - 
10 kDa) and high-glycine/tyrosine (HGTPs) (6-9 kDa) proteins of the matrix [141]. 
Regenerated aqueous SF solution (Figure 3.1b) shows a broad dull band from 
200-30 kDa and a very weak band at approximately 25 kDa [52]. The former band 
might result from the degradation products of the heavy chains (350 kDa) of raw 
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silk protein formed by degumming and dissolution in a solvent system, and the 
latter band at 25 kDa corresponds to the light chain of raw silk protein [399]. 
 
     
 
Figure 3.1. SDS-PAGE of a) wool keratin and b) silk fibroin solutions. 
 
Keratin was extracted from wool by sulphitolysis [158]. During this process 
cysteine disulphide bonds are cleaved by sulphite to give cysteine thiol (reduced 
keratin) and Bunte salts residues [131, 158, 159]. This method gives a keratin 
extraction yield about 30 % of the total protein content of the original wool [160]. 
Keratin extracted by the system using DTT as the reducing agent gives a protein 
extraction yield of approximately 80 % [157]. However, the solution obtained by 
this method became partially insoluble after dialysis. This is due to the fact that the 
high-sulphur proteins responsible for the reoxidation of the SH groups into 
disulphide bridges are insoluble. The SDS-PAGE gel shows that the HSPs (20-
10 kDa) remains on the insoluble fraction of the solution. In the protein solution 
obtained by sulphitolysis this fact is not observed because these type of proteins 
are not extracted by this method (data not shown). In terms of processing this fact 
is an advantage because the solution is ready for film preparation but the films 
obtained have low mechanical strength when compared with the films obtained by 
formic acid casting (Table 3.2). 
 
a) b) 
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3.3.2. Mechanical properties 
The load/elongation curves of pure SF1 films (data not shown) do not present any 
yield point. The load increases almost linearly until a plateau, then the film brakes 
or continues elongating (failure is not sharp).These SF1 films are prevalently 
amorphous. The tensile behaviour can be due to the presence of amorphous 
domains which display a plastic behaviour. Addition of keratin (K1) to SF1 makes 
films weaker. The average values of stress are about half of those of pure SF1 
films when 40% of K1 is present. Elasticity increases slightly at small keratin 
content (Table 3.2). SF films cast from formic acid (SF2) display average stress 
values similar to water cast films, but failure is much sharper. This can be 
attributed to the more crystalline character of these films. The SF2/K2 films 
obtained with formic acid display better tensile properties than those obtained in 
water. At 50 % of K2 the tensile behaviour is typical of brittle films, the failure is 
sharp. At lower K2 content (25 %) failure can be sharp or plastic. Important to note 
that the stress values are quite high, similar to those of pure SF2 films (Table 3.3). 
 
Table 3.2. Mechanical properties of SF1/K1 blends 
 
K1 (%) Stress (MPa) Elongation (mm) Modulus (MPa) 
0 
20 
40 
23,690 ± 7,311 
11,265 ± 5,167 
9,153 ± 3,250 
0,518 ± 0,0416 
0,679 ± 0,1948 
0,407 ± 0,1135 
3411 ± 479 
1597 ± 588 
1409 ± 203 
 
Table 3.3. Mechanical properties of SF2/K2 blends 
 
K2 (%) Stress (MPa) Elongation (mm) Modulus (MPa) 
0 
25 
50 
23,568 ± 7,669 
29,755 ± 6,544 
17,730 ± 4,660 
0,427 ± 0,051 
0,570 ± 0,130 
0,363 ± 0,111 
2893 ± 387 
2724 ± 207 
2005 ± 210 
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3.3.3. FT-IR analysis 
Infrared absorption spectra of blended films of silk fibroin (SF1 and SF2) and 
keratin (K1 and K2) show characteristic absorption bands assigned to the peptide 
bonds (-CONH-) that originate bands known as amide I, amide II and amide III. 
The amide I is useful for the analysis of the secondary structure of the proteins 
and is mainly related with the C=O stretching and it occurs in the range of 1700-
1600 cm-1. The amide II which falls in 1540-1520 cm-1 range is related with the N-
H bending and C-H stretching vibration. The amide III occurs in the range of 1220-
1300 cm-1 and it results from phase combination of C-N stretching and C=O 
bending vibration [399]. In addition, the positions of these bands indicate the 
conformations of the protein materials: 1650 cm-1 (random coil) and 1630 cm-1 (β-
sheet) for amide I; 1540 cm-1 (random coil) and 1520 cm-1 (β-sheet) for amide II; 
1230 cm-1 (random coil) and 1270 cm-1 (β-sheet) for amide III [400-402]. 
The keratin (K1) spectra (Figure 3.2) shows a peak at 1641 cm-1 with a shoulder at 
about 1620 cm-1 for amide I, 1533 cm-1 amide II and 1225 cm-1 for amide III. The 
peaks at 1203 cm-1 and 1024 cm-1 are related, respectively, to the asymmetric and 
symmetric S-O stretching vibrations of the Bunte salts residues [403] that are no 
longer observed in the spectra of K2 (Figure 3.3). The absorption value of the 
amide I band of pure K1 film indicates that the secondary structure of K1 mainly 
consist of α-helix and random coil conformation  The IR spectra of SF showed a 
peak at 1639 cm-1 for amide I, 1518 cm-1 with a strong shoulder at about 1535 cm-
1
 for amide II and 1236 cm-1 for Amide III. This FT-IR pattern is characteristic of SF 
films with prevalently amorphous structure (random coil/Silk I conformation). The 
half-peak width of amide I of K1 is larger than that of SF1 which might reflect a 
more heterogeneous molecular conformation. Wool treatment with formic acid 
increases the amount of β-sheet and disordered keratin structures [404, 405] as it 
can be seen by the appearance of band peaks at 1697-1670 cm-1 range in keratin 
dissolved in formic acid (K2, Figure 3.3) [406, 407]. Amide I appear at 1643 cm-1 
with a strong shoulder at around 1620 cm-1, amide II is showed at 1539 cm-1 with a 
shoulder at about 1529 cm-1 and amide III at 1238 cm-1. The higher wavenumber 
of amide I can be explained by the protein extraction procedure suggesting again 
the presence of α-helix structure. Nevertheless, the decrease in the peak area of 
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the amide I band in K2 spectra in respect to the same band in K1 spectra indicates 
that formic acid destabilized the α-helix conformation and stabilizes the 
supramolecular β-sheet structure of keratin. This occurs because formic acid has a 
higher polarity than water and forms strong interactions with the polar side chains 
groups of keratin. As a consequence, the molecular chains became closer and this 
organization can promote crystallization in β-sheet structure [408]. The FT-IR 
pattern of SF2 dissolved in formic acid is different from the one in water and 
characteristic of SF film with prevalently β-sheet conformation, with β-sheet 
crystallites embedded in an amorphous matrix.  Half-peak width of amide I and II 
of K2 are larger than those of SF2 suggesting a more heterogeneous molecular 
conformation as it was observed for aqueous solutions. 
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Figure 3.2. FTIR spectra of pure films of silk fibroin (SF1) and keratin (K1) 
aqueous solutions. 
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Figure 3.3. FTIR spectra of pure films of silk fibroin (SF2) and keratin (K2) 
dissolved in formic acid. 
 
It can be observed (Figure 3.4 and Figure 3.5) that the position, shape and 
intensity of amide bands show a transition from SF-like to K-like spectral pattern, 
for both SF/K systems, with the increase of keratin present in the film. The plot of 
the intensity ratio between the amide II (Figure 3.6) bands fit a second order 
polynomial curve, suggesting that SF and keratin do not follow additive rules when 
mixed. This might be indicating of intermolecular interactions, more likely hydrogen 
bonding, between SF and keratin. 
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Figure 3.4. FTIR spectra of blended films with silk fibroin (SF1) and keratin (K1) 
aqueous solutions. 
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Figure 3.5. FTIR spectra of blended films with silk fibroin (SF2) and keratin (K2) 
dissolved in formic acid. 
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Figure 3.6. Behaviour of intensity ratio of the amide II bands typical of SF1 
(1518 cm-1) and K1 (1533 cm-1) in water and, SF2 (1514 cm-1) and K2 (1539 cm-1) 
in formic acid. 
 
The amide I band was deconvoluted to determine the fraction of the β-sheets 
formed during crystallization. In this approach, the amide I band is transformed to 
yield a fitted self-deconvoluted set of bands from which the secondary structure is 
determined. The assignment of the amide I region bands was determined by 
reference to the literature [250, 409-412]. The results from Table 3.4 indicated 
higher β-sheet content for the crystallization induced by methanol treatment. The 
increase in crystallization seems to occur due to the random coil/Silk I structure as 
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it can be seen from its decrease from AU→FA→AM. Nevertheless, it can not be 
excluded a formation of a β-type structure intermediate before the final transition 
from random coil to β-sheet. 
 
Table 3.4. Results from the curve fitting of the amide I range of the FT-IR 
spectrum of SF films 
 
 Untreated (AU) Formic acid (FA) Methanol(AM) 
β-sheet (Silk II) 
Random coil/Silk I 
Turns and bends 
29,30% 
43,36% 
27,33% 
40,14% 
37,58% 
22,27% 
58,15% 
19,63% 
22,21% 
3.3.4. DSC analysis 
The DSC curve of SF1 (Figure 3.7) exhibits an endothermic shift at 178 °C that 
corresponds to the glass transition temperature (Tg) of SF, an exothermic peak at 
226 °C (broad and weak) related to crystallization via conformational transition to 
β-sheet structure of amorphous SF chains, and an intense bimodal endotherm at 
274 °C (main peak) and 296 °C assigned to the melti ng/decomposition of SF 
chains. The exothermic peak at 226 °C can be dimini shed by treatment with polar 
solvents [413] that was afterwards observed (Figure 3.8). The thermal behaviour is 
typical of a prevalently amorphous SF film with non-oriented SF chains. Weakness 
of the crystallization peak at 226 °C and presence of a high temperature peak of 
thermal degradation at 296 °C suggest the presence of aggregated SF domains 
embedded in a prevalently amorphous matrix, as suggested by FTIR results. 
The DSC curve of keratin (K1) (Figure 3.7) shows and endothermic peak at 224 °C 
related to the melting of α-helices of the IFPs and an endotherm peaking at 277 °C 
that corresponds to the melting/degradation of keratin proteins which comprise the 
high sulphur (highly cross-linked) keratins of the intermacrofibrillar matrix. The 
glass transition temperature of SF1, Tg, shifts to higher temperature following 
addition of keratin. At higher keratin content (> 60%), Tg is no longer detectable. 
The melting peak of keratin α-helix at 224 °C remains almost unchanged; the 
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value of ∆H (peak intensity) sharply decreases by addition of SF1. When 80% of 
SF1 is present in the blend the melting peak of keratin is hardly detectable. The 
melting/decomposition endotherm of SF1 at 274 °C sh ows a marked low 
temperature broadening (the peak shifts downwards of about 10 °C, from 274 °C 
to about 264 °C). It is still detectable in the 60%  keratin blend as a low 
temperature shoulder of the main keratin degradation endotherm. When silk fibroin 
(SF2) and keratin (K2) were dissolved in formic acid (Figure 3.8) the DSC pattern 
of both components changed. The glass transition temperature and the exothermic 
peak of β-sheet crystallization are no more detectable because formic acid is able 
to induce a partial crystallization to β-sheet structures of SF chains during drying. 
The melting/decomposition endotherm of partially crystallized/non-oriented SF 
chains occurs at 278 °C with a high temperature sho ulder. 
The DSC curve of keratin dissolved in formic acid (K2) is characterized by three 
main endothermic events at 204 °C (weak and broad),  244 °C and the most 
intense at 295 °C. The transition at low temperatur e (204 °C) is hardly attributable 
and could be related to small molecular weight keratin fractions with low thermal 
stability. The thermal transitions peaking at 244 °C and 295 °C can be attributed to 
melting and melting/decomposition of keratin fractions with intermediate and high 
thermal stability, which is probably related to the different extent of cross-linking of 
the various keratin fractions. The characteristic α-helix melting peak of keratin is 
lost upon formic acid casting as already observed elsewhere [408]. This suggests 
that the α-crystallites formed by keratin/formic acid systems are thermally less 
stable. Furthermore, the peak area decrease (Figure 3.8) is a support of the lesser 
α-helix content in the K2 films. In the blends, the melting/decomposition 
endotherm of SF2 at 278 °C shifts to lower temperat ure with the increase of 
keratin present in the film. The energy associated with melting/decomposition of 
pure SF, pure keratin, and SF2/K2 blends was calculated by integrating the 
endothermic peaks in the range 200-350 °C (Figure 3 .9). Values were expressed 
as ∆H (J/g). The energy associated with thermal degradation of SF2 is higher than 
that required by K2 (influence of the different chemical and physical structure). The 
plot of ∆H vs. the composition of the blend does not follow a linear trend. The best 
fit is given by a second order polynomial curve. 
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Figure 3.7. DSC curves of blended films with silk fibroin and keratin (SF1/K1) 
aqueous solutions. (a)100SF, b) 80/20SF1/K1, c) 60/40SF1/K1, d) 40/60SF1/K1 and e) 100K1) 
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Figure 3.8. DSC curves of blended films with silk fibroin and keratin (SF2/K2) 
dissolved in formic acid. (a) 100SF, b) 75/25SF2/K2, c) 50/50SF2/K2, d) 25/75SF2/K2 and e) 
100K2) 
 
The non-linear trend of the different parameters obtained from the DSC curves of 
both SF/Keratin systems indicate that, when the proteins are mixed, the thermal 
behaviour of one component is more or less strongly influenced by the other. This 
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confirm the assumption raised by FT-IR results that SF and Keratin are able to 
establish intermolecular interactions, more likely based on hydrogen bonding  
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Figure 3.9. Enthalpy variation (∆H) of decomposition peak of SF2 and K2 
(temperature range: 200-350°°C)  
3.3.5. In vitro degradation  
In vitro degradation was observed for protein films of both SF/K systems incubated 
in Trypsin. In the water system (Figure 3.10) it can be observed that pure SF1 
films presented very low degradation that remains constant over the time exposure 
to Trypsin. In the blends it can be seen that the weight loss obtained is a function 
of the amount of keratin (K1) present in the blend. When the minimum amount of 
K1 is present (20%), it was obtained a degradation of 23% in a slower manner 
over the time. With the increase of keratin to 40%, the degradation took place 
rapidly during the first 14 days remaining constant after that without exceeding 
70% of degradation. At higher keratin amounts, only debris was obtained after 1 
day of incubation. In the formic acid SF2/K2 system (Figure 3.11) a similar 
behaviour is observed. Nevertheless, pure SF films presented higher weight loss 
values because crystallization to β-sheet, induced by formic acid results in 
decreased β-sheet contents as showed in Table 3.4. As described in the literature 
β-sheet rich regions are degraded in a slower rate. In this way, in the Silk II 
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conformation the molecular chains are entangled leading to a more closed 
structure, which leads to slower degradation rates. 
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Figure 3.10. Weight loss of SF1/K1 films (water system) incubated in buffer (Ct) 
and Trypsin solution (Ez) as a function of time. 
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Figure 3.11. Weight loss of SF2/K2 films (formic acid system) incubated in buffer 
(Ct) and Trypsin solution (Ez) as a function of time. 
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3.4. Conclusions  
In the present study an extensive characterization of wool and silk proteins in the 
film form was presented. Films were made by blending silk fibroin (SF1) and 
keratin (K1) aqueous solutions; silk fibroin (SF2) and keratin (K2) dissolved in 
formic acid. The presence of K1 on the blends makes films weaker with a slight 
increase in elasticity whereas films obtained from formic acid (SF2/K2) presented 
better strength results. The FT-IR spectra of pure K1 indicates that its structure 
mainly consists of α-helix and random coil conformations. The IR spectrum of pure 
SF1 is characteristic of films with prevalently amorphous structure (random coil 
conformation). Pure keratin film cast from formic acid (K2) show an increase in the 
amount of β-sheet and disordered keratin structures. The FT-IR pattern of SF2 is 
characteristic of films with prevalently β-sheet conformation with β-sheet 
crystallites embedded in an amorphous matrix. In the blends, the position, shape 
and intensity of amide bands showed a transition from SF-like to K1-like or SF-like 
to K2-like spectral pattern. The thermal behaviour of the blends confirmed the FT-
IR results. DSC curve of pure SF is typical of amorphous SF and the curve of pure 
K1 show the characteristic melting peak of α-helixes. These patterns were no 
longer observed in the films cast from formic acid due to the ability of formic acid 
to induce crystallization of SF and to increase the amount of β-sheet structures on 
keratin. The non-linear trend of the different parameters obtained from FTIR 
analysis and DSC curves of both systems indicated that wool keratin and silk 
fibroin are able to establish intermolecular interactions. The properties of the films 
depend on the nature and strength of these interactions. The SF/K films cast from 
water underwent a slower biological degradation than the films cast from formic 
acid. The knowledge of the degradation rates will allow the design of matrices for 
the release of active compounds. The results presented showed that the protein 
matrices developed are suitable to further biomedical and biotechnological 
applications. 
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CHAPTER IV 
 
Protein matrices for improved wound healing: Elastase inhibition 
by a synthetic peptide model  
 
Abstract 
 
The unique properties of silk fibroin were combined with keratin to develop new 
wound dressing materials. Silk fibroin/Keratin (SF/K) films were prepared to 
reduce high levels of elastase found on chronic wounds. This improved biological 
function was achieved by the incorporation of a small peptide synthesized based 
on the reactive-site loop of the Bowman-Birk Inhibitor (BBI) protein. In vitro 
degradation and release were evaluated using porcine pancreatic elastase (PPE) 
solution as a model of wound exudate. It was found that biological degradation 
and release rate are highly dependent on film composition. Furthermore, the level 
of PPE activity can be tuned by changing the film composition showing therefore, 
an innovative way of controlling the elastase-antielastase imbalance found on 
chronic wounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: Andreia Vasconcelos, Ana 
Paula Pêgo, Meriem Lamghari, Lara Henriques & Artur Cavaco-Paulo, Protein 
matrices for improved wound healing: Elastase inhibition by a synthetic peptide 
model, Biomacromolecules 2010, 11(9), 2213–2220 
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4.1. Introduction 
Wound healing is a specific biological process related to the general phenomenon 
of growth and tissue regeneration. Wound healing progresses through a series of 
interdependent and overlapping stages in which a variety of cellular and matrix 
components act together to reestablish the integrity of damaged tissue and the 
replacement of lost tissue [300, 302, 303]. The interruption of the orderly sequence 
of events during the healing process results in chronic wounds [297-299]. 
Skin ulcers are the most common types of chronic wounds and are the focus of 
this study. These wounds can be created by many factors including vascular 
insufficiency, prolonged inflammation, pressure necrosis, physical agents, infection 
and cancer [300, 301]. Chronic wounds stop the healing process in the 
inflammatory phase, remaining nonhealed for several months or even years. 
Excessive amounts of exudates are present in these types of wounds. Although 
wound exudate is a key component in all stages of the wound healing, irrigating 
the wound continuously and keeping it moist [305], the excessive production of 
exudates can cause maceration of healthy skin tissue around the wound, inhibiting 
the healing [414]. In addition, exudate from chronic wounds differs from acute 
wounds fluid, containing higher levels of tissue destructive protease enzymes 
namely, matrix metalloproteinases (MMPs) and polymorphonuclear (PMN) 
elastase [307]. The excessive action of elastase leads to reduce amounts of 
growth factors [309] and endogenous proteinase inhibitors, causing the cleavage 
of collagen, elastin and fibronectin, and consequently the destruction of 
extracellular matrix [340]. As a result, there has been considerable interest in the 
design of inhibitors that restore the elastase – antielastase imbalance. 
Bowman-Birk inhibitors (BBIs) are small plant proteins of typically 60 to 90 
residues stabilized by seven disulfide bridges. They have a symmetrical structure 
of two tricyclic domains each containing and independent binding loop [354, 355, 
357, 358]. The inhibition of serine proteases is often mediated by these binding 
regions. The reactive site loop is fixed in a “canonical” conformation which is 
complementary to the proteinase active site [415, 416]. Small peptides mimicking 
the reactive-site loop of BBIs protein have shown to retain much of the inhibitory 
activity of the complete protein [359]. 
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This study focus on the development of wound dressings with the ability to control 
elastase activity. Silk fibroin and keratin blends were used to incorporate a 
synthetic BBI peptide. The peptide sequence was removed from a combinatorial 
library of synthetic BBI-based peptides [359, 362, 363]. The excellent properties of 
silk fibroin such as high mechanical strength, low degradability and 
biocompatibility were combined with keratin protein in order to modulate the 
physical and bifunctional properties of the final material to fulfill the wound healing 
needs. 
4.2. Materials and methods 
Herein it will be given a detailed description of some of the methods presented in 
the previous chapter. All other techniques were performed as described in Chapter 
II. 
4.2.1. Materials 
The Porcine Pancreatic Elastase (PPE) was purchase from Sigma, Spain. The 
peptide 5(6)-Carboxyfluorescein-YCQPPWSATCF-OH was synthesized by JPT 
Peptide Technologies GmbH (Germany). The NIH 3T3 cell line (mouse embryonic 
fibroblasts) was purchased from the European Collection of Cell Cultures 
(ECACC). All other reagents were analytical grade and purchased from Sigma, 
Spain. 
4.2.2. Preparation of aqueous silk fibroin and keratin solutions  
Silk was purified from its sericin content as previously described in section 2.3, 
Chapter II Silk fibroin (SF) solution 1% (w/v) was prepared by dissolving 1 g of 
degummed silk fibers into 10 mL of saturated aqueous LiBr at 60 °C for 3 h. The 
solution was then diluted by adding 90 mL of deionised water. Keratin (K) solution 
1% (w/v) was prepared by immersing 1 g of delipided wool fabric in 10 mL of a 
solution containing 8 M Urea 0.2 M SDS and 0.5 M Na2S2O5. The mixture was 
heated to 60 °C for 12 h. Both solutions were filte red, and dialyzed against distilled 
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water using, cellulose tubing (molecular-weight cut-off of 12000-14000 Da), until 
complete removal of salts. 
4.2.3. Preparation of blended silk fibroin/keratin films 
Keratin (K) and silk fibroin (SF) solutions (10 mL of final volume) were blended in 
the ratios of 80/20, 60/40 and 40/60 of SF/K. The blends were cast in plastic Petri 
dishes with a circular area of 40 cm2 and dried at room temperature. The controls 
are 100% SF and 100% K. The resulting films were 0.03 mm in average thickness. 
In order to induce the transition of SF from random coil to β-sheet structure and 
consequently insolubility, all the films were immersed in 90% (v/v) methanol 
solution for 30 minutes and then washed in distilled water and air dried. All films 
used were submitted to this treatment.  
4.2.4. In vitro degradation  
SF/K films were incubated, for 14 days, at 37 °C in  a solution containing 0.1 U/mL 
of porcine pancreatic elastase (PPE) in 100 mM Tris-HCl buffer, pH 8.0. The 
control samples were incubated in the same buffer without PPE and submitted to 
the same conditions. Solutions were changed every 12 h. At designated time 
points, samples were washed thoroughly with distilled water, dried in a desiccator, 
and weighed to estimate the extent of degradation according to equation 2.3., 
Chapter II. 
4.2.5. Swelling ratio of SF/K films 
Dry SF/K films (60 °C for 24 h) were immersed in 10 0 mM Tris-HCl buffer, pH 8.0 
at 37 °C for 24 h. The excess of buffer was removed  and the wet weight of the film 
was determined. The swelling ratio of the film was calculated by equation 2.2., 
Chapter II. 
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4.2.6. Protein adsorption to protein films 
SF/K films were incubated with 0.1 U/mL of porcine pancreatic elastase (PPE) 
solution at 37 °C for 24 h. Adsorption of the prote ins to the SF/K films was 
determined by measuring the reduction of elastase activity in the supernatant. 
4.2.7. Cytotoxicity evaluation 
SF/K films were tested for cytotoxicity according to the ISO standards (10993-5, 
2009). Both, tests by direct contact and tests on extract were performed to analyse 
the cytotoxicity of the developed materials as previously describe in Chapter II. 
Data are presented as average (standard deviation (SD). For multiple 
comparisons, homogeneity of variances was assessed by Barlett’s test and after 
confirmation of the nonsignificant difference of variances, one-way ANOVA, 
followed by post hoc Bonferroni test was performed. Differences were considered 
statistically significant when p < 0.05. All calculations were performed using SPSS 
software for Windows (version 16.0, SPSS). 
4.2.8. In vitro release 
The release of model compounds from SF/K films was evaluated by the 
incorporation of FITC-BSA in the films. FITC-BSA (2 mg/mL) was mixed with 
protein solutions before film casting. The resulting films incorporating FITC-BSA 
were incubated with 100 mM Tris-HCl buffer, pH 8.0 and 0.1 U/mL of PPE solution 
at 37 °C. Solutions were changed every day. At dete rmined time points, aliquots 
were taken and the FITC-BSA release was monitored by a multiplate reader 
(Synergy HT W/TRF from BioTek) in the fluorescence mode at emission 
wavelength of 490 nm. After each measurement, the samples were added back to 
the medium to restore the equilibrium conditions. The quantification of the release 
was established by a standard fluorescence curve. The release studies were 
performed in triplicate and for a period of 7 days. 
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4.2.9. Elastase activity determinations 
The activity of porcine pancreatic elastase was measured according to a method 
previously reported [387] with some modifications. Briefly, 30 µL of enzyme was 
mixed with 900 µL of reaction buffer 100 mM Tris-HCl, pH 8.0. The reaction was 
started by the addition of 70 µL of 4.4 mM of N-Succinyl-Ala-Ala-Ala-p-nitroanilide, 
a synthetic substrate for PPE. The reaction was carried out for 5 min at 37 °C and 
the cleavage of the substrate was monitored spectrophotometrically at 410 nm. 
One unit is defined as the amount of enzyme that will hydrolyze 1.0 µmol of Suc-
(Ala)3-pNA per minute at 25 °C, pH 8.0. 
To examine the inhibitory activity of 5(6)-Carboxyfluorescein-YCQPPWSATCF-
OH, different peptide concentrations were added to a fixed amount of PPE 
solution. The incubation was carried out a 37 °C an d, at determined time points, 
aliquots were taken to monitor the decrease in elastase activity determined as 
previously described. The peptide, 20 µM, was mixed with the proteins solutions 
before film casting. The films were incubated with PPE solution at 37 °C. In this 
case, a fixed ratio of elastase solution per weight of film (0.2 mL/mg film) was kept. 
The inhibitory activity was determined as described above. 
4.3. Results and discussion 
In this work, films designed to be wound dressing materials, based on silk fibroin 
and keratin proteins with delivery properties were developed. Our previous work 
[15] indicated that SF and keratin are able to establish intermolecular interactions 
like hydrogen bonding. This fact was proven by the nonlinear trend of the different 
parameters such as intensity ratio of amide II bands and, enthalpy variation (∆H) 
of the decomposition peak obtained respectively, from FTIR and DSC analysis. In 
addition, in the presence of protease enzyme, the films underwent a slow 
biological degradation, that is a function of the amount of keratin present in the 
blend. The combination of our results with the excellent biocompatibility both in 
vitro and in vivo [108, 417], the promotion of cellular adhesion and proliferation 
[123, 190, 396] and slow biodegradation already demonstrated, were the main 
factors to study the ability of SF/K films to act as wound dressings. 
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4.3.1. Characterization of protein blend films 
Films were prepared by casting the regenerated solutions of silk fibroin and keratin 
on Petri dishes. After overnight solvent evaporation, uniform and transparent films 
were obtained. Blend films with concentrations of: 100%, 80%, 60%, 40%, 20% 
and 0% of SF were prepared. However, it was observed that with the increase of 
keratin in the blend it was not possible to obtain a film with mechanical integrity. 
Therefore, the maximum concentration of keratin that can be used in the blend is 
60%.  
Degradability of a given material is a very important parameter. It is directly linked 
to the drug release. The fast polymer degradation is not desirable because a high 
drug concentration will be released, which can be disadvantageous. In vitro 
degradation of SF/K films was determined by incubating protein films for several 
days in the presence of elastase enzyme which is one of the major components of 
the chronic wounds exudate. PPE was used as a model. It can be observed 
(Figure 4.1) that pure SF films present a low degradation rate that remains 
constant over the time exposure to elastase. This weight loss can be related with 
the degradation of the small hydrolytically peptide sequences present on the films 
even after crystallization [48]. In the blends, it can be observed that the weight loss 
obtained is a function of keratin content present in the film. At low keratin amounts 
(20%) the degradation is relatively slower. On the other hand, at maximum keratin 
concentration (60%), the degradation took place rapidly and after 7 days we 
obtained debris. Consequently, the weight loss, for this sample, after 14 days of 
incubation, was not measured because of the high error associated with the 
measurement.  It is important to notice that the weight loss obtained for the blends 
is almost the same of the keratin content on the blend. Therefore, the debris 
obtained for 40/60 SF/K film is probably the fibroin that is not degraded but is not 
in sufficient amount to maintain the mechanical structure of the film. From our 
results the maximum keratin amount that promotes a constant degradation is 40%. 
The films kept in buffer solution showed little or no degradation in 14 days. 
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Figure 4.1. In vitro degradation of protein films incubated with 0.1 U/mL of 
elastase solution at 37 °C for several days. 
 
On the wound dressing research, swelling is other important parameter in 
materials characterization. If the material has the ability to swell, it will give 
moisture to the wound contributing for a better healing [303]. Swelling ratio was 
found to increase with the increase of keratin present in the blend (Figure 4.2). It 
results from diffusion, and involves the transport of ions or fluid into the 
biomaterial. The driving forces of film formation by casting and solvent evaporation 
are attributed to hydrophobic interactions and partial electrostatic interactions [48]. 
The increase in keratin amount decreases these types of interactions due to the 
high content in polar residues such as cysteine. This will promote a more open 
structure thereby increasing the film swelling. 
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Figure 4.2. Swelling ratio calculated after 24 h of incubation in 100 mM Tris-HCl 
buffer, pH 8.0 at 37 °C. 
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Silk fibroin/keratin films morphology was assessed by atomic force microscopy 
(AFM). With this analysis we intend to determine the effect of surface topography 
on the degradation as well on cell adhesion. On Figure 4.3 the roughness height 
images are shown. The pure SF film presented the higher roughness value and, 
its surface is characterized by well defined globular structures (Figure 4.3a) as 
already observed by others authors[40]. The formation of these structures is a 
consequence of the methanol treatment.  
In the blends, the addition of keratin enables the formation of the globular 
structures making the surface of the film smoother. It can also be observed a 
decrease in the roughness value with the increase of keratin in the blend (Data not 
shown). Addition of keratin alters surface topography of the films and, as a 
consequence this might cause lost of film strength as already confirmed by in vitro 
degradation results [396]. 
 
         
  
 
Figure 4.3. AFM height images of pure and blend silk fibroin/keratin films. (a) 100 
SF; b) 80 SF; c) 60 SF; d) 40 SF; e) 100 K). The area measured was 10×10 µm. 
 
Biocompatibility is an essential parameter to be evaluated for a biomaterial to be 
used in wound dressing. This was assessed for our materials through the use of 
mouse embryonic fibroblasts cultures. Two parameters were determined, 
cytotoxicity and cell adhesion. The results of the indirect contact study following 
fibroblast incubation with material extracts at different dilutions showed no 
cytotoxicity effect of the protein film extracts regardless of the extraction time. 
a) b) c) 
d) e) 
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Figure 4.4 represents the viability results for cells in contact with undiluted extract 
(extraction time 72 h). In all cases, the metabolic activity of cells in contact with the 
extracts was statistically equal or higher than the one obtained with negative 
control (complete medium). 
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Figure 4.4. NIH 3T3 cell viability at 24 and 72 h of culture post contact with 
extracts of the different materials tested (72 h extraction time). The results obtained 
with the four materials were compared among each other and with the controls: * = significantly 
different from all the other tested conditions; δ = significantly different from 100 SF, 80/20 SF/K and 
60/40 SF/K. 
 
Direct contact study performed by seeding the cells on the membranes showed a 
time dependent increase of cell metabolic activity (Figure 4.5) that may suggest an 
increase of cell proliferation. This was confirmed by cell microscopic observation 
where cell number increased as a function of time. However, at the different time 
points studied, no significant differences were observed among the materials and 
the control suggesting that the structures observed in AFM analysis on the film 
surface did not affect cellular adhesion. Microscopic observations showed similar 
cell number, distribution and morphology on all materials, regardless of the time of 
contact. At 48 h (Figure 4.6), cells exhibited an elongated morphology with 
fusiform fibroblastic appearance already at confluence, as on the control (TCPS). 
F-actin staining revealed a well-defined cytoskeleton and numerous filopodia as 
well as cell-cell contacts. The same result was observed by Shudong et al. using 
mouse fibroblast cell lines [418]. These results are in agreement with the literature 
indicating that the processing steps involving the use of solvent systems will not 
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cause detrimental effects on the resulting material [36, 39, 43, 419]. Despite the 
fact that no cytotoxic effect was observed, it should be consider for posterior work, 
test the materials using cells form human source and use in vivo assays conditions 
such as wound animal models. In this way, parameters like inflammatory reactions 
and wound closing and healing will be determined. 
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Figure 4.5. NIH 3T3 cell proliferation on discs of 100 SF, 80/20 SF/K and 
60/40 SF/K. 
 
 
 
Figure 4.6. Fluorescent labelling of F-actin (green) and DNA (blue) of NIH 3T3 
cells cultured for 48 h on TCPS(a and b) and discs prepared from 80/20 SF/K film 
(c and d). 
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4.3.2. In vitro release  
The release profile of FITC-BSA from SF/K films is presented in Figure 4.7. 
Considering the loaded amount as 100% and normalizing the amount of FITC-
BSA released in PPE solution, the profile is obtained. The release can be divided 
into two phases: an initial burst phase in the first 6 h and, a continuous release 
over the remaining time. The initial burst release might be related to the compound 
molecules that are on the surface of the film. Nevertheless, for pure SF film, the 
release is controlled and slow. In the blends, the release is fast and is dependent 
on the keratin amount. Methanol treatment leads to higher crystallinity making the 
film rigid and compact. Although this treatment leads to physical crosslinking of the 
films, incorporation of keratin, of hydrolytic nature, had a pronounced effect on the 
FITC-BSA release. This may be due to keratin dissolution causing more void 
volume for the release of the compound. The methanol treatment does not provide 
adequate stability for sustained release over days for films with high keratin 
content. The previous results obtained from mechanical tests [15] indicate that 
increase in keratin content leads to the decrease of the mechanical strength of the 
films. This will allow the formation of cracks in the film from where the compound 
can rapidly diffuse out. 
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Figure 4.7. In vitro release profile of the peptide from SF/K films incubated with 
0.1 U/mL of PPE solution. 
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To evaluate if the release from SF/K films is controlled by diffusion or dominated 
by film degradation, experimental data was fitted into the Ritger-Peppas equation 
as described in chapter II, equations 2.4 and 2.5. For a thin film, a Fickian diffusion 
of first-order is observed when n has the limiting value of 0.5; when n = 1, case II 
transport (polymer relaxation/degradation) occurs leading to zero-order release. 
When n lies between 0.5 and 1 anomalous transport is observed, coupling of 
Fickian diffusion and polymer degradation [420]. It can be concluded from the data 
obtained in Table 4.1 that for samples 100 SF and 80/20 SF/K the release is 
dominated by Fickian diffusion of first-order. The n value obtained for the blend 
80/20 SF/K is closer to 0.5 indicating that addition of 20% of keratin decreases the 
rigidity of the compact structure of pure SF film improving the release properties. 
There is an increase in film swelling and consequently the diffusion of FITC-BSA. 
For the blend 60/40 SF/K, the release is non-Fickian nature, “n” lies between 0.5 
and 1 indicating that the release is due to the combination of diffusion and film 
degradation. The sample 40/60 SF/K show the highest “n” value (n>1) indicating 
that for this sample the release is totally dominated by film degradation. The 
sample 40/60 SF/K presents higher swelling ratio, degradation rate and, as a 
consequence, higher release rate. Furthermore, correlation coefficient “R2” is 
above the permissible range, i.e. (R2 = 0.95) indicating the validity of the results. 
 
Table 4.1. Model compound release kinetic data obtained from fitting experimental 
release data to Ritger-Peppas equation where “n” is the diffusion exponent and R2 
is the correlation coefficient 
 
Sample n R2 
100 SF 
80/20 SF/K 
60/40 SF/K 
40/60 SF/K 
0.411 
0.507 
0.551 
1.03 
0.996 
0.997 
0.997 
0.993 
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4.3.3. Inhibitory activity  
The major goal of this work is the development of wound dressings with specific 
biological functionality - the inhibition of high levels of elastase. For this purpose, it 
was important to determine the inhibitory activity of the synthetic peptide selected. 
Several studies have been made to control elastase activity and promote chronic 
wound healing. A cotton-bound serine protease inhibitor has shown to decrease 
elastase activity on a chronic wound fluid [318]. The release of epidermal growth 
factor (EGF) from electrospun silk mats had also shown the promotion of wound 
healing [128]. Even so, there are few or no studies on the release of synthetic 
peptides from protein films to promote the inhibition of high levels of elastase 
found on chronic wounds exudate. Thus, this work presents an original system to 
control high levels of elastase found on chronic wounds. To determine the 
inhibitory activity of the peptide, increasing peptide amounts were incubated with 
elastase solution at 37 °C. At determined time poin ts, aliquots were taken to 
determine the residual activity. From the results obtained on Table 4.2 it can be 
seen that for high peptide concentrations PPE activity rapidly decreases, 
suggesting its ability to act as an elastase inhibitor. For lower peptide 
concentrations the decrease in half-life time of PPE is not so pronounced. It can 
be concluded that the decrease in PPE activity is dependent of peptide 
concentration. 
 
Table 4.2. Hal-life time of PPE activity after 24 h of incubation with different 
peptide (5(6)-Carboxyfluorescein-YCQPPWSATCF-OH) concentrations at room 
temperature 
Sample t1/2 (h) 
PPE 
PPE + 20 µM 
PPE + 40 µM 
PPE + 60 µM 
PPE + 80 µM 
28.3 ± 3.7 
15.3 ± 2.1 
11.6 ± 2.3 
5.3 ± 1.2 
3.8 ± 1.1 
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In order to understand the inhibition mechanism of this peptide, assays were 
performed to determine the inhibition constant. When the residual activity was 
plotted against substrate concentration it was observed that the elastase activity 
curve in the presence of peptide inhibitor converge, over the time, to the curve of 
elastase activity without peptide. This result might indicate that the peptide is being 
hydrolyzed by elastase which was confirmed by mass spectrometry analysis (Data 
not shown). Hydrolytic stability of BBI peptides as the one selected for this study is 
very important. Generally hydrolysis rates are low and are affected by the peptide 
sequence [363, 374]. The hydrolysis of our peptide occurred after 6 h of incubation 
with PPE. Nevertheless, its was observed a high decrease in elastase activity in 
the presence of peptide (Table 4.2) suggesting that its function was not affected by 
hydrolysis. Simulations performed based on the decrease in the mass value (from 
m/z = 1659.83 to m/z = 1512.75) indicated that hydrolysis might occur in one 
amino acid residue of the C-terminal. Probably this will not change the 
conformational structure of the peptide which allows it to retain the inhibitory 
activity. However, this fact has to be further investigated by other techniques such 
as NMR analysis. To determine if the peptide retains its inhibitory activity after 
incorporation onto SF/K films, films with 20 µM of peptide were incubated with 
PPE solution for 24 h. At determined time points the PPE activity was measured 
and the results are presented in Table 4.3 as half-life time of PPE. It can be seen 
that for 100 SF and 80/20 SF/K films, incorporation of the peptide increases the 
half-life time of PPE (22.7 ± 4.2 and 17.5 ± 3.3 h respectively) when compared 
with the peptide alone (15.3 ± 2.1 h). This result indicates the ability of the SF/K 
films to act as elastase inhibitors wound dressings. For the blends 60/40 and 
40/60 SF/K the half-life time of PPE decrease in comparison to the peptide in 
solution (Table 4.3). The release of the peptide from SF/K films was also 
monitored for 24 h by fluorescence measurements (Data not shown). With the 
data obtained it was not possible to determine the release mechanism. 
Nevertheless, the release kinetics obtained with FITC-BSA allows concluding that 
in the first 24 h the decrease in PPE activity is mainly due to the swelling ratio. The 
high swelling ratio obtained for 60/40 and 40/60 SF/K blends means that PPE 
solution is rapidly in contact with inhibitor peptide into the film causing the fast 
decrease in PPE activity. If the measurements were prolonged for more time, the 
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release of peptide and consequently the decrease in PPE activity will be more 
influenced by degradation rate. 
 
Table 4.3. Hal-life time of PPE after 24 h of incubation with SF/K films with 20 µM 
of peptide incorporated 
 
Sample Activity Loss (%) 
PPE 
PPE + 20 µM 
100 SF 
80/20 SF/K 
60/40 SF/K 
40/60 SF/K 
28.3 ± 3.7 
15.3 ± 2.1 
22.7 ± 4.2 
17.5 ± 3.3 
14.1 ± 2.1 
8.1 ± 1.1 
 
In a heterogeneous system like this is important to determine the protein, PPE, 
adsorption to the SF/K films. In particular, it is important to distinguish the 
decrease of PPE activity due to the peptide action from the decrease in activity 
due to adsorption to the films. In order to evaluate this difference, films with and 
without peptide were incubated with PPE solution and the decrease in PPE activity 
was monitored. 
It can be seen from Figure 4.8 that when PPE was incubated with SF/K films 
without peptide, the decrease in activity is much lower in comparison with films 
with peptide. This result validates the action of the peptide when it is incorporated 
into the SF/K films. Furthermore, it can be seen that protein (PPE) adsorption is 
also a function of the keratin amount. 
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Figure 4.8. PPE activity loss after 24 h of incubation with SF/K films with and 
without peptide incorporated. 
4.4. Conclusions  
This study evidenced that blending silk fibroin and wool keratin results into a 
protein matrix suitable for sustained delivery of elastase inhibiting agents. The 
release pattern is affected by the degradation rate of the films and the knowledge 
of this allows the design of matrices with controlled release ability. 
In vitro degradation was evaluated under PPE solution and, it was found that 
biological degradation is a function of keratin amount present in the film. The SF/K 
films were also tested for in vitro release using PPE solution as release medium. 
The results presented indicated that the release mechanism of molecules from the 
films is dominated by film degradation and diffusion. In this work the dehydrating 
step of methanol treatment was used to control the structure and stability of the 
self-assembly SF/K films. Pure fibroin films (100SF) present a rigid and compact 
structure, addition of keratin leads to a decrease in β-sheet content causing a 
more open structure which will affect swelling, degradation and release rates. 
Furthermore, our study indicated that the protein films developed are not cytotoxic 
and are able to support the adhesion of fibroblasts cells, making them suitable for 
biomedical applications such as wound dressings. 
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CHAPTER V 
 
Novel silk fibroin/elastin scaffolds crosslinked with genipin for 
wound dressings 
 
Abstract 
 
Silk fibroin (SF) and elastin (EL) scaffolds were successfully produced for the first 
time by means of lyophilization technique. The self-assembly properties of SF, 
together with the excellent chemical and mechanical stability and, biocompatibility, 
were combined with elastin protein to produce scaffolds with the ability to mimic 
the extracellular matrix (ECM). Porous scaffolds were obtained and were further 
crosslinked with genipin (GE), through the formation of amide bonds. Genipin 
crosslinking induces the conformational transition from random coil to β-sheet of 
SF chains yielding scaffolds with smaller pore size, reduced swelling ratios, 
degradation and release rates. The evaluation of such biochemical properties 
using a human chronic wound exudate and the cytocompatibility demonstrated 
with human skin fibroblasts make these SF/EL scaffolds suitable for wound 
dressing applications. 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: Andreia Vasconcelos, 
Andreia C. Gomes & Artur Cavaco-Paulo, Novel silk fibroin/elastin scaffolds 
crosslinked with genipin for wound dressings, Submitted 
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5.1. Introduction 
Skin wounds are the disruption of normal skin physiology. From the moment the 
wound is created, the healing mechanism is initiated to re-establish skin continuity. 
The healing process is complex and involves an integrate response of different cell 
types and growth factors [297-299, 421, 422]. Promotion of healing is often 
accompanied by the use of biocompatible wound dressings; these should promote 
a moist environment in the wound and serve as a shield against external factors 
like dust and bacteria; enhance water and vapor permeation and promote 
ephitelization by releasing biological agents to the wounds. Due to its unique 
properties of high mechanical strength and excellent biocompatibility, silk fibroin 
has been explored for the development of wound dressings. The degradation rates 
of electrospun silk materials applied to wound dressing have been evaluated [127] 
and the incorporation of growth factors into electrospun silk mats have shown to 
accelerate wound healing [128]. Moreover, silk films have been shown to heal full 
thickness skin wounds in rats faster than traditional porcine-based wound 
dressings [122]. Blending silk fibroin with other components has shown to improve 
the properties of the resulting material. This allows the modulation of 
biodegradation and release rates, important parameters in the biomaterials field. 
Recently, we developed silk fibroin/keratin films incorporating a synthetic inhibitor 
of elastase, to control the high levels of this enzyme produced in a chronic wound 
environment [326]. Silk fibroin/alginate sponges demonstrate higher healing effect 
than both components acting alone [123]. In this work, scaffolds based on silk 
fibroin and soluble elastin were developed and tested. 
Elastin is an insoluble extracellular matrix protein that provides elasticity and 
resilience to the arteries, lungs and skin [203-205]. Due to it’s highly crosslinked 
nature, elastin is highly insoluble and difficult to process into new biomaterials. As 
a consequence, soluble forms of elastin including tropoelastin [243], α-elastin 
[251, 253] and elastin-like polypeptides [233, 255, 261] are frequently used to 
develop elastin-based biomaterials. Nevertheless, a crosslinking step is required 
to obtain an insoluble material. There are several crosslinking methods for elastin 
including chemical [243, 251, 263], enzymatic [423], physical [253, 424-426] and  
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γ-irradiation [258]. Among them, chemical crosslinking agents are widely used. 
Aldehydes and epoxy compounds have been commonly used in biomaterial 
constructs due to their efficient formation of crosslinks with amino acid side chains, 
low antigenicity and sufficient mechanical strength. Despite these advantages, 
they exhibit high cytotoxicity [263, 427, 428]. Genipin (Ge) is a natural covalent 
crosslink agent isolated from the fruits of Gardenia jasminoides Ellis [375] that 
offers comparable crosslinking efficacy. It has been reported that genipin binds 
with biological tissues [381, 429] and biopolymers [380, 430] leading to matrices 
with good mechanical properties, reduced swelling extent and significantly 
reduced cytotoxicity when compared to synthetic crosslinking agents like 
glutaraldehyde and epoxy compounds [379, 380]. 
To our knowledge, elastin has been crosslinked with collagen [278, 279], fibrin 
[269, 270] and gelatin [279, 280] for the development of biomaterials, but never 
with silk fibroin. In this work, we developed silk fibroin/elastin (SF/EL) scaffolds 
crosslinked with genipin. The resulting materials were characterized by their 
physical-chemical properties and the effect of crosslinking on those properties was 
evaluated. Moreover, the wound dressing functionality of these materials was 
tested with a real chronic wound exudate. 
5.2. Materials and methods 
Herein it will be given a detailed description of some of the methods presented in 
the previous chapter. All other techniques were performed as described in Chapter 
II. 
5.2.1. Materials 
Elastin soluble from bovine neck ligament was purchased from Sigma (Spain). 
Genipin is a product of Wako Chemicals (Germany). The BJ5ta cell line 
(telomerase-immortalized human normal skin fibroblasts) was purchased from 
ATCC through LGC Standards. All other reagents, including those used in cell 
culture, were analytical grade and purchased from Sigma, Spain. 
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5.2.2. Preparation of Silk fibroin solution 
Silk was purified from its sericin content as previously described in section 2.3, 
Chapter II. Silk fibroin (SF) solution (2% (w/v)) was prepared by dissolving fibroin 
in 9.6 M LiBr solution at 60 °C for 3 h. The result ing solution was filtered, and 
dialyzed against distilled water until complete removal of salts, using cellulose 
tubing (Sigma, Spain) (molecular-weight cut-off of 12000-14000 Da). 
5.2.3. Silk fibroin/Elastin blends preparation; Crosslinking reaction; Scaffold 
formation 
Elastin (EL) solution was prepared by dissolving the elastin powder in distilled 
water. SF (2%) and EL (1%) were mixed to prepare blends of 100/0 SF/EL, 80/20 
SF/EL and 50/50 SF/EL. Genipin (GE) powder, 0.1% and 0.5% (w/v) was added to 
blend solutions under constant stirring at room temperature until complete 
dissolution of GE powder. The crosslinking reaction was carried out for 3, 6 and 
24 h at 37 °C. The resulting solutions were cast on  96-well plates and frozen at -
20 °C for 2 days and freeze dried for 2 days to rem ove the solvent completely. 
SF/EL scaffolds without genipin were used as controls and were prepared by the 
same process described above. The control samples were identified as 100SF, 
80SF and 50SF which correspond to 0, 20 and 50% of elastin and, crosslinked 
sponges were identified as 100SFyGE, 80SFyGE and 50SFyGE where y is the 
genipin concentration used. In order to induce the transition of SF from random 
coil to β-sheet structure and consequently insolubility, scaffolds were immersed in 
90% (v/v) methanol solution for 30 minutes and then washed in distilled water and 
air dried. 
5.2.4. Degree of crosslinking 
The crosslinking degree was determined by the ninhydrin assay [45, 383, 384]. 
Samples (6.0 ± 0.7 mg) were heated with a ninhydrin solution (2% (w/v)) at 100 °C 
for 20 min. The optical absorbance of the resulting solution was recorded at a 
wavelength of 570 nm using a Heλios γ ThermoSpectronic spectrophotometer. 
The amount of free amino groups in the test sample after heating with ninhydrin is 
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proportional to the optical absorbance of the solution. The concentration of free 
NH2 groups in the sample was determined from a standard curve of Glycine 
concentration vs. absorbance. SF/EL scaffolds prepared without genipin were 
used as control materials. Triplicate samples were evaluated. The degree of 
crosslinking was determined by the equation 2.1., Chapter II. 
5.2.5. Swelling ratio 
SF/EL scaffolds, treated with methanol and completely dry (60 °C for 24 h) were 
immersed in PBS buffer (pH 3.0; 7,4 and 11) at 37 °C for 24 h. The excess of 
buffer was removed and the wet weight of the scaffolds was determined. The 
swelling ratio of the film was calculated accordingly to equation 2.2., Chapter II. 
5.2.6. In vitro degradation 
Porcine pancreatic elastase (PPE): SF/El scaffolds previously treated with 
methanol, with and without crosslinking were incubated for 21 days at 37 °C in a 
solution containing 0.1 mg/mL of PPE in 100 mM Tris-HCl buffer, pH 8.0. The 
control samples were incubated in PBS buffer solution (pH 7.4) without enzyme 
and submitted to the same conditions. The solutions were replaced every 24 h. 
Wound exudate: Wound exudate was collected from pressure wounds using a 
vacuum assisted closure system. Wound fluid was diluted 10-fold in PBS solution 
and centrifuged to remove cells and tissue material. SF/EL scaffolds were 
incubated with exudate in the same conditions described above in a fixed ratio of 
exudate per mg of scaffold of 6 mg/mL. At designed time points, samples were 
washed thoroughly with distilled water, dried in a desiccator and weighted to 
estimate the extent of degradation by equation 2.3., Chapter II. 
5.2.7. In vitro release 
The release of model compounds from SF/EL scaffolds was examined by the 
incorporation of Trypan-Blue (100 µg/mL) and FITC-BSA (2 mg/mL). For control 
samples, dyes were dissolved in the protein solution and stirred for 5 min at room 
temperatures. The resulting solutions were casted in 96-well plates to prepare the 
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SF/EL scaffolds. In the case of crosslinked ones, dyes were dissolved in the 
protein solution before crosslinking reaction. Before release studies, control and 
crosslinked scaffolds were treated with methanol. SF/EL scaffolds were incubated 
at 37 °C in PBS buffer and in a solution containing  0.1 mg/ml of PPE. Solutions 
were changed every 24 h, at determined time points aliquots were taken and, 
Trypan-blue release was determined by measuring the absorbance at 595 nm 
using a Heλios γ ThermoSpectronic spectrophotometer. FITC-BSA release was 
monitored by a multiplate reader (Synergy HT W/TRF from BioTek) in the 
fluorescence mode at emission wavelength of 490 nm. After each measurement, 
the samples were added back to the medium to restore the equilibrium conditions. 
The quantification of the release was established by a standard curve of both 
dyes. Release studies were performed in triplicate samples and for a period of 21 
days. 
5.2.8. Cytotoxicity evaluation 
SF/EL scaffolds were tested for cytotoxicity according to the ISO standards 
(10993-5, 2009). Tests on extract were performed to analyse the cytotoxicity of the 
developed materials as previously describe in Chapter II. Data are presented as 
average ± S.D. Two-way Anova with Bonferroni post-tests was performed, with 
statistically significant differences when p < 0.001. All calculations were performed 
using GraphPad software (version 5.03) [431]. 
5.3. Results and discussion 
5.3.1. Biochemical and biophysical properties of SF/EL scaffolds  
Amino acid composition of the proteins used in this work was determined by HPLC 
analysis and the result is present on Table 5.1. The SF molecule is mainly 
composed of glycine (43.68%), alanine (29.34%) and serine (11.48%) amino acids 
which forms the typical -(-ala-gly-)n- repeating motifs responsible for the formation 
of the β-sheet crystals [12]. Elastin is mainly composed of glycine (32.15%), 
alanine (24.12%), proline (11.85%) and valine (11.36%). In vivo, elastin results 
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from the directed crosslinking of its precursor, tropoelastin whose hydrophobic 
region is mainly composed of the mentioned amino acid residues [207-209]. 
 
Table 5.1. Amino acid composition of silk fibroin and soluble elastin 
 
Amino acid Silk fibroin (mol %) Elastin (mol %) 
Cyst 
Asp 
Ser 
Glu 
Gly 
His 
Arg 
Thr 
Ala 
Pro 
Cys 
Tyr 
Val 
Met 
Lys 
Ile 
Leu 
Phe 
- 
1.67 
11.48 
1.37 
43.68 
0.20 
0.62 
0.96 
29.34 
0.67 
0.10 
5.30 
2.23 
0.10 
0.33 
0.66 
0.58 
0.72 
- 
0.54 
1.17 
1.72 
32.15 
0,36 
0,74 
1.07 
24.12 
11.85 
0.37 
1.49 
11.36 
0.31 
0.33 
2.24 
6.03 
4.16 
 
The formation of covalent bonds on blended systems may produce stable and 
ordered materials with benefic effect on their properties.  To achieve such effect, 
genipin was used to crosslink SF/EL scaffolds. Different crosslinking conditions 
were tested and the results are summarized on Table 5.2. After 3 h of reaction it 
was observed a color change in the solutions from light yellow to light blue 
indicating the reaction between both SF and elastin with genipin. It is described 
that genipin react with amino acids or proteins to form dark-blue pigments 
associated with the oxygen-radical polymerization of genipin [429, 430, 432]. After 
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6 h of reaction, the solutions became dark-blue and, from the results in Table 5.2, 
the maximum crosslinking degree was reached for the different scaffolds. 
The exact mechanism behind the interaction of genipin with both SF and elastin is 
yet to be fully described. The generally accepted mechanism is similar to that 
observed for amino-group containing compounds [430, 433] where the ester 
groups of genipin interact with the amino groups of SF and elastin leading to the 
formation of secondary amide linkages. Moreover, the amino groups initiate 
nucleophilic attacks which results in the opening of the genipin dihydropyran ring. 
An inherent phenomenon of genipin crosslinking is self-polymerization which 
occurs by radical reaction of two amino-attached open rings [381, 382]. Some 
authors [432] reported that genipin preferentially reacts with the amino acids lysine 
and arginine. SF and elastin contain respectively, 0.95% and 1.07% of these 
amino acids (Table 5.1) which is a very low fraction. The crosslinking sites are 
thus low in number which results in lower crosslinking degrees when compared 
with other genipin crosslinked blend systems [44]. The highest crosslinking degree 
obtained for sponges containing elastin (Table 5.2) might be related with the 
slightly higher fraction of lysine and arginine amino acids. 
 
Table 5.2. Degree of crosslinking obtained for SF/EL scaffolds for the different 
reaction conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
The genipin crosslinking of SF/EL scaffolds might induce conformational changes 
due to the structural rearrangement of chains to form covalent bonds. FT-IR 
spectra of SF and elastin, with and without crosslinking, in the range of 600-
Degree of cross-linking (%) Cross-linking 
treatment 100SF 80/20 SF/EL 50/50 SF/EL 
3h; 0.1% GE 
6h; 0.1% GE 
24h; 0.1% GE 
3h; 0.5% GE 
6h; 0.5% GE 
24h; 0.5% GE 
15.2 ± 1.1 
22.1 ± 1.3 
23.5 ± 2.1 
20.3 ± 1.9 
28.6 ± 1.4 
29.4 ± 1.6 
18.4 ± 1.5 
29.3 ± 1.1 
30.2 ± 1.5 
24.2 ± 1.1 
48.3 ± 2.2 
46.7 ± 1.3 
22.6 ± 2.1 
31.7 ± 1.8 
29.8 ± 2.5 
27.3 ± 2.1 
52.2 ± 1.6 
50.6 ± 2.2 
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2000 cm-1 are represented on Figure 5.1 and 5.2. SF protein exists in three 
conformations namely random coil, Silk I (α-form) and Silk II (β-sheet 
conformation).  
The 100SF spectrum in Figure 5.1 showed bands at 1640 cm-1 for amide I (C=O 
stretching), 1517 cm-1 with a shoulder at 1532 cm-1 for amide II (N-H deformation) 
and 1238 cm-1 for amide III (C-N stretching, C=O bending vibration) indicating a 
random coil/Silk I conformation [45, 51, 78, 434]. SF molecules can structurally 
rearrange due to changes in the hydrogen bonding by methanol treatment 
acquiring a β-sheet conformation. Genipin crosslinking is also able to induce β-
sheet conformation of SF molecules. Comparing the SF spectra obtained after 
genipin crosslinking (Figure 5.1) it is clearly the transition of random coil to β-sheet 
conformation confirmed by the shifting to lower wavenumbers of amide I (1620 cm-
1) and amide II (1514 cm-1) bands [45, 51, 78, 434]. The shoulder observed at 
1532 cm-1 for amide II assigned to random coil, progressively disappears with the 
increase in genipin concentration. Moreover, characteristic band of genipin at 
1105 cm-1 (-COH) that appeared in the spectra of 100SF0.1GE and 100SF0.5GE 
confirms once again the reaction between genipin and SF. The FT-IR results 
evidenced that genipin crosslinking of SF is followed by protein conformational 
changes already shown by other authors [44, 45]. 
Figure 5.2 shows the spectrum for elastin protein that was acquired in powder 
form by diffuse reflectance. Due to the higher background obtained with this 
technique, the wavenumbers obtained are relatively higher. 100EL spectrum 
shows characteristic protein bands at 1689 cm-1 (amide I), 1550 cm-1 (amide II) 
and 1238 cm-1 (amide III), assigned to random coil conformation [26, 435, 436]. It 
can be seen that genipin induces in elastin structural changes into a more β-sheet 
conformation. This was confirmed by the shifting to lower wavenumbers of the 
bands mentioned above. In addition, the appearance of a new peak at 1109 cm-1, 
characteristic of genipin, confirms the crosslinking reaction. The results obtained 
after methanol treatment of the scaffolds (Data not shown) show no additional 
changes, for both proteins, when compared with genipin crosslinked spectra.  
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Figure 5.1. FT-IR absorbance spectra of pure silk fibroin (100SF) and crosslinked 
with genipin (100SF0.1GE and 100SF0.5GE). 
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Figure 5.2. FT-IR absorbance spectra of pure elastin (100EL) and crosslinked with 
genipin (100EL0.1GE and 100EL0.5GE). 
 
Deconvolution was limited to the amide I range (1590-1720 cm-1) because protein 
conformation can be identified in this range [44, 437, 438].The results are shown 
in Table 5.3, indicated that pure SF scaffolds, without methanol treatment, are 
mainly in the conformation of random coil (46.06%) but presents also other 
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conformations like β-sheet and some intermediate forms like turns and bends 
[437, 438]. The addition of genipin promoted conformational changes into SF, 
especially with the sample with higher genipin concentration (100SF0.5GE). It can 
be observed an increase in the β-sheet content from 30.57% (100SF) to 57.96% 
(100SF0.5GE) indicating the crystallization of the SF chains. Moreover, the 
deconvolution results obtained after methanol treatment are similar to the results 
obtained for 100SF0.5GE sample indicating that methanol treatment will not cause 
additional conformational changes in the scaffolds. These results support the 
hypothesis that SF molecules can be structurally rearranged after addition of 
genipin as already demonstrated by others [44]. Deconvolution analysis was also 
performed on elastin (Data not shown). As already showed [439], the secondary 
structure of elastin is mainly characterized by a β-sheet conformation with the 
presence of undefined conformations. Our results correlate previous ones and, it 
can also be observed that after genipin crosslinking, there is an increase of 
undefined conformations for elastin. 
 
Table 5.3. Deconvolution results obtained from the amide I region in the FT-IR 
spectra of SF scaffolds 
 
FT-IR spectra of blend systems show slightly changes of the wavenumbers and on 
the areas of the bands due to mixing effects of SF with elastin. The areas under 
the peaks for pure and blend systems were calculated by integration and, the ratio 
AN-H (area of N-H bending) to AC=O (area of C=O stretching) is presented in Table 
5.4. It can be observed that addition of elastin decrease the ratio of AN-H/AC=O. 
Moreover, the area of C-O-C, attributed to genipin, increases along with the ratio 
AN-H/AC=O due to carboxyl group from genipin. This fact is an evidence of the 
crosslinking reaction. The higher decrease in the ratio AN-H/AC=O obtained for the 
blend systems is the combined effect of addition of elastin and crosslinking. 
 100SF 100SF0.1GE 100SF0.5GE Methanol 
β-sheet (Silk II) 
Random coil/Silk I 
Turns and bends 
30.57% 
46.06% 
23.34% 
29.43% 
48.02% 
22.56% 
57.96% 
18.87% 
23.17% 
58.15% 
19.63% 
22.21% 
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Table 5.4. Peak areas of AC-O-C (1150-940 cm-1), AN-H (1580-1470 cm-1) to AC=O 
(1790-1580 cm-1) as a function of scaffold composition and crosslinking conditions 
 
Sample AC-O-C AN-H/AC=O (%) 
100SF 
80SF 
50SF 
100EL 
100SF0.1GE 
80SF0.1GE 
50SF0.1GE 
100EL0.1GE 
100SF0.5GE 
80SF0.5GE 
50SF0.5GE 
100EL0.5GE 
- 
- 
- 
- 
6.8 
8.4 
9.4 
11.3 
13.9 
14.1 
15.1 
15.4 
99.6 
89.4 
70.0 
58.1 
98.4 
87.0 
70.3 
57.4 
77.1 
74.0 
69.3 
55.5 
 
The interaction between SF and elastin, crosslinked with genipin, was further 
investigated using thermal analysis (DSC). DSC scans for SF and elastin are 
shown in Figures 5.3 and 5.4 respectively. The DSC curve for 100SF shows an 
endothermic shift at 184 °C that corresponds to the  glass transition temperature 
(Tg) of SF. This value is in the range of others previously reported for SF with a 
random coil conformation [15, 93]. The exothermic peak at 226 °C is related to the 
crystallization of amorphous SF chains cause by the transition to β-sheet structure 
[26, 27, 78]. The DSC curve of SF is also characterized by an intense endothermic 
peak at 284 °C (Td) related to the decomposition of  SF chains. The thermal 
behavior of 100SF is typical of an amorphous SF with random coil conformation as 
previously shown by FT-IR results. Addition of genipin induces a small decrease in 
the Tg and an increase in the decomposition temperature. The increase in the 
thermal stability, given by the increase in Td, of 100SF scaffolds containing genipin 
is due to the increase in the extent of covalent crosslinks. This fact is the 
confirmation of the crosslinking reaction between genipin and SF. Furthermore, 
the exothermic peak at 226 °C shifts to lower tempe rature (100SF0.1GE) and 
CHAPTER V. Novel Silk Fibroin/Elastin Scaffolds Crosslinked with Genipin for Wound 
Dressings 
120 
disappears for the sample 100SF0.5GE. This result shows once again the change 
in the SF conformation from random coil to β-sheet after genipin crosslinking and, 
how this change is affected by the concentration of crosslinking agent. 
The DSC curve of elastin (Figure 5.4) shows an endothermic shift at 197 °C 
assigned to the glass transition temperature of soluble elastin peptides [226]. The 
thermogram is further characterized by a weak and broad endothermic peak at 
265 °C, related to the decomposition of small aggre gated structures and, a more 
intense endothermic peak at 320 °C related to compo nent decomposition at high 
temperature. Addition of genipin caused the decrease in the Tg and, although it 
was not observed an increase in the decomposition temperature (320 °C), the 
weak peak at 265 °C progressively disappears with t he addition of genipin. This 
fact indicates that the small aggregates disappeared due to the crosslinking 
reaction between genipin and elastin. In the blend system (Data not shown) it is 
observed an increase in the decomposition temperature suggesting once again 
the crosslinking effect. Nevertheless, the increase in Td is not dependent on blend 
composition because blends with higher crosslinking degree will not have higher 
thermal stability. 
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Figure 5.3. DSC scans of pure silk fibroin (100SF) and crosslinked with genipin 
(100SF0.1GE and 100SF0.5GE). 
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Figure 5.4. DSC scans of pure elastin (100EL) and crosslinked with genipin 
(100EL0.1GE and 100EL0.5GE). 
 
The 3D morphology of the SF/EL scaffolds was analyzed by SEM. The images 
presented are related to control and crosslinked samples without methanol 
treatment. 100SF scaffold (Figure 5.5a)) shows a disordered pore-like structure 
with a rough surface. The pores are interconnected by a number of even smaller 
pores. Addition of elastin creates a more open and loose structure with thinner 
walls (Figure 5.5b) and 5c)). In the case of 50SF (Figure 5.5c)) it can be observed 
a fibrilar structure. The presence of large pores in the scaffolds facilitates cellular 
infiltration and growth within the 3D structure [252, 253]. However, such loose 
network will have detrimental effects on mechanical, swelling and release 
properties. To overcome this, genipin crosslinking was performed and the results 
clearly evidenced that genipin changes the scaffold morphology. 100SF0.5GE 
sample (Figure 5.5d)) shows a more ordered pore structure interconnected 
between sheets, characteristic of a β-sheet conformation [27, 56]. In addition, the 
SEM images obtained after methanol treatment (Data not shown) showed the 
same morphology observed with genipin crosslinking. This result indicated the 
interaction between genipin and SF with conformational changes that are patent 
on the scaffold morphology. This was further confirmed by FT-IR and DSC results. 
In the blended system, it can be seen that the loose network obtained upon 
addition of elastin becomes more closed and compact due to genipin crosslinking. 
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The fibrils observed in 50SF sample disappeared after crosslinking originating 
thicker walls (Figure 5.5f)). 
 
 
 
Figure 5.5. SEM images of SF/EL scaffolds without genipin (100SF a), 80SF b) 
and 50SF c)) and after genipin crosslinking (100SF0.5GE d), 80SF0.5GE e) and 
50SF0.5GE f)). 
 
Water-binding of scaffolds is an important parameter of biomaterials properties. To 
study the swelling ratio in response to external pH conditions, SF/EL scaffolds 
were immersed in PBS buffer solutions at pH 3, 7.4 and 11 for 24 h at 37 °C. The 
swelling ratio of SF/EL samples was lower in acidic conditions and became 
progressively higher at neutral and alkaline media. The lowest swelling ratio 
obtained at pH 3 might be attributed to the formation of hydrogen bonds between 
SF and elastin due to the presence of carboxylic acid groups (-COOH) and 
hydroxyl groups (-OH). Increasing the pH, the carboxylic acid groups became 
ionized (-COO-) and consequently, higher swelling ratios are observed due to a 
higher swelling force induced by the electrostatic repulsion between the ionized 
acid groups. The swelling ratio was found to be dependent on scaffold composition 
50SF, with and without genipin, showed maximum swelling ratios (Figure 5.6). 
SEM analysis (Figure 5.5) indicates that 50SF samples presented larger pores 
with a loose network, still observed after crosslinking, which results in a higher 
a) b) c) 
d) 
500 µm 500 µm 
500 µm 500 µm 
e) f) 
500 µm 
500 µm 
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hydrodynamic free volume to accommodate more of the solvent molecules thus, 
increasing scaffold swelling [49, 440]. Crosslinking with genipin also affects the 
swelling ratio of the scaffolds, increasing genipin concentration leads to a 
decrease in the swelling ratios. Generally, the swelling behavior of the scaffolds 
can be controlled by its composition and crosslinking degree. In the SF/EL 
scaffolds, genipin crosslinking created stable structures that hinders the mobility 
and relaxation of the macromolecular chains, lowering the swelling ratio due to 
water restrict mobility [441]. This effect is more pronounced in 80SF and 50SF 
samples that attained higher crosslinking degrees when compared with 100SF 
(Table 5.2). The decrease in the swelling ratio can also be correlated with the 
scaffold compact structures formed after crosslinking (Figure 5.5d) e) f)). 
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Figure 5.6. The pH-dependent swelling ration of 100SF a) 80SF b) and 50SF c) 
scaffolds after 24 h of immersion at 37 °C. 
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5.3.2. In vitro and ex vivo biological degradation 
Degradation rate of matrices plays an essential role on the determination of the 
release of entrapped bioactive agents. The in vitro degradation of SF/EL scaffolds 
was investigated by incubation in a physiological pH solution (PBS, pH 7.4) and a 
protease rich medium (PPE and human exudate from chronic wounds) at 37 °C for 
several days. At determined time points, samples were removed, washed with 
distilled water, dried and weighted to determine the extent of degradation.  
The results are presented in Figure 5.7. Scaffolds incubated with PBS solution 
showed almost no degradation within 21 days. From the results in Figure 5.7 it can 
be seen that the degradation is dependent on scaffold composition. Higher weight 
loss was obtained for scaffolds containing higher amounts of elastin. After 21 days 
of incubation, the weight loss obtained for 100SF, 80SF and 50SF in PPE solution 
around 26, 36 and 49% respectively. The low weight loss obtained for 100SF is 
related to the crystallinity of fibroin due to the presence of β-sheet structures. 
Therefore, the observed weight loss is probably due to the degradation of small 
hydrolytically peptide sequences that remain after sponge crystallization [48]. 
Nevertheless, this effect is minimized after genipin crosslinking that increases the 
β-sheet content creating a closed and compact scaffold network (Figure 5.5d)). 
This will diminish the diffusion of solution within the scaffold increasing the 
resistance to protease degradation. The higher weight loss obtained with scaffolds 
containing elastin is because elastin is a substrate for elastase. In the human 
body, elastin, one of the major components of connective tissues, is degraded by 
human leukocyte elastase (HLE) [442-444]. In this way, SF/EL scaffolds might be 
used as elastase-specific wound dressings for chronic wounds. Moreover, elastin-
based dressings have already demonstrated to promote a better wound healing 
either by an improvement of fibroblasts adhesion and proliferation [252, 253] or by 
the reduction of wound contraction [284, 445]. The loose network observed for 
scaffolds containing elastin (Figure 5.5c)) is also responsible for the higher weight 
loss obtained due to the increase in the surface area. As observed before, the 
genipin crosslinking decreases the weight loss observed. The creation of a more 
compact structure between SF and elastin hinders the scaffold degradation. These 
results show that genipin crosslinking was effective on the control of degradation. 
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The results obtained with wound exudate show the same degradation pattern but 
with higher values. The exudate solution used for incubation was less 
concentrated than PPE solution (2.4 µg/mL of total protein content). Nevertheless, 
the wound exudate is a mixture of several proteases, including HLE, that act 
synergistically increasing the hydrolysis. 
Plotting the percentage of weight loss versus time, the degradation rates (%weight 
loss/day) can be calculated from the linear slope. The results on Table 5.5 show 
the degradation rates obtained for PPE and exudate in the first 7 days, during 
which the degradation is linear. It can be seen that scaffold degradation is faster 
for higher amounts of elastin and in the presence of wound exudate. The genipin 
crosslinking of the scaffolds induces a slower degradation. 
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Figure 5.7. In vitro degradation of SF/EL scaffolds incubated with 0.1 mg/ml of 
PPE and wound exudate (2.4 µg/mL of total protein content) at 37 °C for 21 days. 
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Table 5.5. Degradation rates of SF/EL scaffolds calculated from the linear slope of 
the weight loss (%) versus time (days) 
 
Degradation rate (%weight loss/day) 
Sample 
PPE R2 Exudate R2 
100SF 
80SF 
50SF 
100SF0.1GE 
80SF0.1GE 
50SF0.1GE 
100SF0.5GE 
80SF0.5GE 
50SF0.5GE 
1.8 ± 0.3 
2.1 ± 0.3 
3.6 ± 0.3 
1.6 ± 0.3 
2.1 ± 0.2 
2.9 ± 0.2 
1.4 ± 0.1 
1.5 ± 0.1 
2.6 ± 0.4 
0.941 
0.958 
0.981 
0.907 
0.974 
0.984 
0.996 
0.998 
0.945 
2.4 ± 0.5 
2.7 ± 0.6 
4.0 ± 0.4 
2.1 ± 0.3 
2.6 ± 0.5 
3.7 ± 0.5 
2.0 ± 0.5 
2.4 ± 0.4 
3.2 ± 0.6 
0.943 
0.924 
0.971 
0.926 
0.921 
0.954 
0.907 
0.915 
0.905 
5.3.3. In vitro release 
The effect of scaffold composition and genipin crosslinking on the release of model 
compounds was investigated. The release behaviour of Trypan blue and FITC-
BSA from SF/EL scaffolds in PPE solution is shown on Figure 5.8. The release of 
these compounds was monitored in PBS solution (Data not shown) and the 
release observed was low. Trypan blue has a small molecular weight (961 Da) 
while FITC-BSA has a molecular weight of 66 kDa, therefore, the release 
behaviour was also evaluated as a function of compound size. 
In Figure 5.8 the release profile shown can be divided into three parts: an initial 
burst release in the initial 24 h, due to the release of the compound bound to the 
surface of the scaffold; a continuous phase release from 24 to 72 h and a stagnant 
phase release for the remaining period of time. This release profile is observed for 
both molecules but with higher released amounts attained for trypan blue. Due to 
its small molecular weight and hydrophilic nature, the diffusion through the scaffold 
and dissolution into the release medium is higher giving higher release. In 
contrast, the release of FITC-BSA is lower primarily because of its higher 
molecular weight but also to the relative hydrophobicity of FITC that hinders the 
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dissolution into PPE solution and, consequently, the release. Furthermore, for both 
molecules, it was observed that higher release was obtained for scaffolds 
containing higher amounts of elastin. The release of a compound from a matrix is 
governed by several factors such as nature and size of the compound, degree and 
density of crosslinking and pore size among others. From the SEM results 
discussed previously, it was concluded that higher elastin content leads to 
scaffolds with higher pore size which in turn cause the release of higher amounts 
of compounds. The effect of genipin crosslinking on the release profile was also 
evaluated. It can be observed from Figure 5.8 that crosslinking makes the release 
slower. This is attributed to the fact that genipin crosslinking enhances the 
decrease of pore size. In this way, the diffusion of the compounds through the 
sponge pores is more difficult and lower release is attained. 
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Figure 5.8. Cumulative release of trypan-blue a) and FITC-BSA b) from SF/EL 
scaffolds incubated with 0.1 mg/ml of PPE at 37 °C for 21 days. 
a) 
b) 
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To determine the release mechanism present in the SF/EL scaffolds, the 
experimental data was fitted to the semi-empirical power law model [446, 447] 
given by the Ritger-Peppas equation (equation 2.4., Chapter II). This equation is 
further modified to determine the diffusional exponent, n (equation 2.5., Chapter II) 
that depends on the release mechanism and on the geometry of the matrix [386, 
446]. There are three different mechanisms that can be concluded from the n 
value. Therefore, the release, from a cylindrical geometry like the scaffolds 
developed, is purely Fickian diffusion when n = 0.45; for 0.45 < n > 0.89 
anomalous (non-Fickian) transport is present and, for n = 0.89 the release is 
dominated by Case II transport (matrix relaxation or swelling-controlled 
mechanism). From the results presented on Table 5.6, for control samples without 
crosslinking, it can be concluded that the release of both compounds is dominated 
by anomalous transport because n values are above 0.45. In the blends, it can be 
seen that the increasing elastin content, the diffusional exponent, n, and release 
rate, k, values became progressively higher. As previously discussed, addition of 
elastin increases the swelling ratio and degradation rate. Thus, the higher n and k 
values obtained for the blends indicated that the influence of swelling and/or 
erosion in the release mechanism is higher for these samples. On the other hand, 
the n value for 100SF closest to 0.45 suggests that diffusion may play the major 
role on the mechanism. Moreover, the lowest k values obtained for the release of 
FITC-BSA confirm the considerations made earlier about the steric hindrance of 
the molecule size and nature on the release rate. Addition of genipin gradually 
changes the mechanism from anomalous transport to Fickian diffusion which is 
given by the n values closest to 0.45. Furthermore, the crosslinking effect on the 
scaffold morphology (compact and closed structure with smaller pores) also 
influences the release rate that becomes slower with higher amounts of genipin 
(lower k values). The release results clearly support the fact that the release from 
SF/EL scaffolds is affected by compound size and sponge composition and that 
genipin crosslinking can be used to modulate the release mechanism and rate of 
the compounds.  
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Table 5.6. Model compound release kinetic data obtained from fitting the 
experimental release data to Equation 5, Chapter II 
 
Trypan Blue FITC-BSA 
Sample 
n k R2 n k R2 
100SF 
80SF 
50SF 
100SF0.1GE 
80SF0.1GE 
50SF0.1GE 
100SF0.5GE 
80SF0.5GE 
50SF0.5GE 
0.481 
0.523 
0.553 
0.467 
0.517 
0.531 
0.451 
0.474 
0.485 
0.383 
0.683 
1.03 
0.344 
0.636 
0.920 
0.137 
0.491 
0.771 
0.960 
0.956 
0.947 
0.954 
0.958 
0.948 
0.990 
0.952 
0.941 
0.474 
0.503 
0.500 
0.466 
0.478 
0.498 
0.433 
0.452 
0.463 
0.255 
0.416 
0.618 
0.125 
0.187 
0.397 
-0.010 
0.148 
0.317 
0.945 
0.958 
0.938 
0.975 
0.984 
0.965 
0.982 
0.973 
0.976 
5.3.4. Cytocompatibility of SF/EL scaffolds in vitro 
Biocompatibility of SF/EL scaffolds, with and without genipin crosslinking, was 
assessed in human skin fibroblasts in vitro cultures. The results of the indirect 
contact study after fibroblast incubation with material extracts showed no 
cytotoxicity caused by medium conditioned by the scaffolds regardless of the 
incubation time. Figure 5.9 represents the viability results for cells in contact with 
undiluted conditioned medium. In all cases, the metabolic activity of cells in 
contact with the extracts was statistically similar or higher than the one obtained 
with negative control (complete culture medium). This result constitutes a 
preliminary study of the biocompatibility of SF/EL scaffolds. Further evaluation of 
the cytotoxicity by direct contact is necessary. 
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Figure 5.9. Viability of human normal skin fibroblasts after 24 h, 48 h and 72 h of 
contact with conditioned medium (culture medium where scaffolds were 
incubated). Only the positive control (treatment with Triton detergent) revealed diminished cell 
viability. (***= significantly different from all the other tested conditions, p<0.001). 
5.4. Conclusion 
Novel SF/EL scaffolds crosslinked with genipin were successfully prepared. The 
genipin crosslinking results in the conformational transition of SF chains from 
random coil to β-sheet conformation. The SF/EL scaffolds presented different pore 
sizes and distinct morphologies which are related with the elastin ratio and genipin 
crosslinking. The biochemical and biophysical properties of the scaffolds such as 
higher thermal stability, pH-swelling dependence and reduced biological 
degradation and drug release rates were obtained after genipin crosslinking with a 
concentration of 0.5%. A very important and new approach of this study was the 
use of a human wound exudate. Scaffolds degradation was evaluated using 
wound exudate and, genipin crosslinking promotes the decrease in the 
degradation rate. SF/EL scaffolds showed no cytotoxicity for human skin 
fibroblasts. The results presented are important in the design and application of 
tailor-made biomaterials for wound dressings. 
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CHAPTER VI 
 
Tailoring elastase inhibition with synthetic peptides 
 
Abstract  
 
Chronic wounds are the result of excessive amounts of tissue destructive 
proteases such as human neutrophil elastase (HNE). The high levels of this 
enzyme found on those types of wounds inactivates the endogenous inhibitor 
barrier thus, the search for new HNE inhibitors is required. 
This work presents two new HNE inhibitor peptides, which were synthesized 
based on the reactive-site loop of the Bowman-Birk inhibitor (BBI) protein. The 
results obtained indicated that these new peptides are competitive inhibitors for 
HNE and, the inhibitory activity can be modulated by modifications introduced at 
the N- and C-terminal of the peptides. Furthermore, these peptides were also able 
to inhibit HNE from a human wound exudate while showing no cytotoxicity against 
human skin fibroblasts in vitro, greatly supporting their potential application in 
chronic wound treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: Andreia Vasconcelos, 
Nuno G. Azoia, Ana C. Carvalho, Andreia C. Gomes & Artur Cavaco-Paulo, 
Tailoring elastase inhibition with synthetic peptides, Submitted 
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6.1. Introduction 
Elastases belong to the family of serine proteases that hydrolytically degrade 
connective tissues components such as elastin, proteoglycan, fibronectin and 
collagen types I, II, III and IV [448] Human neutrophil elastase (HNE) (EC 
3.4.21.37) is a serine protease of the chymotrypsin family that is stored in the 
primary (azurophil) granules of polymorphonuclear neutrophils (PMNs) and is 
released by inflammatory stimuli. Under normal conditions the activity of HNE is 
regulated by endogenous inhibitors of the serpin (α1-PI, MNEI, PI9), chelonianin 
(SLPI, elafin) families, and to a lesser extent by the polyvalent protease inhibitor 
α2-macroglobulin. The serpins are high molecular weight inhibitors (40 to 50 kDa: 
350 to 500 amino acids) that fold into a conserved, metastable structure and act 
as suicide substrate-like inhibitors using their reactive centre loop [348, 349] 
The continuous activation of inflammatory cells is followed by the release of large 
quantities of HNE which inactivate the inhibitor defense. Excessive and 
uncontrolled HNE activity has been implicated in mediating tissue damage 
associated with chronic wounds and other major chronic inflammatory diseases 
including rheumatoid arthritis, chronic obstructive pulmonary disease, cystic 
fibrosis and adult respiratory distress syndrome [309, 338, 339]. 
In the area of wound healing, the presence of high levels of HNE is associated 
with the degradation of important growth factors [309] and major proteins of the 
extracellular matrix like fibronectin [449] which are vital for the normal wound 
healing process. Due to its involvement in such pathological processes, there has 
been considerable interest in the design of HNE inhibitors that may restore the 
normal levels of this enzyme in the above diseases. Apart from natural or 
engineered inhibitor proteins of high molecular mass, there has been an 
increasing interest in studying both peptide-based and non-peptide small inhibitor 
compounds [350]. In many natural inhibitor proteins, the portion responsible for the 
inhibitory activity is an extended or canonical loop which is complementary to the 
proteinase active site [354]. 
The Bowman-Birk inhibitors (BBI) are bi-headed serine proteinase inhibitors found 
in plants of the Fabaceae family [358]. These proteins have a low molecular 
weight (6-9 kDa) and are characterized by the presence of seven disulphide 
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bridges which allow the formation of a symmetrical structure comprising two 
independent heads located at opposite sides of the molecule (see Figure 6.1). 
Each head is made of a tricyclic domain in which the functional reactive site loop is 
located. Loop I typically inhibits trypsin and loop I inhibits chymotrypsin [354-357]. 
The interaction of BBI with serine proteases occurs via a well-defined disulfide 
linked short beta-sheet region which generates a non-covalent complex that 
renders the serine protease inactive [359]. The conformation of the reactive site 
loop is complementary to the active site of the protease inhibited and allows BBI to 
tightly bind to the protease [354]. BBI-derived synthetic peptides have previously 
been demonstrated to retain the inhibitory activity of the complete protein [359]. 
The present work is based on the ability in retaining the inhibitory activity of short 
peptide sequences that reproduce the reactive site-loop of BBI protein [359, 362, 
363]. The synthetic peptide sequences were tested as inhibitors of HNE and PPE 
to determine the specificity of the peptides. Furthermore, the inhibitory activity of 
these peptides was also tested using chronic wound exudate, in order to evaluate 
their ability to be used as a part of a wound management strategy. 
 
 
 
Figure 6.1. Three-dimensional structure of soybean trypsin/chymotrypsin 
Bowman-Birk inhibitor in solution (PDB code 1BBI [355]). Loop I is shown is red, 
loop II is blue and the disulphide bond is yellow.  
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6.2. Materials and methods 
Herein it will be given a detailed description of some of the methods presented in 
the previous chapter. All other techniques were performed as described in Chapter 
II. 
6.2.1. Materials 
The Porcine Pancreatic Elastase (PPE), Human Neutrophil Elastase (HNE) and 
Elastatinal were purchase from Sigma, Spain. The peptides 1 
(MGWCTASVPPQCYG, 1499.75 g/mol) and 2 (MGWCTASVPPQCYG(GA)7, 
2339.62 g/mol) were synthesized by JPT Peptide Technologies GmbH (Germany). 
The BJ5ta cell line (telomerase-immortalized human normal skin fibroblasts) was 
purchased from the European Collection of Cell Cultures (ECACC) and cultured 
according to ATCC recommendations. All other reagents, including those used in 
cell culture, were analytical grade and purchased from Sigma, Spain. 
6.2.2. Collection of wound exudate 
Wound exudate was collected from pressure wounds using a vacuum assisted 
closure system by the Medisch Spectrum in Twente. Wound fluid samples were 
weighed and 100 µL of phosphate buffer pH 7.0 were then added to 10 mg of 
wound fluid. Samples were incubated at room temperature for 1 h and then 
centrifuged at 2500 rpm for 20 min to remove cells and tissue-material. After 
centrifugation the wound exudate was sterilized using Oxy Fil Centrifugal Filter 
(0.2 µm membrane pore diameter). The samples were then ready for storage at -
20 °C until further use. The total protein content in the wound exudate was 
determined by the Lowry method [450]. 
6.2.3. Determination of activity loss over time  
The half-life times for HNE, exudate and PPE were determined following the 
incubation with different concentrations of inhibitor peptides (20-80 µM) at 25 °C. 
The concentrations of HNE, exudate and PPE were 20 µg/mL, 2.4 µg/mL and 
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175 µg/mL respectively. At determined time points, aliquots were taken and the 
activity was determined against the synthetic substrates, 5 mM of N-
Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide for HNE and exudate. A stock 
solution of this substrate of 20 mM was prepared in DMSO (dimethyl sulfoxide). To 
prepare the 5 mM solution, the required amount of the stock solution was added to 
0.1 M HEPES buffer, 0.5 M NaCl, pH 7.5. The substrate used for PPE was N-
Succinyl-Ala-Ala-Ala-p-nitroanilide, 4.4 mM prepared in 0.1 M Tris-HCl buffer, pH 
8.0. The absorbance was monitored for 5 min at 410 nm using a Heλios γ 
ThermoSpectronic spectrophotometer. Control assays were performed in the 
same conditions but without inhibitor. Measurements were recorded in triplicate 
and the results were expressed as mean value ± S.D. (standard deviation). 
6.2.4. Inhibition kinetics 
The inhibition kinetics of the peptides was determined by competitive binding 
studies [370, 374]. Briefly, 15 µL of proteases (HNE (20 µg/mL), exudate 
(2.4 µg/mL) and PPE (175 µg/mL)) were incubated with 15 µL of peptide inhibitors 
(20-80 µM) for 30 min at 25 °C. The final volume of  each sample was adjusted to 
300 µL with 0.1 M HEPES buffer, 0.5 M NaCl, pH 7.5 (HNE and exudate) and 
0.1 M Tris-HCl buffer, pH 8.0 (PPE). The reaction was initiated with the addition of 
an adequate volume of substrate to obtain a substrate concentration range of 100-
3000 µM. The substrate for HNE and exudate is N-Methoxysuccinyl-Ala-Ala-Pro-
Val-p-nitroanilide 5 mM and for PPE is N-Succinyl-Ala-Ala-Ala-p-nitroanilide 
4.4 mM prepared in the respective buffer solutions. The residual activity was 
determined by the increase in the optical density at 410 nm over 10 min using a 
microplate reader (Varian). Control assays were performed in the same conditions 
without inhibitor peptides. All assays were done in triplicate and the results are 
expressed as the mean value ± S.D. Ki was determined by nonlinear regression 
analysis [451] using the GraphPad Prism software [431] 
6.2.5. Determination of IC50 for proteases using synthetic substrates 
To determine the IC50 values of the inhibitor peptides against proteases, 15 µL of 
proteases (HNE (20 µg/mL), exudate (2.4 µg/mL) and PPE (175 µg/mL)) were 
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incubated with 15 µL of peptide inhibitors (20-80 µM) for 30 min at 25 °C. The 
volume was adjusted to 300 µL with respective buffer solutions. The reaction was 
started after the addition of 27 µL of 400 µM of N-Methoxysuccinyl-Ala-Ala-Pro-
Val-p-nitroanilide (HNE and exudate) and N-Succinyl-Ala-Ala-Ala-p-nitroanilide 
(PPE). The increase in optical density at 410 nm was monitored over 10 min using 
a microplate reader (Varian). All assays were done in triplicate and the results are 
expressed as mean value ± S.D. IC50 was determined using the GraphPad Prism 
software, version 5.03 [431]. 
6.2.6. Determination of IC50 for HNE and exudate using insoluble elastin 
The ability of the synthetic peptides to inhibit the hydrolysis of insoluble elastin by 
HNE was determined spectrophotometrically using elastin congo-red as a 
substrate according to the method previously described [452]. Briefly, elastin 
congo-red (2 mg/mL) and HLE (20 µg/mL) and exudate (2.4 µg/mL) were 
incubated with various concentrations of peptides (20-80 µM) in 1.5 mL of 0.1 M 
Tris-HCl buffer, pH 8.0 containing 0.2 M NaCl at 30 °C for 1 h. After incubation, the 
reaction was stopped by the addition of 1.5 mL of 0.1 M acetic acid and, the 
mixture was centrifuged at 3000 rpm for 10 min at room temperature. After 
centrifugation, the absorbance of the supernatant was measured at 495 nm using 
a Heλios γ ThermoSpectronic spectrophotometer. Triplicate measurements were 
made for each inhibitor concentration and the results are expressed as mean 
value ± S.D. 
6.2.7. Silk fibroin films preparation and peptide incorporation  
Silk fibroin films (SF) were prepared as described [326]. Briefly, SF solution 
1% (w/v) was prepared by dissolving degummed silk fibers into a saturated 
solution of LiBr at 60 °C for 3 h. The solution was  then filtered, and dialyzed 
against distilled water using, cellulose tubing (molecular-weight cut-off of 12000-
14000 Da), until complete removal of salts. The peptides (40 µM) were mixed with 
the SF solution for 5 min at room temperature. After this time, solutions were cast 
in 24-well plates and dried overnight at room temperature. In order to induce the 
transition of SF from random coil to β-sheet structure and consequently 
CHAPTER VI. Tailoring Elastase Inhibition by Synthetic Peptides 
140 
insolubility, the films were immersed in 90% (v/v) methanol solution for 30 minutes 
and then washed in distilled water and air dried. Films were incubated with HNE 
for 1 h at 25 °C and then aliquots were taken for t he evaluation of HNE activity 
decrease as described above. 
6.2.8. Cytotoxicity evaluation 
The peptides were tested for cytotoxicity using the BJ5ta cell line (normal human 
skin fibroblasts) was used to determine the cytotoxicity of the peptides as 
described in Chapter II. Data are presented as average ± S.D. Non-parametric, 
Wilcoxon matched samples test was used, with statistically significant differences 
when p < 0.05. All calculations were performed using GraphPad Prism software, 
version 5.03 [431]. 
6.3. Results and discussion 
In this study synthetic peptides based on the anti-trypic loop of the BBI protein 
were used for the design of new inhibitor peptides. Based on the nomenclature of 
Schechter and Berger [328], the primary contact region between the inhibitor and 
the enzyme is the scissile peptide bon P1-P1’. Therefore, the specificity of the 
inhibition is dictated by the P1 residue which typically reflects the substrate 
preference of the target enzyme [366, 367]. The peptide selected from the 
combinatorial library [362] has an alanine residue in the P1 position (Figure 6.2). 
This residue in this position is consistent with the substrate specificity of elastase 
for small alkyl side chains [335, 453, 454]. The stability and consequently the 
biological activity of the BBI-based peptides are supported by an extensive 
intramolecular hydrogen-bond network. The main-chain to main-chain hydrogen 
bond between P2 and P1’ (Figure 6.2, dash lines) is responsible for projecting the 
P1 side-chain outwards for the primary interaction with the enzyme [356, 357]. The 
cis-Pro-trans-Pro motif in the P3’-P4’ positions and, the disulphide bridge 
covalently linking the P3-P6’ positions together with the hydrogen bond network 
guarantees the β-hairpin conformation typical of the BBI protein [359, 362, 455]. 
In this study, the 9-residue motif was maintained in the new peptides but, without 
generate de disulphide bond between P3-P6’ positions. To this 9-residue motif, 
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modifications were made in the N-terminal, by the introduction of methionine (M) 
and glycine (G) (Peptide 2, MGWCTASVPPQCYG, Figure 6.2, light gray circles). 
This sequence was maintained and a glycine/alanine (GA) tail (n=7) was added to 
the C-terminal (Peptide 3, MGWCTASVPPQCYG(GA)7, Figure 2, dark gray 
circles). 
 
 
 
Figure 6.2. Representation of the peptide sequences mimicking the reactive site 
loop of the Bowman-Birk Inhibitor protein. 
6.3.1. Activity loss over time 
The time of incubation necessary to obtain a decrease in 50% of elastase activity, 
was determined by incubating the peptides with PPE, HNE and wound exudate 
and the decrease in activity was monitored over the time as described in 
experimental section. In our study, it was also used elastatinal, a small molecular 
weight elastase inhibitor, as a control.  
Figure 6.3, represents the activity loss obtained with the lowest concentration of 
peptides used (20 µM) after 30 min of incubation. It can be observed that after 
30 min it was obtained more than 50% of activity loss for all the peptides. 
Nevertheless, both peptide 3 and elastatinal present higher activity loss than 
peptide 2, especially for human elastase, indicating the higher inhibitory activity. 
The time of incubation determined (30 minutes) will be used in the further 
experiments.  
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Figure 6.3. Activity loss obtained after 30 min of incubation at 25 °C of elastases 
with 20 µM of peptides 2, 3 or elastatinal. (Peptide 2 = MGWCTASVPPQCYG, peptide 
3 = MGWCTASVPPQCYG(GA)7) 
6.3.2. Inhibition kinetics 
In order to establish the inhibition mechanism, PPE, HNE and wound exudate 
were incubated with different peptide concentrations. To analyse the inhibition, 
Lineweaver-Burk plots, i.e. double-reciprocal plot for the hydrolysis of the synthetic 
substrates were determined for all the peptides and enzyme (Data not show for 
PPE and wound exudate). Figure 6.4 represents the progress curves for the 
inhibition of HNE by both peptides (Figures 6.4a) and 6.4b)) and the 
correspondent Lineweaver-Burk plot (Figures 6.4c) and 6.4d)). From the analysis 
of the last, it can be determined the mechanism of inhibition and from the results, 
peptide MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 are competitive 
inhibitors for HNE, PPE and wound exudate. Then, non-linear regression was 
applied to determine the Michaelis-Menten constant (Km) and Vmax by equation 
2.6., Chapter II. 
The results also confirmed the type of inhibition present because Vmax remains 
unchanged in the presence of different peptide concentrations and, there is an 
increase in the Km. These values are higher for HNE in the presence of peptide 
MGWCTASVPPQCYG(GA)7, indicating that this peptide causes higher inhibition. 
Protein matrices for wound dressings 
 
143 
The competitive inhibition exhibited for peptides MGWCTASVPPQCYG and 
MGWCTASVPPQCYG(GA)7 may work through direct competition with the substrate 
by binding to the active site, or binding to a remote site and causing a 
conformational change in the enzyme. 
Competitive inhibitors cause an apparent increases of Km (i.e., the inhibitor 
interferes with substrate binding) without affecting Vmax (inhibitor cannot bid to the 
complex enzyme-substrate). Therefore, inhibition constants (Ki) were determined 
by the modified Michaelis-Menten equation for competitive inhibition using the 
equation 2.7., Chapter II. 
 
0 250 500 750 1000 1250 1500 1750 2000 2250
0,005
0,010
0,015
0,020
0,025
0,030
0,035
0,040
 I=0 µM
 I=20 µM
 I=40 µM
 I=60 µM
 I=80 µM
Ve
lo
ci
ty
, 
O
D
 
41
0 
n
m
[Substrate] (µM)
0 250 500 750 1000 1250 1500 1750 2000 2250
0,005
0,010
0,015
0,020
0,025
0,030
0,035
0,040
 I=0 µM
 I=20 µM
 I=40 µM
 I=60 µM
 I=80 µM
Ve
lo
ci
ty
, 
O
D
 
41
0 
n
m
[Substrate] (µM)
 
 
0
20
40
60
80
100
120
140
160
-0,002 0 0,002 0,004 0,006 0,008 0,01 0,012
1/[Substrate]
1/
v
el
o
ci
ty
I=0
I=20
I=40
I=60
I=80
0
40
80
120
160
200
240
280
-0,002 0 0,002 0,004 0,006 0,008 0,01 0,012
1/[Substrate]
1/
v
el
o
ci
ty
I=0
I=20
I=40
I=60
I=80
 
 
Figure 6.4. Progress curves for the inhibition of HNE by peptide 2 (a) and peptide 
3 (b) for the hydrolysis of the synthetic substrate. The correspondent Lineweaver-
Burk plots are represented in c) peptide 2 and d) peptide 3. (Peptide 2 = 
MGWCTASVPPQCYG, peptide 3 = MGWCTASVPPQCYG(GA)7) 
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The inhibition constants (Ki) obtained for the peptides are presented in Table 6.1. 
It can be observed that the inhibition constants obtained for peptide 
MGWCTASVPPQCYG(GA)7 presents the best results, especially for HNE. There is 
an improvement in Ki for HNE obtained for peptide WCTASVPPQCYG [363], when 
amino acid residues were added to both N- and C-terminals. 
The Ki ratio presented shows the selectivity of the peptides for HNE. The results 
indicate that peptide MGWCTASVPPQCYG(GA)7 presents higher specificity for 
HNE. Moreover, Ki values obtained for PPE, HNE and wound exudate with the 
peptides are comparable, and in some cases better (peptide 
MGWCTASVPPQCYG(GA)7 for HNE), with the Ki obtained for elastatinal. 
A very important result and approach of this study, is the use of a human wound 
exudate. The peptides MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 
present good inhibition constants and the differences obtained when compared 
with HNE (Sigma) might be related with the presence of other proteases present in 
the exudate that can interfere with the inhibition. 
 
Table 6.1. Inhibition constants (Ki) obtained for the peptides against PPE, HNE 
and wound exudate. (*Values were obtained from the literature [363], Peptide 1 = 
WCTASVPPQCYG, peptide 2 = MGWCTASVPPQCYG, peptide 3 = 
MGWCTASVPPQCYG(GA)7) 
 
Ki (µM) 
Peptide 
PPE HNE Exudate 
KiPPE/ KiHNE 
Peptide 1* 
Peptide 2 
Peptide 3 
Elastatinal  
13 
8.1 ± 1.6 
7.0 ± 2.0 
9.7 ± 1.4 
2.77 
6.3 ± 1.2 
0.4 ± 0.01 
6.7 ± 1.1 
- 
7.0 ± 1.8 
3.1 ± 0.9 
7.8 ± 1.2 
- 
1.3 
17.5 
1.2 
6.3.3. IC50 for proteases 
The inhibitory activity of peptides MGWCTASVPPQCYG and 
MGWCTASVPPQCYG(GA)7 against PPE, HNE and wound exudate were evaluated 
using synthetic and natural substrates. The results were compared with the activity 
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of elastatinal inhibitor as control. IC50 values obtained for peptides 
MGWCTASVPPQCYG, MGWCTASVPPQCYG(GA)7 and elastatinal, using synthetic 
substrates, are presented in Table 6.2 and are within the range of 11 – 19 µM. 
Once again peptide MGWCTASVPPQCYG(GA)7 shows the lowest IC50 values which 
are the results of a higher inhibitory activity already demonstrated by the Ki values. 
The ability of peptides MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 to 
inhibit the hydrolysis of insoluble elastin by HNE was also evaluated. Peptides 
MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 present lower IC50 values in 
comparison with elastatinal under our assay conditions. Peptide 
MGWCTASVPPQCYG(GA)7 presents higher inhibitory activity in the presence of a 
natural substrate. 
 
Table 6.2. Inhibitory activity of peptides and elastatinal against PPE, HNE and 
wound exudate using synthetic and natural substrates. (Peptide 2 = 
MGWCTASVPPQCYG, peptide 3 = MGWCTASVPPQCYG(GA)7) 
 
IC50 (µM) 
Enzyme 
MGWCTASVPPQCYG MGWCTASVPPQCYG(GA)7 Elastatinal 
PPE 
HNE 
Exudate 
HNE (insoluble elastin) 
Exudate (insoluble elastin) 
18.7 ± 0.06 
19.2 ± 0.07 
16.0 ± 0.09 
29.3 ± 0.1 
31.8 ± 0.04 
16.0 ± 0.06 
11.5 ± 0.06 
13.1 ± 0.06 
25.3 ± 0.1 
26.9 ± 0.05 
13.8 ± 0.06 
12.2 ± 0.05 
14.3 ± 0.07 
37.6 ± 0.09 
41.9 ± 0.04 
6.3.4. Peptides inhibitory activity after incorporation into SF films 
The primary objective of adding the GA tail was to increase the affinity of this 
peptide to silk fibroin-based materials. In this way, SF-based wound dressings will 
be easily obtained with a specific biological activity: elastase inhibition [326]. 
Nevertheless the results presented indicated that this GA tail has a very important 
role in the HNE inhibition. Peptide MGWCTASVPPQCYG(GA)7, presented Ki and 
IC50 values for HNE of 0.4 µM and 11.5 µM respectively. The Ki was 7-fold lower 
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when compared with the peptide WCTASVPPQCYG [359] indicating a higher 
inhibitory activity. In contrast, the modifications introduced only at the N-terminal 
(peptide MGWCTASVPPQCYG) show a slightly improvement in the inhibition of 
pancreatic elastase (PPE), but a worst result for the inhibition of HNE when 
compared with peptide WCTASVPPQCYG. The better results obtained with peptide 
MGWCTASVPPQCYG(GA)7 might be related with the increase in hydrophobicity 
resulting from the GA tail which corresponds to the preference of HNE for 
hydrophobic substrates. Although not possible, from the activity measurements, to 
quantify the exact number of binding sites, one might speculate that the potent 
binding between peptide MGWCTASVPPQCYG(GA)7 and HNE might be due to the 
binding of this GA tail to the active centre or adjacent active sites of HNE. The 
differences in inhibitory activity between peptide MGWCTASVPPQCYG and 
MGWCTASVPPQCYG(GA)7 might be related with the GA tail introduced in the C-
terminal of peptide MGWCTASVPPQCYG(GA)7. To test this hypothesis, peptides 
were incorporated in SF films prepared as described in the experimental section 
and, the decrease in activity was monitored after 1 h of incubation of SF films, 
containing peptide MGWCTASVPPQCYG, MGWCTASVPPQCYG(GA)7 and 
elastatinal, with HNE. SF film without peptides was used as control. It can be seen 
from Figure 6.5 that the activity loss obtained for peptide MGWCTASVPPQCYG and 
MGWCTASVPPQCYG(GA)7 is similar. The amino acid composition of silk fibroin 
(SF) consists primarily of glycine, alanine and serine amino acids which form 
typical -(-ala-gly-)n- repeating motifs [12]. In the fiber, fibroin chains are aligned 
along the fiber axis held together by a close network of interchain hydrogen bonds 
with adjacent -(-ala-gly-)n- sequences forming the well known β-sheets crystals 
[14, 456]. Therefore, peptide MGWCTASVPPQCYG(GA)7 will have a high affinity 
towards SF films due to the GA tail. The activity loss of HNE obtained in the 
presence of SF films incorporating peptides indicated that the inhibitory activity of 
peptide MGWCTASVPPQCYG(GA)7 decreases. The activity loss obtained was 
similar to the one obtained for peptide 2 (MGWCTASVPPQCYG) which is a less 
potent inhibitor already demonstrated by inhibition kinetics results. This fact clearly 
demonstrates the importance of GA tail on the inhibitory activity. The loss in 
activity verified for peptide MGWCTASVPPQCYG(GA)7 is explained by the fact that 
after film crystallization a transition from random coil to β-sheet of SF films occurs 
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and the GA tail of peptide MGWCTASVPPQCYG(GA)7 may thus become a part of 
these β-sheet crystals being unavailable for the inhibitory activity. 
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Figure 6.5. Activity loss of HNE after 1 h of incubation at 25 °C with SF films 
incorporating peptide 2, 3 and elastatinal. (Peptide 2 = MGWCTASVPPQCYG, 
Peptide 3 = MGWCTASVPPQCYG(GA)7) 
6.3.5. Molecular-docking analysis 
Molecular-docking analysis was done in order to better understand the mechanism 
of HNE inhibition by the new peptides. Docking calculations were made using 
AutoDock Vina version 1.1.1 [457]. For the calculations we use the X-ray structure, 
PDB code 1B0F [332], after removing the ligand present in this structure. This 
structure was used as the receptor without flexible side chains. The ligands were 
made flexible turning all possible bonds rotatable. Cyclic and amide bonds were 
considered as non-rotatable. Considering these we get 37 torsions for peptide 1 
(WCTASVPPQCYG), 44 torsions for peptide 2 (MGWCTASVPPQCYG) and 72 
torsions for peptide 3 (MGWCTASVPPQCYG(GA)7). For peptides 1 and 2 the grid 
size was chosen in order to included not only the known catalytic site of HNE but 
also all the surrounding area. The surface in the opposite side of the enzyme was 
not considered. For the peptide 3, and because this peptide is bigger, the grid was 
centred at the centre of the protein and big enough to include all the protein and 
peptide 3 interacting with any spot of the surface. This procedure allows us to 
CHAPTER VI. Tailoring Elastase Inhibition by Synthetic Peptides 
148 
obtain the most favourable configuration representing the interaction between 
peptide 3 and HNE, without any kind of external impositions. Docking analysis 
indicated that the reactive site-loop of the BBI-peptides occupied most of the 
active site, inhibiting the HNE activity as already demonstrated by others [362, 
368, 369, 458]. This also confirms the competitive inhibition obtained for BBI-
peptides that was confirmed by our kinetic analysis. Nevertheless, modifications 
made on the C- and N-terminal of peptides had influence on the binding mode to 
the active site of HNE. 
Peptide MGWCTASVPPQCYG had two more residues (MG) at the N-terminal, 
which increases the hydrophobic interactions between P-P’ side-chains 
(methionine is hydrophobic) thereby closing the loop (Figure 6.6b)) when 
compared to peptide WCTASVPPQCYG (Figure 6.6a)). This might increase the 
distance of P1 (Ala) to the active centre decreasing the inhibition. On the other 
hand, the increase in hydrophobicity of peptide MGWCTASVPPQCYG(GA)7, given 
by the GA tail at the C-terminal causes the opening of the loop (Figure 6.6c)). This 
peptide showed the best HNE inhibitory activity. Docking analysis suggested that 
the primary interaction with the active site is also made by the P1, as observed for 
the other two peptides. Nevertheless the interaction of peptide 
MGWCTASVPPQCYG(GA)7 with the enzyme tends to be more favourable. The 
hydrophobic GA tail has the ability to interact with the remaining enzyme, leading 
to a stronger interaction between the two species (Figure 6.6c)). This is consistent 
with what others observed for this particular enzyme. It was shown that HNE 
activity increases with the length of the synthetic substrates indicating that HNE 
has an extended binding site [329, 336]. It is possible, as shown by docking 
analysis, that HNE accommodates the GA tail due to the high length and 
hydrophobicity leading to stronger interactions and, therefore, to higher inhibition 
rates. 
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Figure 6.6. Docking images of the interactions between HNE and peptides 1 (a), 2 
(b) and 3 (c). The catalytic triad is shown in red. (Peptide 2 = MGWCTASVPPQCYG, 
Peptide 3 = MGWCTASVPPQCYG(GA)7) 
6.3.6 Cytotoxicity evaluation 
The biocompatibility of the designed peptides was assessed through the use of 
fibroblast cultures. A preliminary screening was made using murine embryonic 
fibroblasts cells (MEFs) as a measure of global cytotoxicity. In this study, a wide 
range of peptide concentrations (20-80 µM) used for inhibition assays was 
evaluated and no toxicity was observed (Data not shown). The results obtained 
with MEFs were then confirmed with human skin fibroblasts, testing the lowest and 
highest peptide concentrations were previously used and no additional damage to 
the cells was detected in any case. Figure 6.7 shows the cell viability of human 
skin fibroblasts after 24 h (a) and 48 h (b) of incubation with the various peptides. 
In all cases, the cell viability was close to 100% indicating that peptides 
MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 can be safely applied to the 
skin at these concentrations. 
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Figure 6.7. Viability of human normal skin fibroblasts after 24 h (left panel) and 
48 h (right panel) of contact with peptides 2, 3 and elastatinal. Only the positive control 
(treatment with Triton detergent) revealed diminished cell viability. (* = significantly different from all 
the other tested conditions, p<0.05). (Peptide 2 = MGWCTASVPPQCYG, Peptide 3 = 
MGWCTASVPPQCYG(GA)7) 
6.4. Conclusion 
The results presented in this study confirmed the ability of BBI-peptides to inhibit 
HNE. Peptide MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 are competitive 
inhibitors of HNE being peptide MGWCTASVPPQCYG(GA)7 the one that presents 
higher inhibitory activity. This is due to the presence of the GA tail that increases 
hydrophobicity. Consequently, the affinity for HNE increases because of the 
preference of this enzyme for hydrophobic residues. The importance of the GA tail 
in the inhibition HNE was confirmed by incorporating peptides in a silk fibroin 
matrix and by molecular-docking analysis. After incorporation and subsequent 
crystallization of SF films, the inhibitory activity was similar to that obtained for 
peptide MGWCTASVPPQCYG. This happens because the GA tail, upon 
crystallization, is no longer available for the inhibition. 
Peptide MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 were also able to 
inhibit HNE present on a chronic wound exudate. This fact, along with the 
cytocompatibility observed with human skin fibroblasts, indicates that these 
peptides, especially peptide MGWCTASVPPQCYG(GA)7, are potential bioactive 
agents against deleterious HNE-derived inflammatory episodes such as chronic 
wounds.
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CHAPTER VII 
7.1. General conclusions 
This thesis reports for the first time the use of protein blend systems as wound 
dressing materials. Herein a summary of the major achievements will be given. 
This work can be divided into two parts: Development of new protein materials 
based on silk fibroin, keratin and elastin were developed for wound dressing 
applications; Use of innovative peptide sequences based on the reactive site-loop 
of the Bowman-Birk inhibitor (BBI) protein were used to control the high levels of 
human neutrophil elastase (HNE) found on chronic wounds. 
The general conclusions of the research work produced in the present thesis, 
which extends from Chapter III to VI, are summarized as follows: 
 
Development of new protein-based materials 
Silk fibroin (SF), keratin (K) and elastin (EL) are proteins with distinctive properties 
such as mechanical strength, biodegradability, secondary structure and amino 
acid composition. This was determined for the three proteins; SF is characterized 
by a high content in glycine (44%), alanine (29%) and serine (12%) amino acid 
residues that are responsible for the formation of the β-sheet crystal that 
characterize the secondary structure of SF. 
Keratin is distinct from the other studied proteins by the high content of cysteine 
(9%) residues responsible for the formation of disulfide bonds, which gives high 
strength to the keratin materials. Elastin is mainly composed of glycine (32%), 
alanine (24%), proline (12%) and valine (11%) that characterizes the hydrophobic 
regions of elastin in the human body.  
Blending often allows modulating the final properties of the resulting materials, 
thus we used this approach to develop SF/K films and SF/EL porous scaffolds. 
SF/K films were prepared by solvent casting and evaporation, by aqueous and 
formic acid-derived systems.  
The two proteins were mixed in several ratios being 100% SF and 100% K the 
controls. Nevertheless, although native keratin materials present high mechanical 
strength, the same is not observed for regenerated keratin. Thus, the first 
conclusion observed during this study was that the maximum keratin that can be 
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used, in our test conditions, to obtain a handled film is 60%. In addition, the non 
linear trend obtained from FT-IR (intensity ratio of amide II bands of SF and K) and 
DSC analysis (energy for the decomposition of SF and K) indicated that SF and K 
are able to establish intermolecular interactions, most likely, hydrogen bonds.  
Pure SF films obtained from regenerated SF solutions are prevalently 
amorphous/silk I. After methanol or formic acid treatment, the films underwent a β-
sheet conformation, which confers a closed and compact structure to the materials 
giving high mechanical strength. In our study, addition of keratin that is highly 
polar, decreases the β-sheet content causing a more open and hydrophilic 
structure. This alters the properties of materials such as: decrease of tensile 
strength with the increase of keratin content; higher swelling ratio for higher keratin 
amounts; higher and faster degradation rates by trypsin and porcine pancreatic 
elastase (PPE): at low keratin contents (20%) the degradation is relatively slower 
but at high keratin amounts (60%), the degradation is fast and, after 7 days of 
incubation the film is completely disintegrated; the surface topography of the SF/K 
films also changes by the addition of the keratin, exhibiting a smoother surface 
which will affect the mechanical strength; the release rate of model compounds is 
also influenced by the presence of keratin: at low keratin content (20%) the 
release of FITC-BSA is modulated by Fickian diffusion, a high keratin content 
(60%) the release is totally controlled by the degradation of the film. 
SF/EL porous scaffolds were prepared by lyophilization. 3D architectures are 
recognized to be important for cellular infiltration and proliferation. For the 
development of these scaffolds, soluble elastin was used. It is reported that 
soluble elastin enhances elastin synthesis in vivo. Nevertheless, the resulting 
materials often presented poor mechanical properties. To overcome this, SF and 
EL were fixed with a natural agent, genipin, due to its low toxicity. The proteins 
were successfully crosslinked with genipin after 6 h of reaction (maximum 
crosslinking degree). It was demonstrated that genipin induces conformational 
changes on SF, increasing the β-sheet content, and on EL, increases the amount 
of undefined conformations. It was also found that the thermal stability of SF and 
EL increased after genipin crosslinking. 
For SF/EL scaffolds it was concluded that addition of elastin influences the 
physical and chemical properties of the materials. The morphology of the scaffolds 
after addition of EL is characterized by high pores with a loose and open network. 
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Even though, porous morphologies are required for cellular attachment and 
growth, such loose network might have negative effects on swelling, degradation 
and release rates as demonstrated by our results. 
The swelling ratio was higher for samples with higher EL amounts (50%). It was 
found that the swelling ratio of SF/EL scaffolds was lower in acidic conditions, 
attributed to the formation of hydrogen bonds between SF and EL, becoming 
progressively higher at neutral and alkaline media, as a consequence of the 
electrostatic repulsion between the ionized acid groups. 
Our ultimately goal is to use these protein materials as wound dressings therefore, 
the degradation was evaluated under a human wound exudate obtained from 
decubitus wounds. The results indicated that higher degradation rates are 
obtained for higher EL amounts. This was an expected result because in the 
human body, elastin is degraded by HNE. However, addition of EL to the sponges 
allows us to obtain biomaterials mimicking the extracellular matrix (ECM). 
The genipin crosslinking changes the properties mentioned above: scaffolds with 
smaller pore sizes and compact structures are obtained; the swelling ratio 
decreased because the formation of covalent bonds hampers the mobility and 
relaxation of the macromolecular chains and, the biological degradation is 
decreased. The release of model compounds from SF/EL scaffolds (Trypan-blue 
and FITC-BSA) that was characterized by anomalous transport, influenced by 
swelling and degradation, becomes dominated by Fickian diffusion, with slower 
release rates, after genipin crosslinking. 
The results presented in this thesis indicated that SF/K films and SF/EL scaffolds 
are degraded, which is an important feature if the materials have to be implanted 
in vivo; have the ability to swell maintaining a moist environment in the wound 
promoting the healing; present drug delivery options and showed no cytotoxicity 
with mouse and human skin fibroblasts cells. These are essential parameters that 
make the developed protein materials suitable candidates for wound dressings. 
 
Control of human neutrophil elastase (HNE) activity 
Chronic wound exudates presented high levels of tissue destructive proteases 
such as HNE. The activity of this enzyme, in an acute wound environment, is 
controlled by endogenous inhibitors, which are inactivated in the presence of high 
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levels of HNE. Therefore, the use of synthetic peptides is necessary to control the 
elastase-antielastase imbalance. 
In this study, peptides based on the reactive site-loop of the BBI protein were 
used. These were removed from a combinatorial peptide library created to obtain 
peptide sequences that greatly inhibit HNE. 
In a first approach, the peptide 5(6)-Carboxyfluorescein-YCQPPWSATCF-OH was 
used to inhibit PPE (used here as a model for HNE) in solution and after 
incorporation into the SF/K films. The results indicated that the peptide is able to 
inhibit PPE in solution and, that the inhibitory activity increases with the increase of 
peptide concentration. The highest peptide concentration used (80 µM) decreases 
the half-life time of PPE by 7-fold. 
The peptide was further incorporated into SF/K films, before film casting, to 
determine if the peptide retained its inhibitory activity. This originates films with the 
peptide incorporated by physical entrapment. The results indicated that 
incorporation of the peptides in pure SF films and blend films with low keratin 
content (80/20 SF/K) increases the half-life time of PPE when compared with the 
peptide alone, indicating that the peptide is slowly released showing that SF/K 
films can act as mechanism-based wound dressings with a specific target: the 
control of HNE activity. 
In a second approach, we used another BBI-based peptide with the sequence, 
WCTASVPPQCYG. For this, modifications were made at both N- and C-terminal: 
MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7. It was found that these 
peptides are competitive inhibitors for PPE and HNE, being peptide 
MGWCTASVPPQCYG(GA)7 the one that presents higher inhibitory activity, with 
an inhibition constant, Ki, 7-fold lower when compared with the peptide 
WCTASVPPQCYG. This is due to the presence of the GA tail that increases 
hydrophobicity. As a consequence, the affinity for HNE increases because of the 
preference of this enzyme for hydrophobic residues, increasing the inhibitory 
activity. Furthermore, the peptides showed no cytotoxicity with human skin 
fibroblasts and, are also able to inhibit HNE present in a human chronic wound 
exudate. The results demonstrated that MGWCTASVPPQCYG(GA)7, can be used 
as HNE inhibitor for chronic wounds. 
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As a final remark, one can say that the work described in the present thesis 
intends to give another positive contribute for the development of novel protein-
based biomaterials. Each of the individual work performed addresses some of the 
needs in the treatment of chronic wounds. SF/K films and SF/EL scaffolds were 
developed and evaluated for the first time. Moreover, new HNE inhibitors were 
developed in order to obtain interactive wound dressings: tailor-made materials to 
target high levels of HNE elastase. The results obtained clearly indicate the 
suitability of the developed materials for wound dressings which is the main 
innovation coming from this thesis. 
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7.2. Future perspectives 
The results presented in this thesis showed that SF/K films and SF/EL sponges 
are promising candidates for wound dressing materials. Following the same 
approaches, new morphologies can be developed with these three proteins and, 
their properties can be further modulated. 
The materials developed should also be evaluated in vivo through the use of 
animal models. Important parameters such as inflammation, cellular proliferation 
and differentiation and elastin synthesis should be determined.  
New analysis must be done to fully understand the mechanism of HNE inhibition 
by the designed peptides. 
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